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The Evolution of Glioblastoma: A single Case Study
Astrid Svenja Wendler
Glioblastoma multiforme (GBM) is the most malignant and common primary brain
cancer in adults, with a 2.5-year survival of only 8%. In this single case study
we have analysed the development of a primary GBM over four years. We per-
formed WGS and RNAseq on three, spatially distinct samples of the treatment
naïve primary tumour, the first recurrence and the fatal second recurrence. We
observed a massive increase in mutations from the first to the second recurrence,
showing predominantly C?T and A?G transitions, which is a pattern typical of
TMZ treatment. The fact that the hypermutation did not appear until the second
recurrence raises questions about the mechanism of hypermutation. The thera-
peutic apoptotic action of TMZ relies on the function of the mismatch repair (MMR)
pathway. In the second recurrence we observed disruptive mutations of MSH6,
MSH2, PMS2 and MLH1 all of which are crucial to the MMR pathway. The pattern
of mutations of these genes varied between the samples taken from the second
recurrence, however, all three samples showed hypermutation. This suggests
that the hypermutation observed after TMZ treatment only occurs if the MMR is
damaged, but that this damage does not need to be at a specific locus.
Using the CRISPR-Cas9 technology we explored the impact of MMR muta-
tions on patient derived GBM cell lines. Results on MSH2 and MSH6 knockout
cell lines treated with TMZ showed the reproduction of the hypermutation pheno-
type in vitro, but only in MGMT promoter methylated cell lines.
Moreover, the DNA analysis of the patient showed one shared mutation in
high copy number in all of the nine samples: a mutation in EGFR (G598V). We
hypothesise that subsequent tumours developed from an original clone bearing
this mutation. This mutated oncogene is located on an extrachromosomal circular
DNA structure known as a double minute (DM), which is found in an estimated
40% of GBM. We performed linked-read sequencing using the 10X Genomics
Chromium technology to reconstruct the DM and shed light on its emergence.
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A tumour is more than the sum of its mutations. It is a highly dynamic system, that
can be thought of in terms of Darwinian evolutionary biology (Greaves and Maley
[90]).This idea was first postulated by Peter Nowell in 1976, in a seminal paper that
established the evolutionary theory of cancer (Nowell [201]). This theory moved
back into focus with novel sequencing strategies revealing that some tumours are
even more heterogeneous in their genetic landscape than expected.
As glioblastoma multiforme (GBM), a malignant tumour of the central nervous
system, is the cancer studied and discussed in this thesis, I will explore current
knowledge about cancer and its survival mechanisms in the context of GBM.
GBMs are highly diverse tumours showing heterogeneity within (intra-tumour) and
between (inter-tumour) individual patients (Sottoriva et al. [252] and Soeda et al.
[251]). Tumour heterogeneity has been reported in several cancer types, such as
acute myeloid leukaemia (AML) (Anderson et al. [4]), high-grade serous ovarian
cancer (Schwarz et al. [241]), colon (Tsao et al. [270]) and prostate cancer (Macin-
tosh et al. [179]). Subpopulations of cells with distinct genotypes and phenotypes
that may display divergent biological behaviours are found within a primary tumour
or between tumours of the same histological subtype.
The model of clonal evolution in cancer suggests a single founder cell (stem
cell or progenitor) sequentially acquiring mutations and expanding into distinct
subclones, which in turn can divide and mutate further. Emerging heterogen-
eity may give rise to subclones that possess a fitness advantage over the others
within the tumour environment. Competing for space and resources these sub-
clones may become dominant in the tumour over time, or may coexist with other
subclones in spatially segregated focal lesions. Selective pressure may have en-
dogenous causes (nutrition or space shortage), but may also be externally caused
by treatment (resection, chemo- and radiotherapy) inducing a bottleneck effect;
where resistant subclones will survive and propagate to re-form a heterogeneous
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recurrent tumour (Greaves and Maley [90]) (Figure 1.1). The existence of resist-
ant subpopulations within otherwise drug susceptible tumours can be a challenge
for cancer treatment, reflected by progression or recurrence, which is almost in-
evitable in GBM. Our group, for instance, illustrated the phylogeny of 11 GBMs
based on integrated genomic analysis of spatial copy number data and showed
that a single tumour could fall into different molecular subtypes of GBM depending
on the spatial origin of the analysed tumour fragment (Sottoriva et al. [252]). One
extreme example of tumour heterogeneity in GBM is the mosaic amplification of
receptor tyrosine kinases (RTKs) (Snuderl et al. [250]). It was shown that different
RTKs can be co-amplified in a single cancer cell, but can additionally be ampli-
fied in different cancer cells within a single tumour forming subpopulations with
distinct growth factor responses (Szerlip et al. [263]) (for further details on EGFR
see Section 1.2.3 (EGFR amplification, variants and point mutations)).
Branched and linear evolution are not the only models of evolution, but they
are the least controversial and most frequently discussed forms of evolution in the
context of tumours. The discovery of chromothripsis, a single catastrophic event
"shattering" the genome causing multiple re-arrangements at once, has required
a change in how we think about tumour evolution (Stephens et al. [253], Forment,
Kaidi and Jackson [68] and Rausch et al. [222]). Tumourigenesis does not only
progress by gradual accumulation of oncogenic alterations, but can also occur
punctuatedly, suddenly and independent of selective pressure. In this context, the
theories of neutral evolution and punctuated evolution are gaining increasing at-
tention (Baca et al. [7], McGranahan and Swanton [184], Williams et al. [296] and
Davis, Gao and Navin [47]). Punctuated evolution, in which rapid bursts of genetic
alterations alternate with periods of relative genetic equilibrium, can be placed
between gradualism and catastrophe (Baca et al. [7]). Whereas selective pres-
sure plays a role in punctuated evolution, neutral evolution occurs independently
of selection, by genetic drift or by linkage with a nearby gene that is undergoing a
selective sweep (Williams et al. [296]).
1.1.1 The hallmarks of cancer
Darwinian evolutionary principles can be applied to cancer, but what permits some
cancer cells to live and be selected while others die? Cancer sequentially ac-
quires mutations, which accumulate and create a cancer genome that is often
significantly distinct from the germline genome. The mutational processes that
create a cancer genome can be operative from the very first division of the fer-
2
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Figure 1.1 | An illustration of clonal evolution in GBM.
A single founder cell (stem or progenitor) sequentially acquires mutations and expands into dif-
ferent subclones with distinct genotypes and phenotypes. These subclones compete for space
and nutrition, but can also coexist in spatially distinct niches causing intra-tumour heterogeneity.
Treatment (resection, radio- and chemotherapy) of the tumour may apply a selective pressure,
inducing a bottleneck effect, where resistant subclones will survive and propagate to re-form a
heterogeneous recurrent tumour.
tilised egg, but can also be sporadically triggered through individual life events.
Mutational processes are the consequence of many biological factors; exogen-
ous and endogenous mutagen exposure, enzymatic DNA modification (including
epigenetic remodelling), impaired DNA repair or the intrinsic infidelity of the DNA
replication machinery.
Specific mutations can give a cell certain advantages, but it is the interplay of
multiple distinct cell types in close interaction with each other and the surround-
ing tumour associated stroma, which defines a tumour. This tumour microen-
vironment consists of extracellular matrix (ECM), cellular components of haema-
topoietic origin, such as various types of immune cells, and cellular components
of mesenchymal origin, such as fibroblasts, myofibroblasts, mesenchymal stem
cells, adipocytes and endothelial cells. Taking the interplay between tumour and
its environment into account Douglas Hanahan and Robert Weinberg published
an article in Cell in 2000, summarising the complexity of cancer into six under-
lying principles (Hanahan and Weinberg [100]). The traits ("hallmarks") shared
3
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by all cancers are (1) Cancer cells stimulate their own growth (self-sufficiency in
growth signals); (2) They resist inhibitory signals that might otherwise stop their
growth (insensitivity to anti-growth signals); (3) They resist programmed cell death
(evading apoptosis); (4) They can multiply indefinitely (limitless replicative poten-
tial) (5) They stimulate the growth of blood vessels to supply nutrients to tumours
(sustained angiogenesis); (6) They invade local tissue and spread to distant sites
(tissue invasion and metastasis). In 2011 the authors updated their work and pro-
posed four additional hallmarks: (7) abnormal metabolic pathways, (8) evading
the immune system, (9) genome instability, and (10) inflammation (Hanahan and
Weinberg [99]).
In the following sections I will explore these hallmarks and give examples
in GBM (Figure 1.2). Many of these effects are achieved by disregulation
in three major core pathways: the receptor tyrosine kinase/ Rat sarcoma/
phosphatidylinositol-3-OH kinase (RTK/RAS/PI(3)K) pathway, tumour protein p53
pathway and the retinoblastoma pathway. All three pathways play major roles in
cell growth, proliferation and survival of the cell and their disregulation was the
key finding of The Cancer Genome Atlas (TCGA) project covering GBM altera-
tions (Cancer Genome Atlas Research Network [31]).
Figure 1.2 | The ten hallmarks of cancer with examples in gliomas.




1.1.2 Sustaining proliferative signalling
Cells normally grow and divide in a controlled manner; protecting tissue archi-
tecture and function through highly regulated processes in which the production
and release of growth-promoting signals are an important first step. Cancer cells
have the ability to disregulate this signalling, thereby promoting their own growth
and progression through the cell cycle. Division and growth are primarily initiated
by growth factors that bind cell-surface receptors, typically containing intracellu-
lar tyrosine kinase domains (receptor tyrosine kinase (RTK)). Activated receptors
phosphorylate downstream molecules, which in turn activate a branched network
of intra-cellular pathways controlling growth and proliferation, but can also influ-
ence survival and energy metabolism.
One frequently altered growth receptor in gliomas (and also in a variety of
other cancers including bladder tumours, breast carcinomas, squamous cell car-
cinomas of the lung, and head and neck cancer) is the epidermal growth factor
receptor (EGFR) (Gullick [96]). EGFR is activated through binding of its ligands,
epidermal growth factor (EGF) and members of the EGF-family (Ushiro and Co-
hen [274]), leading to autophosphorylation of the receptor followed by activation
of its downstream pathways: JAK/SRC/STAT, PI3K/Akt, MAPK/ERK pathway and
PLC/DAG/PKC 1 (Oda et al. [203]). The activation of these pathways results in
the up- or downregulation of genes encoding important players in cell cycle pro-
gression, cell survival, proliferation, differentiation, angiogenesis and apoptosis
(Oda et al. [203]). In gliomas EGFR can either be highly amplified (Libermann
et al. [160]), resulting in enhanced signalling, or it can be structurally altered en-
abling it to be constitutively active (ligand-independent activation), as is the case
with the EGFR variant III (EGFRvIII) (Huang et al. [118]). The amplification of a
mutant, constitutively active EGFR is also quite common. A detailed summary
of EGFR alterations and their implications can be found in Section 1.2.3 (EGFR
amplification, variants and point mutations).
Besides EGFR, which is (at 45%) the most frequently altered member of this
signalling pathway in GBM (Cancer Genome Atlas Research Network [31]), a
disregulation of proliferation can also be caused by structure altering mutations
in downstream proteins. Amplification or activating mutations of PIK3CA and
PIK3R1, encoding a subunit of PI3K (a family of proliferation associated en-
zymes), have been found in approximately 15% of patients with GBM (Cancer
Genome Atlas Research Network [31]).
1januskinase (JAK), tyrosine kinase sarcoma (Src), signal transducers and activators of tran-
scription (STAT), phosphoinositide 3-kinase (PI3K), mitogen-activated protein kinase (MAPK), ex-
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1.1.3 Evading growth suppressors
Enhanced signalling can be achieved not only by the activation of oncogenes,
but can also be the result of altered tumour suppressor gene function or expres-
sion. This leads us to the second fundamental trait of cancer cells, the capacity to
evade the molecular mechanisms of growth suppression that negatively regulate
cell proliferation. Loss of function mutations, chromosomal deletions, or epigen-
etic gene silencing of phosphatase and tensin homolog (PTEN), an inhibitor of
PI3K, have been found in approximately 36% of GBM cases (Cancer Genome At-
las Research Network [31]). Many other tumour suppressors operate in pathways
linked to proliferation. The most studied examples are the suppressor genes tu-
mour protein 53 (TP53), which plays a key role in the apoptosis pathway and cell
cycle arrest (Levine, Vogelstein and Lane [157]), and retinoblastoma-associated
(RB) which operates as a central node in cell cycle progression (Giordano and
Giacinti [86] and Burkhart and Sage [27]). Both pathways are frequently found to
be altered in GBM (Cancer Genome Atlas Research Network [31]).
The p53 pathway responds to various cellular stress signals, including DNA
damage, cell cycle abnormalities, and hypoxia. Upon activation TP53 changes
confirmation and acts as transcription regulator for many different genes involved
in DNA-repair, cell cycle arrest, and apoptosis. Loss of function mutations and
deletion of TP53 are detected in more than half of human cancers (Levine, Vo-
gelstein and Lane [157]). Although more common in low-grade glioma (LGG),
approximately 35% of GBM harbour TP53 mutations (Cancer Genome Atlas Re-
search Network [31]). Without functioning TP53, damaged cells which cannot be
repaired will escape apoptosis, leading to the proliferation of cells which would
not normally progress in the cell cycle. The replication of damaged genomes can
lead to catastrophic genomic instability including gross changes in chromosome
number and arrangement (Hanel and Moll [101]).
1.1.4 Resisting cell death
The two major pathways of cell death are apoptosis and necrosis, which remove
unwanted or damaged cells. These mechanisms are interconnected on several
levels and there are a large number of highly diverse cell death inducing signals.
A major feature of cancer cells is their ability to overcome and avoid cell death in-
ducing signals. Apoptosis is a cell-intrinsic programmed suicide mechanism that
results in the controlled breakdown of the cell into apoptotic bodies, consisting of




cytoplasm with tightly packed organelles (Elmore [58]). These bodies are sub-
sequently recognised and engulfed by surrounding cells and phagocytes and no
cellular constituents are released into the surrounding interstitial tissue. The apop-
totic signals can either be intrinsic (including DNA damage and cytotoxic insults)
or extrinsic (via death receptor activation), converging in a caspase cascade that
results in cellular shrinkage, DNA fragmentation and eventually apoptosis. These
pathways are disrupted in GBM. TP53, earlier mentioned as transcription factor
in the context of evading growth suppressors (1.1.3), also regulates pro-apoptotic
B-cell lymphoma 2 (BCL-2) family members (BCL2 Associated X (BAX) and Bcl-
2 homologous antagonist/killer (BAK)), and binds and inhibits the anti-apoptotic
family members (B-cell lymphoma-extra large (Bcl-xL), Bcl-2-like protein 2 (Bcl-
w), Induced myeloid leukemia cell differentiation protein (Mcl-1) and Bcl-2-related
protein A1 (A1)). In a healthy cell these regulatory proteins are carefully counter-
balanced. In a study comparing the expression of Bcl-2 family proteins in initial
and recurrent GBM, a significant upregulation of the anti-apoptotic proteins Bcl-
2, Bcl-xL, and Mcl-1 and a significant downregulation of pro-apoptotic BAX was
shown in treated and untreated recurrent tumours (Strik et al. [258]). A majority
of studies report decreasing Bcl-2 levels with increasing tumour grade in astrocyt-
omas, but no correlation between Bcl-2 expression and progression-free survival
(Eisele and Weller [57]).
The prevailing form of spontaneous cell death found in GBM is necrosis, which
is one of the characteristics for the neuropathological diagnosis of GBM and cor-
relates negatively with patient survival (Lacroix et al. [147]). Necrosis is character-
ised by cytoplasmic and organelle swelling, followed by the loss of cell membrane
integrity, and the release of the cellular contents into the surrounding extracellular
space. As opposed to apoptosis, necrosis was for a long time considered to be
an uncontrolled, more accidental form of cell death, which is true for really severe
forms of physical damage. However, accumulating evidence supports the exist-
ence of caspase-independant necrotic cell death pathways that can function even
in a strictly regulated developmental context (Galluzzi and Kroemer [75]). Import-
antly, necrotic cells can recruit inflammatory cells of the immune system by releas-
ing pro-inflammatory signals into the surrounding tissue (Grivennikov, Greten and
Karin [94]). While inflammatory cells in non-neoplastic tissue remove debris and
asses the damage, immune inflammatory cells can be actively tumour promot-
ing by supporting cancer cells in angiogenesis, proliferation, and invasiveness; all
processes typically found highly active in GBM which will be further discussed in
1.1.6 (Inducing angiogenesis) and 1.1.9 (Tumour-promoting inflammation). This
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tumour promoting aspect of necrosis is hypothesised to be responsible for the
shorter survival of patients with high necrosis (Kepes [139]).
1.1.5 Enabling replicative immortality
Even kept under optimal growth conditions, a normal human cell population will
only divide for a limited number of cycles before reaching senescence, a phe-
nomenon demonstrated by Leonard Hayflick (Hayflick and Moorhead [104] and
Shay and Wright [244]). In contrast, cancer cells have a limitless ability to divide,
overcoming the cellular restrictions normally preventing immortality. A major step
in understanding immortality was the finding that telomeres, which protect the
ends of linear chromosomes, are centrally involved in the capability for unlimited
proliferation (Blasco [14] and Shay and Wright [244]). Telomeres are specialised
repetitive DNA sequences composed of multiple tandem hexanucleotide repeats
that serve to maintain the integrity of chromosomes. These repeats shorten pro-
gressively in non-immortalised cells propagated in culture. Stem cells in self-
renewing tissues, which need to divide for a lifetime, have the capability to main-
tain telomere length by expressing telomerase, a ribonucleoprotein DNA poly-
merase complex that elongates the chromosome ends (Morin [189] and Hiyama
and Hiyama [112]). Telomerase, which comprises the protein telomerase reverse
transcriptase (TERT) and a catalytic RNA (TERC), is absent in most normal hu-
man somatic cells (Greider and Blackburn [92] and Feng et al. [64]). Without
telomerase, telomere shortening eventually limits cell growth, either by senes-
cence, in cells with intact cell cycle checkpoints (a G1 cell cycle block), or by
crisis in cells with inactivated checkpoints (telomeric end-to-end fusions cause
chromosome breakage and mitotic catastrophe) (Shay and Wright [245]). Ex-
pression of TERT in cells that otherwise lack telomerase activity causes cells to
bypass senescence and crisis.
It was shown that certain cancer types harbour point mutations in the promoter
of the gene TERT, which encodes the catalytic subunit of the telomerase (Vinagre
et al. [280]). In a study comparing the abundance of TERT mutations between dif-
ferent tumour types it was shown that the frequency of TERT promoter mutations
was remarkably high in primary GBM (83% of 78 tumours), while it was rarely
found in any other astrocytoma (Killela et al. [140]). Specifically, one of two G?A
transitions (G228A and G250A), is also frequently altered in other cancer types.
Both mutations are associated with increased TERT expression and telomerase
activity. The resulting sequence creates a de novo binding site for E26 transform-
ation specific (ETS) transcription factors (Horn et al. [116], which was shown to
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selectively bind the transcription factor GA-binding protein (GABP) activating the
mutant TERT promoter (Bell et al. [10]).
Another player in telomere biology, frequently mutated in cancer, is the ౖ-
thalassemia/mental retardation syndrome X-linked (ATRX) protein (Heaphy et al.
[105], Jiao et al. [132] and Schwartzentruber et al. [240]). ATRX and its binding
partner, death-associated protein 6 (DAXX), are central components of a chro-
matin remodelling complex required for the localisation and incorporation of H3.3
histone proteins into the telomeric regions of chromosomes (Goldberg et al. [88]
and Lewis et al. [158]). ATRX mutations are hypothesised to cause alternative
lengthening of telomeres (ALT) leading to genome instability. In gliomas ATRX
mutations are shown to be restricted to IDH-mutant subtype (Jiao et al. [133] and
Kannan et al. [136]) (see Section 1.2.2 (Genetic markers and classification of
glioma into subtypes (isocytrate dehydrogenase (IDH) mutations)).
1.1.6 Inducing angiogenesis
The ability of cancer cells to induce angiogenesis is crucial for the tumour to main-
tain a sufficient nutrient and oxygen influx and metabolic waste efflux while grow-
ing. Angiogenesis is the physiological process through which new blood vessels
form from pre-existing vessels, while vasculogenesis is the de novo formation
of blood vessels (Patan [213]). The latter happens through the birth of new en-
dothelial cells from mesodermal cell precursors and is, in healthy individuals, re-
stricted to the developing embryo. In contrast, angiogenesis can be transiently
switched on in adult tissue in physiologic processes such as wound healing and
during the female reproductive cycle.
Cancer cells, however, can gain the ability to keep this "angiogenic switch"
turned on. Normally quiescent vasculature receives a continuous signal to sprout
new vessels, which supply the tumour with necessary nutrients allowing for sus-
tainable neoplastic growths. Brain tumours, especially GBM, show the highest
degree of vascular proliferation, compared to other solid tumours (Brem, Cotran
and Folkman [23]). In gliomas angiogenesis is accepted as a key event in the pro-
gression of gliomas and is used in glioma classification to distinguish low-grade
from high-grade diffuse astrocytoma. Microvascular proliferation is a diagnostic
criterion and an independent prognostic marker for gliomas, correlating directly
with the aggressiveness of the tumour, its clinical recurrence, the degree of malig-
nancy and the post-operative survival of patients. The vascular endothelial growth
factor (VEGF) plays a central role in the angiogenic switch, but it is further or-
chestrated by a simultaneous increase in the expression of other genes, such
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as FGF, IL-8 and -6, hypoxia-inducible factor 1 alpha (HIF-1ౖ) and the angiopoi-
etins. Moreover, downregulation of endogenous angiogenesis inhibitors, such as
thrombospondins, angiostatin, endostatin and interferons contributes to sustained
angiogenesis. VEGF binding to VEGF receptor initiates an increase of vascular
permeability and leads to characteristic morphological changes of the blood ves-
sels, such as enlargement of the diameter, basement membrane degradation, an
increase in endothelial cells and a decrease in pericyte number and their detach-
ment.
Drugs have been developed to disrupt tumour angiogenesis, many of them
blocking the interaction of VEGF and its receptor. For instance, Bevacizumab
(Bev), a humanised anti-VGF monoclonal antibody, was approved by the food and
drug administration (FDA) as a second line treatment for GBM in 2009 based on
two single-arm trials (AVF3708g and NCI 06-C-0064E) (Friedman et al. [72]) and
is still under review in clinical trials testing combination treatments in newly dia-
gnosed GBM. Although Bev improves progression-free survival (PFS) and overall
survival (OS) in recurrent GBM, an improvement in newly diagnosed GBM was not
observed (Diaz et al. [52]). Another, more controversial, type of vascularisation is
vasculogenic mimicry in which certain types of tumour cells can mimic endothelial
function, instead of endothelial cells forming blood vessels (Hendrix et al. [108]).
This has also been demonstrated in GBM (Angara, Borin and Arbab [5]). Since
the discovery of vasculogenic mimicry in 1999 (Maniotis et al. [180]) an emerging
field of research is looking into pathway identification to exploit this feature as an
alternative way to prevent vascularisation.
1.1.7 Activating invasion and metastasis
The best characterised mechanism of invasion and metastasis is the epithelial-
mesenchymal transition (EMT) in carcinomas; tumours originating from epithelial
cells. EMT is a regulatory program during embryonal development and wound
healing, in which cells lose their epithelial characteristics by breaking their cell-
cell contacts and by downregulation of adhesion molecule expression, such as
E-cadherin. This enables cells undergoing EMT to migrate from the basal mem-
brane to their new destination, where they can change back into epithelial cells
(mesenchymal-epithelial transition (MET)). EMT-derived migratory cancer cells
typically establish secondary colonies at distant sites that resemble, at the his-
topathological level, the primary tumour from which they arose. The classical
EMT-mediated model for tumour metastasis was developed through studies in
colon cancer (reviewed in Brabletz et al. [20] and Tsai and Yang [269]), but sim-
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ilar, EMT-like mechanisms also operate in non-epithelial cancers like GBM (Iser
et al. [124]).
Some cancers, mainly originating from lung and breast, commonly spread
into the brain, whereas metastases originating from glioma are rarely found out-
side the central nervous system (CNS) (0.4-2%) (RAY et al. [223]). Patients who
present with multiple cerebral tumours with no existing history of a primary tumour
are more common (Giannopoulos and Kyritsis [81]). In recurrent GBM approxim-
ately a third of patients will present with a tumour remote to the primary lesion.
Phylogenetic analysis of such remotely occurring tumours traced their lineage
back to the primary lesion, demonstrating the migrative capabilities of GBM (Kim
et al. [142]). The limitation of GBM metastasis within the brain is hypothesised to
have several reasons: the blood-brain-barrier (BBB), a short patient survival after
initial diagnosis (which does not allow sufficient time for extra-cranial metastasis
to develop), the extra-neural tissues may not contain the right milieu of growth
factors that are capable of supporting glioma growth, and the involvement of the
immune system when a GBM cell has breached the BBB.
Even though metastasis formation is rare, invading brain parenchyma, due to
the infiltrative nature of glioma growth, is well established and considered to be
a hallmark of GBM (Scherer [235]). The invasive nature of GBM leads to local
destruction of healthy tissues, and is the main source of recurrence, as single
cells away from the main mass are difficult to detect and are often left behind in
surgery. Migrating GBM cells use routes along blood vessels (Gritsenko, Ilina and
Friedl [93]) and along white matter tracts (Esmaeili et al. [61]). Cell migration in
glioma is tightly coupled to a change in energy metabolism which allows the cells
to switch from a proliferating to a migrating phenotype, which are shown to be mu-
tually exclusive (Giese et al. [83]). This metabolic change is caused by increas-
ing hypoxia and nutrient deprivation in the necrotic core of the tumour, causing
the surrounding, pseudopalisading cells to produce or activate pro-migratory and
pro-invasive factors. Among these factors are metalloproteases, disintegrins and
other ECM remodellers, but also EMT- transcriptional regulators like Slug (SNAI2)
and Snail (SNAI1) that repress E-cadherin expression. Apart from ECM remod-
elling and loosening cell attachments, glioma cells also undergo a shape change
to be able to navigate through the narrow space of the brain parenchyma. Glioma
cells are able to reduce their volume by more than 30% by releasing cytoplasmic
water (Watkins and Sontheimer [288]). This release is regulated by aquaporins




1.1.8 Genome instability and mutation
In normal tissue, genome maintenance systems protect the integrity of the DNA,
including its methylation and histone modifications, ensuring low rates of spon-
taneous mutations and epigenetic alterations. In the process of tumour formation,
however, these maintenance systems themselves can be affected by alterations
leading to a decreased efficiency in repair and detection of further alterations
and, subsequently, to an accelerated mutation rate. For instance, a congenital
biallelic mutation in the mismatch repair (MMR) system is characterised by sys-
temic somatic hypermutation and leads to a form of childhood GBM as well as
other tumours. A deficiency in the MMR system, caused by either an inherited
germline mutation in a MMR gene or its epigenetic silencing, also leads to gen-
ome instability in form of microsatellite instability (MSI) and can be found in ap-
proximately 15% of colorectal cancers. Furthermore, there is evidence that LGGs
treated with temozolomide (TMZ) are more likely to recur as a hypermutated GBM
than LGGs that were not treated with TMZ, which depends by its mode of action
on a functioning MMR pathway. This topic will be further discussed in Section
1.2.1 (Treatment) and Section 1.2.2 (Mutations in DNA mismatch repair). TMZ
treatment-independent MSI in GBM, however, is a rare event (Cortes-Ciriano et
al. [45]). Genome instability refers, moreover, to accelerated rates of chromo-
somal alterations, such as copy number alteration (CNA) and aneuploidy. Chro-
mosome aberrations will be further discussed in Section 1.1.13 (Chromosomal
aberrations).
1.1.9 Tumour-promoting inflammation
The infiltration and invasion of cells of the immune system into tumour tissue was
noted as early as 150 years ago. Rudolf Virchow hypothesised that inflammation
is a predisposing factor of tumourigenesis, whereas later research focused on im-
mune cell infiltration as solely being an attempt of the immune system to destroy
the tumour (Balkwill and Mantovani [9] and Bremnes et al. [24]). Further stud-
ies made clear that the tumour associated inflammation paradoxically contributes
to enhanced tumourigenesis and tumour progression rather than to an effective
anti-tumour response. Moreover, epidemiological studies have shown that people
prone to chronic inflammatory diseases have an increased risk of cancer devel-
opment and that 15 to 20% of all cancer deaths worldwide have been associated
with underlying infections and inflammatory response, which brought Virchow’s
idea back into the picture (Balkwill and Mantovani [9] and Bremnes et al. [24]).
Cross talk between tumour cells and inflammatory cells in the tumour microenvir-
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onment can lead to the release of bioactive molecules, such as growth factors that
sustain proliferative signalling, survival factors that limit cell death, pro-angiogenic
factors, extracellular matrix-modifying enzymes that facilitate angiogenesis, inva-
sion, and metastasis, that lead to activation of EMT and other hallmark-facilitating
programmes. In gliomas, pro-inflammatory gene and protein expression patterns
compared to peritumoural tissue was observed and are also induced in vitro in
GBM derived stem cells under hypoxia. This led to the conclusion that hypoxia,
due to rapid tumour growth, causes the expression of pro-inflammatory proteins
(such as nuclear factor ’౟-light-chain-enhancer’ of activated B-cells (NF-౟B)) that,
in turn, allow tumour stem cells to activate molecular survival mechanisms, such
as the ability to migrate, in response to necrotic cell death (Tafani et al. [265]).
1.1.10 Reprogramming energy metabolism
In 1956 Otto Warburg postulated that a change in metabolism is the fundamental
cause of cancer. As compared to normal cells, which produce energy at a low
rate by glycolysis followed by oxidation of pyruvate in mitochondria (aerobic), most
cancer cells predominantly produce energy at a high rate by glycolysis followed
by lactic acid fermentation in the cytosol (anaerobic) (Warburg [285] and Wein-
house et al. [290]). The glycolytic rates of malignant, rapidly growing tumour cells
can be up to 200 times higher than those of their healthy tissues of origin even if
oxygen is plentiful, yet glycolysis does not account for the total adenosine triphos-
phate (ATP) production in many types of cancer cells (Vander Heiden, Cantley
and Thompson [277]).The Warburg Effect has been observed in gliomas (Oudard
et al. [210]), but primary-cultured human GBM cells were also highly oxidative
and largely unaffected by treatment with glucose or inhibitors of glycolysis (Lin
et al. [161]). Further evidence that glycolysis is not always the primary pathway of
metabolism in gliomas is that imaging recurrent GBM using fluorodeoxyglucose
uptake as a method (e.g., FDG-PET) is not reliable. More than 30% of recurrent
gliomas are not detected with this technique, despite being detected by contrast
magnetic resonance imaging (MRI) (Belohlávek et al. [11]).
There is growing evidence that due to the heterogeneous nature of GBM,
there are different cells using different pathways to produce energy. For instance,
proliferating glioma cells produce their energy mainly through the pentose phos-
phate pathway, whereas glycolysis is the main energy source during migration
(Kathagen-Buhmann et al. [137]). A cell cannot display both phenotypes at the
same time, but the coexistence of proliferating and migrating populations within
the same tumour is possible. Moreover, it was shown that glioma stem cells
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(GSCs) consume less glucose and produce lower amounts of lactate while main-
taining higher ATP levels compared to differentiated glioma cells. As the radio-
resistance of this cell population is correlated with higher mitochondrial reserve
capacity, the authors concluded that glioma stem cells primarily rely upon oxid-
ative metabolic strategies (Vlashi et al. [281]). Detailed reviews on gliomas and
their metabolism have recently been published by (Agnihotri and Zadeh [1] and
Strickland and Stoll [257]).
1.1.11 Evading immune destruction
An interesting question which arises is how cancer cells can evade the immune
system, which is constantly scanning for defective or infected cells in the body.
In 1970 Burnet proposed that the immune system is responsible for eliminating
or inactivating potentially dangerous mutant cells (Burnet [28]). Evidence for the
involvement of a defective immune system in cancer formation was provided by
the observation of a striking increase of certain cancers in immunocompromised
individuals (Vajdic and Leeuwen [275]) and immunocompromised mice. How-
ever, most of these tumours were of viral origin, suggesting that the compromised
immune system failed to suppress the virus rather than promoted the tumour.
However, cancer does not only arise in immunodeficient individuals, but also in
otherwise healthy people. If cancer cells acquire genetic changes that allow them
to withstand or avoid the surveillance or killing process by normal immune cells,
they can continue to grow and proliferate. These cells can then signal the immune
system to slow down immune reactions or stop them completely, shaping the im-
mune landscape in which they are growing (Wellenstein and de Visser [292]).
The brain, compared to the rest of the body, exhibits a unique environment
with a distinctive composition of the ECM and physical protection by the BBB and
was originally described as an almost immune-cell free environment. With fur-
ther investigation it became apparent though that the brain, even with essentially
no trafficking or patrolling peripheral immune cells in the healthy state, is cap-
able of immune responses (Louveau, Harris and Kipnis [171] and Louveau et al.
[172]). The main type of active immune cells in the brain are microglia, a special
type of macrophage. Microglia develop from embryonic yolk sac progenitor cells
(Ginhoux et al. [85] and Gomez Perdiguero et al. [89]) and are not replenished
postnatally through peripheral mononuclear hematopoiesis. Their maintenance in
the adult brain is thought to occur through local proliferation and prolonged cellular
longevity (Ajami et al. [2] and Gomez Perdiguero et al. [89]).
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Under pathological conditions, bone marrow-derived macrophages (BMDMs)
get recruited to the site of disruption (Shi and Pamer [246]) and, in brain tumours,
get replenished during tumour progression where the integrity of the BBB can
become compromised and permissive to inflammation (Weiss et al. [291]). Both
types of macrophage are present in high numbers in the microenvironment of
brain tumours as tumour-associated macrophages (TAMs), which tend to be pro-
tumourigenic. TAMs accumulate with higher tumour grade (Komohara et al. [144])
and can comprise up to 30% of the tumour mass. The switch from a tumour-
suppressive to a tumour-supportive, immunosuppressive phenotype can be initi-
ated by GBM cells in a hypoxic environment. It has been shown that TAMs are
modulated by GSCs under hypoxic conditions inducing an immunosuppressive
phenotype via the STAT3 pathway (Wu et al. [298]).
A common mechanism by which tumours evade the immune system is by ex-
ploiting programmed death signalling. Programmed cell death protein 1 (PD-1) is
constitutively expressed on activated T cells, B cells and other myeloid cells. Re-
lease of interferon gamma (IFN-ౘ) by activated T-cells during inflammation directly
induces local Programmed cell death ligand 1 (PD-L1) expression on surrounding
cells. The interaction of lymphocyte-expressed PD-1 and PD-L1 leads to an in-
hibitory feedback signal that suppresses T cell proliferation and cytokine release
and induces T cell anergy, apoptosis and the development of regulatory T cells.
In normal tissue this signalling minimises the tissue damage incurred with pro-
longed inflammatory responses and prevents the development of autoimmunity
by inducing peripheral tolerance of self antigens (Keir et al. [138]).
Elevated PD-L1 expression has been associated with aggressive disease and
poor prognosis in several cancers, while in others PD-L1 expression was asso-
ciated with evidence of a strong anti-tumour immune response, in which patients
benefitted from robust anti-tumour inflammation, but some were also lacking PD-1
expression in infiltrating effector cells (Filley, Henriquez and Dey [66]). A blockage
of this pathway with monoclonal antibodies, such as Nivolumab and Pembroli-
zumab, led to promising results in the first clinical trials and they are now FDA
approved for the treatment of a variety of cancers, such as melanoma, colorectal
cancer, renal cancer and small cell lung cancer (https://www.drugs.com). The
first large phase III trial of Nivolumab in patients with GBM (CheckMate 143,
NCT02017717) was initiated in January 2014, but was prematurely terminated
as Nivolumab failed to extend OS in patients with recurrent GBM compared to
Bev (Filley, Henriquez and Dey [66]. It was shown that circulating monocytes in
patients with GBM had significantly increased expression of PD-L1 compared to
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healthy controls and that TAMs from matched GBM tissue had even higher pre-
valence of PD-L1 expression (Bloch et al. [15]).
1.1.12 Mutational patterns and signatures in cancer
So far we have looked at single mutations in specific genes in the context of al-
terations in important pathways, but neglected the bigger picture in which they
occur. The first description of a signature produced by a mutational process was
made by in vitro experiments on UV light exposure, where C?T or CC?T muta-
tions were observed at dipyrimidine sites (Pfeifer, You and Besaratinia [216]). The
formation of these pyrimidine dimers is linked to skin cancer (Brash [22]). With
the development of Sanger Sequencing in the early 1990s it became possible to
explore mutational signatures through a small number of frequently mutated can-
cer genes like TP53. Several studies analysed the mutational pattern in TP53 of
different cancer types and compared the mutational spectra to mutations gener-
ated in in vitro or in vivo systems, confirming the mutational pattern of UV light in
skin cancer and allowing researchers to associate other mutational patterns with
known carcinogens (Pfeifer et al. [217] and Olivier, Hollstein and Hainaut [205]).
There were two limitations to this approach though. Firstly, the actual mutational
pattern caused by DNA damage and repair mechanisms is superimposed on, and
needed to be distinguished from, the mutational pattern left by the selective pres-
sure on driver genes. Secondly, the focus was mostly on cancer types caused
by known carcinogens, such as tobacco or UV light. In 2012, Nik-Zainal et al.
published their work on the mutational processes which formed 21 breast can-
cers (Nik-Zainal et al. [197]) and expanded their work to all cancer types one year
later (Alexandrov et al. [3]). In these studies the mutations found were separated
into mutational patterns caused by mutational processes with different strength,
driven by different factors and active at different time points and for different peri-
ods. To increase the resolution of these derived mutational signatures, mutations
were analysed in their immediate base pair context. The base pair context of a
substitution includes the base immediately 6༚ before the substitution and the base
immediately 4༚ after the substitution, leading to 96 mutation types, six types of
somatic substitutions (C?A, C?G, C?T, T?A, T?C, T?G) in 16 possible base
pair constellations. Taking the immediate base pair context into account allows
a distinction between C?T transitions caused by UV light (i.e. C?T mutations at
dipyrimidine sites such as TpCpC or CpCpC) from C?T transitions due to deam-
ination of 5-methylcytosine (i.e. C?T mutations at CpG sites), which can occur
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spontaneously. C?T transition due to deamination of 5-methylcytosine is the most
common single nucleotide mutation (Waters and Swann [287]).
Deamination of DNA can also happen to other bases, leaving lesions such
as uracil (cytosine), hypoxanthine (guanine) and xanthine (adenine). One major
contributor to deamination are reactive oxigen species (ROS) produced by redox
chemicals, physical agents like ionising radiation or oxidative phosphorylation as
part of the normal aerobic respiration. Deamination does not only occur under
oxidative stress, but can also be actively induced by "natural mutators" such as
the deaminases activation-induced cytidine deaminase (AID) and apolipoprotein
B mRNA-editing enzyme, catalytic polypeptide-like (APOBEC) (reviewed in Swan-
ton et al. [262]). In their normal roles, AID is responsible for B cell diversification by
its involvement in the processes of class switch recombination and somatic hyper-
mutation to help generate a diverse and high-affinity repertoire of immunoglobulin
isotypes (reviewed in Chaudhuri and Alt [36]) and APOBEC enzymes convert
cytosine to uracil during RNA editing and retrovirus or retrotransposon restriction
(reviewed in Smith et al. [248]). If not tightly regulated in their expression and
activity, these enzymes can be dangerous to the integrity of the genome and can
cause distinctive mutational patterns. Under normal circumstances, the cellular
repair of deamination products is predominantly carried out through base excision
repair (BER), involving DNA glycosylases and abasic site endonucleases to re-
pair the lesions. Mutations found in this pathway can facilitate the development of
cancer. One example is the higher risk of colorectal cancer with MYH-associated
polyposis, in which mutations of the MutY homologue (MYH) glycosylase lead to
the development of multiple adenomatous colon polyps. These can then turn from
benign to malignant and spread (Sampson et al. [231]). Besides BER, there are
other DNA repair pathways, such as the nucleotide excision repair (NER), special-
ising in the removal of bulky DNA adducts (i.e. bulky adducts of guanine caused
by tobacco carcinogens) or the MMR system, specialising in the repair of other
base-base mismatches and small indels.
In a high-throughput study, referred to as the "first global road map deciphering
the signatures of mutational processes in human cancer", 4,938,362 mutations
from 7,042 cancers across 30 different cancer types where analysed and classi-
fied (Alexandrov et al. [3]). The analysis revealed 27 distinct mutational signatures
of which 22 could be validated, three were classified as sequencing artefacts and
two remained un-validated. It was found that each cancer type harboured at least
two signatures, with up to six different signatures being operative in liver and uter-
ine cancer. By comparison of signatures with experimental data, possible causes
could be attributed to 11 signatures, of which two were signatures associated
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with the age at diagnoses and were present in 26 of the analysed cancer types.
One of these signatures (signature 1) showed clear features of the earlier men-
tioned C?T transitions at CpG sites caused by deamination of 5-methylcytosine
by normal cellular processes. These mutations happen prior to neoplastic devel-
opment. Signatures 2 and 23 were associated with APOBEC deaminases, which
predominantly cause C?T and C?G mutations at TpC sites. These signatures
were observed in 16 cancer types. With 17% of all cancer samples being af-
fected, the activity of this mutational process is one of the most significant human
carcinogens, more than tobacco and UV exposure.
For the identification of the aetiology of some signatures, it was not only the
type of substitution in its base pair context that helped to decipher the mutational
process, but also a clear strand bias of the mutations. Signature 4, for instance,
showed C?A mutations more prevalent on the transcribed strand than the coding
strand. Found in lung adeno, squamous and small cell carcinomas, head and
neck squamous, and liver cancers, this signature is associated with the removal
of tobacco smoke induced bulky DNA adducts to guanine by transcription-coupled
NER. In recurrent cancers previously treated with mutagenic cancer drugs, sig-
natures caused by the drug can be detected. For instance, Signature 11 is found
in malignant melanomas and GBM pretreated with the alkylating agent TMZ and
has mutational features very similar to those reported in GBM studies containing
recurrent samples (Hunter et al. [122]).
Figure 1.3 shows the three mutational patterns which have been identi-
fied in GBM. Signature 1, resulting from the spontaneous deamination of 5-
methylcytosine, is the most prevalent signature found in non-hypermutated GBM.
In recurrent GBM hypermutated by treatment with the alkylating agent TMZ
(explained in Section 1.2.2 (Mutations in DNA mismatch repair) on page 30),
C?T transitions still prevail, but instead of being in a NpCpG context they are
found in a NpCpC context (Hunter et al. [122]). Signature 5, which, like sig-
nature 1, has been found in all cancers and most cancer samples, exhibits
transcriptional strand bias for T?C substitutions in ApTpN context, but this sig-
nature is of unknown aetiology. More details and literature on mutational pat-




Figure 1.3 | Mutational signatures identified in GBM
Each signature is displayed according to the 96 substitution classification defined by the substitu-
tion class and sequence context immediately 4༡ and 6༡ to the mutated base. The probability bars
for the six types of substitutions are displayed in different colours. The mutation types are on the
horizontal axes and the vertical axes depicts the percentage of mutations attributed to a specific
mutation type. All mutational signatures are displayed on the basis of the trinucleotide frequency




In the previous section the focus was on the mutational landscape of cancer,
but another fundamental feature of cancer are chromosomal aberrations, both at
the numerical as well as the structural level. The first chromosomal abnormal-
ity described in cancer was the shortening of chromosome 22 in chronic myeloid
leukaemia (CML), named "Philadelphia chromosome" after the location where it
was discovered (Nowell and Hungerford [202]). Thirteen years later, with improv-
ing cytogenetic techniques, it was shown to arise due to a reciprocal translocation
between chromosomes 9 and 22 (Rowley [226]). It took another decade to identify
the resulting gene fusion of breakpoint cluster region (BCR) and abelson murine
leukemia viral oncogene homolog 1 (ABL) (Heisterkamp et al. [107] and Groffen
et al. [95]), which led to the development of BCR-ABL-tyrosine kinase inhibitor
Imatinib.
In GBM a lot of work on chromosome abnormalities was conducted in the
late 80s, summarised in Bigner et al. (Bigner, Mark and Bigner [13]). More re-
cent comprehensive genetic screens of GBM have confirmed these genetic al-
terations, re-defined their boundaries and identified others (Parsons et al. [212],
Cancer Genome Atlas Research Network [31] and Brennan et al. [25]). Chro-
mosome alterations in GBM are scattered across the entire genome, affecting
numerous chromosomes: 1p, 6q, 9p, 10p, 10q, 13q, 14q, 15q, 17p, 18q, 19q,
22q, and Y are frequently lost, whereas chromosome regions of 4, 7 and 12
are frequently gained. Losses of chromosome regions mostly include the loss
of specific tumour suppressors, such as the highly recurrent homozygous dele-
tions in cyclin-dependent kinase Inhibitors 2A and B (CDKN2A/B) on chromo-
some 9p21(Brennan et al. [25]) or heterozygous deletion of PTEN located on
10q23. Loss of heterozygosity (LOH) on chromosome 10 is the most frequent
genetic alteration in GBM, occurring in 60 to 80% of cases (Rasheed et al. [221]).
Genetic alterations resulting in elevated gene expression of the altered locus
are manifold and have been identified in GBM in the form of duplication of entire
chromosomes, focal amplifications (FAs) and activating mutations. FA of specific
genes can occur intrachromosomally, as homogeneously staining region (HSR),
or extrachromosomally, as double minute (DM), also referred to as extrachromo-
somal DNA (ecDNA). DMs are circular DNA molecules found in the nucleus, or
cytoplasm as micronuclei, and can propagate and replicate without centromere
and telomeres. Compared to chromosomal amplicons, which segregate equally to
daughter cells during mitosis, DMs segregate unequally to daughter cells thereby
possibly increasing tumour heterogeneity. The mechanism of segregation during
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mitosis is hitchhiking with chromosomes in a similar manner to viral nuclear epi-
some segregation during cell division. DMs have been identified in several cancer
types including GBM, LGG, ovary, breast, lung (Nielsen et al. [195]), colon (Quinn
et al. [219]), neuroblastoma (Balaban-Malenbaum and Gilbert [8]) and, in lower
frequency, in hematopoietic cancers (Streubel et al. [256]), but the scale at which
they occur has been underestimated for a long time. Based on the Mitelman data-
base, DMs occur in 1.4% of cancers with a maximum of 31.7% in neuroblastoma,
but a single large scale study specifically looking at ecDNA in 11 cancer types
detected ecDNA in nearly 90% of patient-derived brain tumour models (Turner
et al. [272]). DMs almost never occur in normal cells. Like HSRs, DMs contain
various types of oncogenes such as mouse double minute 2 homolog (MDM2),
cyclin-dependent kinase 4 (CDK4), MYC and EGFR, but can also contain genes
not classified as oncogenes.
The structure of DMs varies greatly from simple forms, with one amplified frag-
ment breaking off a chromosome and circularising without further rearrangements
(Storlazzi et al. [255]), to more complex structures, carrying multiple copies of the
same sequence or several fragments from different loci (Gibaud et al. [82]). The
structural differences of DMs are also reflected in their size range, which varies
from 0.1 Mb to 1 Gb. The formation of DMs is a topic of great debate. In some
cases it was shown to involve non-homologous end joining (NHEJ), especially act-
ive in tumours with defective homologous recombination, but other mechanisms
have also been confirmed. The formation seems to depend on the complexity
of the DM, its size and the loci involved. In AML the MYC locus, often amplified
on very simple small DMs, was shown to be deleted at one copy of chromo-
some 8, suggesting that this fragment has broken off the original sequence to
form an extrachromosomal molecule, and the mechanism was described as the
episome model (Storlazzi et al. [255] and Huh et al. [119]). In contrast, GBM,
frequently bearing EGFR amplifications on DMs, did not show any deletions or
re-arrangements at the original locus on chromosome 7 (Vogt et al. [282]). Look-
ing at a more complex structure in GBM involving four different loci, Gibaud et
al. showed microhomology-based-NHEJ involved in the formation of three frag-
ments, but proposed V(D)J-like illegitimate recombination for the fourth fragment
(Gibaud et al. [82]).
Other groups working on tumours with shattered genomes propose chromo-
thripsis as the mechanism responsible for DM formation (Sanborn et al. [232] and
Stephens et al. [253]), but the order in which events occur still remains unclear
so that one model does not necessarily exclude another. One approach to bring
more clarity into the formation of DMs is to distinguish smaller episomally replicat-
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ing circular structures lacking centromeres from bigger neochromosomes, which
carry centromeres and can also exist in linear form (giant markers) with telomeres
(Garsed et al. [78]). Taking all the results on DM formation together, it is clear that
there is not one single mechanism responsible for DM formation, but rather an
interplay of different events and different repair mechanisms leading to different
types of DMs or neochromosomes.
The question whether extra- and intrachromosomal amplifications share a
common origin and which came first may vary from case to case, but reintegration
of ecDNA into chromosomes is possible. It was shown that, in a spontaneously
occurring sub-clone of GBM39 cells, a high copy number of EGFRvIII shifted from
ecDNA exclusively to a HSR, not present in the original cells (Turner et al. [272]).
This dynamic reintegration of ecDNA to chromosomal HSRs while maintaining
key structural features such as specific mutations and CNAs contributes greatly
to the development of drug resistance. Standard short-range bulk sequencing
cannot spatially resolve amplicons to specific chromosomal or extrachromosomal
regions, but DMs can be detected through bioinformatic analysis inferring DNA
circularity by gene fusions. Due to the unequal distribution of ecDNA during cell
division, the number of extrachromosomal amplicons can vary from cell to cell.
Consequently, oncogene copies amplified extrachromosomally may be greatly un-
derestimated when using only standard sequencing techniques, but numbers can
be revealed by integrating cytogenic analysis of tumour cells during metaphase. A
major drawback of this approach is that DMs are lost in cell culture after a couple
of passages, possibly due to the absence of the selective pressure that supported
their formation and establishment in the first place. To avoid this problem, groups
working on EGFR amplifications and mutations in GBM may passage their cell
lines in matrigel in the flank of nude mice (Carlson et al. [34]).
1.2 Glioblastoma multiforme
Gliomas are tumours of the central nervous system, which develop in the brain,
and less frequently, in the spine. The World Health Organisation (WHO) sub-
divides these tumours according to their histological grade, which indicates the
differentiation status of the tumour, its malignant potential, the response to treat-
ment and the survival of the patient. The classes range from grade I, the least ag-
gressive form with the best outcome, to grade IV, Glioblastoma multiforme, which
is the most malignant form of astrocytoma and the most common primary brain
cancer in adults (Louis et al. [168]) (Table 1.1). GBM is characterised by aggress-
ive invasion, diffuse infiltration of the surrounding brain tissue, strong vascularisa-
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Table 1.1 WHO glioma classification (2007) based on the histological features of the tumour.
WHO
grade











































tion, necrosis and high proliferation. It can arise de novo as primary GBM or can
evolve from a lower-grade tumour (secondary GBM). In 2016 the WHO updated
and restructured their classification system by incorporating molecular paramet-
ers to complement histological features (Louis et al. [169]). A short summary of
glioma classification will be given in 1.2.2. The median survival in the untreated
general patient population is around four months. Even under optimal treatment
the median rate increases to only 14 to 16 months with a 2.5-year survival around
8% (Gil-Salú et al. [84], Erpolat et al. [60] and Smoll, Schaller and Gautschi [249]).
The standard therapy is resection, radiation and treatment with TMZ, described in
more detail in 1.2.1 (Treatment).
1.2.1 Treatment
The current treatment of GBM is a multimodal approach of maximal surgical re-
section followed by six weeks of radiotherapy with a total of 60 Gray (Gy) given
as two Gy per daily fraction (Monday to Friday) with concomitant chemotherapy
75 mg per square meter of body-surface area TMZ daily. This is followed by six
cycles of adjuvant chemotherapy consisting of 150-200 mg per square meter for
five days during each 28-day cycle (Stupp et al. [260]). The treatment for the
23
1. Introduction
patient is decided individually based on tumour progression, the patient’s age
and the patient’s general medical performance calculating risk against benefit.
For instance, patients older than 70 years often receive less aggressive therapy
employing radiotherapy or TMZ alone (Iwamoto et al. [127]). The MD Anderson
Cancer Center found that resecting 98% or more of the tumour volume strongly
correlated with longer survival rates in patients with GBM (Lacroix et al. [147]). It
was shown that extensive resection increases the median survival of patients from
8.8 to 13.2 months. The development of fluorescence-guided surgical resection
(FGR) improved the quality of the surgery noticeably by helping distinguish and
identify tumour tissue (Stummer et al. [259]). FGR is based on the oral adminis-
tration of 5-aminolevulinic acid (5-ALA), an endogenous intermediate of the por-
phyrin biosynthesis pathway, six hours prior to surgery (Colditz, Leyen and Jeffree
[42]). The fluorescent protoporphyrin IX (PPIX) accumulates in high-grade glioma
(HGG) tissue and can be visualised under ultraviolet light (440 nm). In the nor-
mal and peri-tumoural brain tissue, PPIX can only be detected as low background
concentrations due to its quick conversion into heme by ferrochelatase (FECH).
One hypothesis for PPIX accumulation in HGG is a downregulation of FECH in
the malignant tissue (Teng et al. [267]).
Due to the challenges of crossing the blood brain barrier, drug treatment is
often limited, contributing to the poor prognosis of GBM patients. Currently, the
standard drug used in chemotherapy is the lipophilic, monofunctional alkylating
agent TMZ, which was first approved for anaplastic astrocytoma in 1999 and be-
came a first line treatment for GBM shortly thereafter (Newlands et al. [193] and
Friedman, Kerby and Calvert [71]). It is administered orally and is well tolerated,
with main toxicities of mild nausea, vomiting, and dose limiting myelosuppres-
sion (Newlands et al. [192]). It can be given in combination with other cytotoxic
drugs, cytostatic agents and signal transduction modulators. TMZ is a prodrug,
which rapidly decomposes after uptake at a pH greater than 7 to form monomethyl
triazene 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide. This compound fur-
ther reacts with water to form 5-amino-imidazole-4-carboxamide and the methyl-
diazonium cation. The cation then introduces alkyl groups at multiple sites along
the DNA backbone, also at methylated O6-position in guanine (O6-meG), thereby
impairing DNA replication and inducing tumour cell death by apoptosis (Zhang,
Stevens and Bradshaw [304]). Patients showing promoter methylation of the
MGMT gene are more susceptible to TMZ activity than patients with an unmethyl-
ated promoter. The benefit of TMZ for the treatment of LGG still remains contro-
versial. For instance, the possibility that treatment of LGG with TMZ leads to
a resistant genetic landscape in recurrent tumours compared to untreated LGGs
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cannot be ruled out (Johnson et al. [135]). Details about the action of TMZ, MGMT
promoter methylation and MMR mutations will be given in Section 1.2.2 (Genetic
markers and the classification of gliomas into subtypes).
1.2.2 Genetic markers and the classification of gliomas into
subtypes
Considering the high inter-tumour heterogeneity in gliomas it is necessary to clas-
sify patients into different subgroups. A drug may fail to work in the general pa-
tient population but could potentially work in a defined subgroup. The grading
system of the WHO from 2007 was a good prognostic indicator, but was based
on the histopathological features of the tumour, completely lacking molecular in-
formation, which is the key to successful treatment. Brain tumours had only been
classified according to light microscopic features in hematoxylin and eosin (H&E)
stains, focusing mostly on vascularisation, necrosis and cellularity, and in immun-
ohistochemistry (IHC) stains of cell lineage-associated proteins to identify the pu-
tative cell of origin (astrocytoma, oligodendroglioma, oligoastrocytoma) and to
determine the level of differentiation. The first attempts to associate the differ-
ent histopathologic glioma grades with molecular signatures were done looking
at transcriptional patterns (Godard et al. [87] and Rickman et al. [224]). This ap-
proach led to multiple disease subtypes, however, all these studies were based
on a single tumour sample per patient, making a definite classification of a tumour
into a subgroup debatable considering the emerging evidence for genomic intra-
tumour heterogeneity (ITH) (Sottoriva et al. [252]). For instance, ITH of RTKs in
gliomas was shown by several independent studies (Francis et al. [69], Snuderl et
al. [250] and Szerlip et al. [263]). One way to overcome the issue of bias caused
by single-sample analysis is to focus on genetic alterations and biomarkers that
were shown to be early drivers of gliomagenesis and found to be fairly homo-
geneous throughout a whole tumour. Even though some of the markers were
known as of the 2007 CNS WHO classification, these markers were neglected
in the classification and used rather as prognostic and predictive data within the
diagnostic categories based entirely on microscopy.
A more recent analysis of 1,087 gliomas (WHO grade II, III & IV) defined five
molecular subgroups based on combinations of three robust biomarkers: IDH
mutations, TERT promoter mutations and 1p/19q co-deletions (Eckel-Passow et
al. [56]). Most importantly, the subgroups defined by the lack of IDH mutations
and no 1p/19q co-deletion was associated with typical GBM alterations, such as
inactivating mutations of neurofibromatosis type 1 (NF1), PTEN deletion and ac-
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tivating EGFR amplification. The subgroup harbouring only TERT mutations con-
sisted almost entirely of GBM, which presented at a later age compared to the
triple-negative group (bearing neither IDH and TERT mutations nor 1p/19q co-
deletion) and showed the worst prognosis. The triple-positive group (harbouring
all three alterations) was enriched for capicua (CIC) and far upstream element-
binding protein 1 (FUBP1) mutations, while two subgroups positive for IDH muta-
tions but negative for 1p/19q co-deletion (either with or without TERT mutation),
were associated with ATRX and TP53 mutations. The group with only IDH muta-
tions showed the earliest mean age of onset (37 years) and intermediate pro-
gnosis. Looking specifically at LGG these three markers correlate closely with
clinical outcome, with the highest survival difference between the TERT muta-
tion only subgroup and all others. These findings were further supported by two
other independent studies (Cancer Genome Atlas Research Network et al. [32]
and Weller et al. [293]). The molecular findings considered as most meaningful
were incorporated in the most recent update of the classification of tumours of the
CNS by the WHO (Louis et al. [169]). Some of the more important biomarkers or
alterations with diagnostic, prognostic and predictive value will be reviewed below
and the new classification system will be explained briefly.
IDH mutations
IDH1 and IDH2 are NADP+ dependent isocytrate dehydrogenases, decarboxylat-
ing isocytrate to ౖ-ketoglutarate (ౖ-KG), an intermediate in the tricarboxylic acid
(TCA) cycle. Point mutations in these enzymes have been discovered in gliomas
but always occur independently of one another (Parsons et al. [212]). IDH1 muta-
tions occur more frequently than IDH2 mutations, and are proposed as an early
event during gliomagenesis (driver mutation) (Watanabe et al. [286]).
Mutant IDH loses its normal enzymatic activities but gains the ability to cata-
lyse the reduction of ౖ-KG to 2-hydroxyglutarate (2-HG), a potential oncometabol-
ite (Dang et al. [46]). How exactly the mutations lead to the neomorphic enzymatic
activity is still controversial, but there is evidence for how IDH mutations promote
glioma tumourigenesis (see 1.2.2 (Glioma-CpG island methylator phenotype)).
The mutations are predominantly found in low-grade diffusive gliomas, ana-
plastic astrocytomas, oligodendrogliomas and oligoastrocytomas, but rarely found
in primary GBM or pilocytic astrocytoma. A major event, however, has been the
finding that IDH1 mutations represent a diagnostic molecular biomarker of sec-
ondary GBM (Nobusawa et al. [199]). This allows separation of GBM arising de
novo (IDH wild-type primary GBM) from those arising from a presumed lower-
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grade tumour (IDH mutated secondary GBM) (Ohgaki and Kleihues [204]). In
addition to its diagnostic value, the assessment of IDH mutations provides pro-
gnostic value, as the mutations are shown to significantly correlate with young
age and to predict prolonged progression-free survival as well as increased over-
all survival (Parsons et al. [212], Weller et al. [294] and Bujko et al. [26]).
ATRX mutations are shown to be restricted to IDH-mutant tumours but are mu-
tually exclusive with 1p/19q co-deletion (Jiao et al. [133] and Kannan et al. [136]).
While ATRX mutations are markers for astrocytic lineage tumours (Jiao et al.
[133]), 1p/19q co-deletion is associated with oligodendrogliomas or oligodendro-
features.
Co-deletion of 1p/19q
Co-deletion of the chromosome arms 1p and 19q occurs as the result of an un-
balanced translocation of the chromosome and is an early event in tumourigen-
esis. It is strongly associated with gliomas that carry an oligodendroglial com-
ponent (Chen et al. [38]). Co-deletion of complete chromosome arms 1p and
19q is a favourable prognostic marker in anaplastic gliomas, but as a marker in
GBM it is highly controversial (Boots-Sprenger et al. [16]). The studies on 1p/19q
co-deletion in GBM have mixed result. By some studies, the presence of com-
plete 1p/19q co-deletion and IDH1 mutations have been considered incompatible
with the diagnosis of GBM (Tabatabai et al. [264]), while others claim that com-
plete 1p/19q co-deletion in GBM is rare but associated with a shortened survival
(Jansen, Yip and Louis [129]). In complete contrast, a third study concluded that
1p/19q co-deletion predicts long survival, independent of the pathological grade
(Schmidt et al. [236]). A more recent analysis of 561 gliomas (grade II n=110,
grade III n=118, grade IV n=333) by Boots-Sprenger et al. supported the observa-
tion that complete 1p/19q co-deletion lacks prognostic meaning for GBM patients
and claims that different results may be partly caused by different techniques to
identify 1p/19q losses or by differences in GBM diagnose criteria (as opposed to,
for example, anaplastic oligoastrocytoma) (Boots-Sprenger et al. [16]).
IDH mutations and 1p/19q co-deletion were found to be meaningful and ro-
bust markers that could be incorporated with histological features to subdivide
diffuse gliomas (Louis et al. [169]). Diffuse astrocytic and oligodendroglial tu-
mours now form an entity, different from other astrocytic tumours, which lack IDH
mutations, but are frequently associated with other alterations, such as BRAF
(proto-oncogene B-Raf) alterations in pilocytc astrocytoma and pleomorphic as-
trocytoma or tuberous sclerosis 1/2 (TSC1/TSC2) mutations in subependymal
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giant cell astrocytoma. Diffuse gliomas encompass diffuse astrocytoma (IDH-
mutant, grade II), anaplastic astrocytoma (IDH-mutant, grade III), Glioblastoma
(IDH-mutant, grade IV), Glioblastoma (IDH-wildtype, grade IV), diffuse midline
glioma (H3K27-mutant, grade IV), oligodendroglioma (IDH-mutant and 1p/19q-
codeleted, grade II) and anaplastic oligodendroglioma (IDH-mutant and 1p/19q-
codeleted, grade III).
While WHO grade determinations are still made on the basis of histologic
criteria a determination of the cell of origin is now supported by the integration
of genetic information. Tumours which either show inconclusive results, or where
genetic testing has not been done, fall into the Not Otherwise Specified (NOS)
category. To define a tumour as IDH-wildtype, sequencing for IDH1 codon 132
and IDH2 codon 172 needs to be negative. The evaluation of IDH mutations
needs to be performed carefully to avoid misclassification, especially because
IDH-wildtype diffuse astrocytomas are uncommon and IDH-wildtype anaplastic
astrocytomas share genetic features with IDH-wildtype GBM (Louis et al. [167]
and Cancer Genome Atlas Research Network et al. [32]). A schematic overview
of diffuse glioma classification based on histology and genetics is depicted in
Figure 1.4.
Figure 1.4 A schematic overview of the new glioma classification system by the WHO (ad-




TP53 is one of the most frequently altered genes in cancer; mutations in its path-
way are found in nearly all human cancers (Hanahan and Weinberg [99]). It was
shown that more than a third of gliomas harbour a direct alteration (mutation or
deletion) in TP53 (Cancer Genome Atlas Research Network [31]). Transcription
factor P53 is a key player in protecting the integrity of the cell, having versatile
functions in cell-cycle control, apoptosis, and in the maintenance of genetic sta-
bility. A loss of function in P53 allows damaged cells to survive and proliferate
promoting the accumulation of further genetic alterations (Lane [150]).
In contrast to findings in chronic lymphocytic leukaemia (CCL), where TP53
alterations were found to be rather late events in disease development (Landau
et al. [149]), TP53 alterations in gliomas were shown to be early driver mutations
in LGGs (Fulci et al. [73]) and associated with tumour progression to HGGs (Ishii
et al. [125]). However, TP53 mutation/deletion as a prognostic factor in gliomas
is highly controversial. The correlation between TP53 mutations and outcome
range from unfavourable (Ishii et al. [125]) to a better outcome (Kim et al. [141]).
TP53 mutations have been shown to be associated with an increased fraction of
subclonal mutations independent of patient age, which may reflect the effects of
TP53 alterations on genetic instability (Kim et al. [141]). In CLL, both subclonal
and clonal mutations in TP53 were associated with poor outcome (Rossi et al.
[225]), contrary to Kim’s study in GBM where patients younger than 55 and with a
high abundance of subclones showed significantly longer event-free survival than
patients with a higher abundance of clonal mutations. TP53 alone, however, did
not show any correlation with outcome (Kim et al. [141]).
TERT promoter mutation and ATRX mutation
During the process of DNA replication small segments of DNA at each end of
the DNA strand cannot be copied, as the enzyme polymerase cannot replicate
the DNA to the end (Watson [289]). To protect DNA integrity eukaryotic chromo-
somes are capped with several hundred nucleotides of telomere repeats, which
shorten with each cell division until the telomeres are completely depleted and the
cell reaches senescence or eventually undergoes apoptosis. Stem cells in self-
renewing tissues have the capability to maintain telomere length by expressing
telomerase, a ribonucleoprotein elongating the chromosome ends (Morin [189]
and Hiyama and Hiyama [112]). As already briefly explained in 1.1.5 (Enabling
replicative immortality) mutations in the promoter region of TERT activates its ex-
pression and telomeres don’t shorten while cells are proliferating. Another genetic
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alteration leading to cell immortality are ATRX mutations, which allow ALT. ATRX
and TERT mutations are mutually exclusive in gliomas, suggesting that these two
genetic alterations confer equivalent selective growth advantages (Killela et al.
[140]).
Methylation status
Part of the standard treatment of gliomas is the administration of the alkylating
agent TMZ, which impairs DNA replication by introducing alkyl groups at multiple
sites along the DNA backbone, N7 positions of guanine in guanine-rich regions
(N7-MeG), N3 adenine (N3-MeA), and O6 guanine residues (O6-meG) (Denny et
al. [51] and Zhang, Stevens and Bradshaw [304]). Although N7-MeG is the major
DNA adduct induced by TMZ, the cytotoxicity is primarily attributed to the O6-
meG lesion (Loveless [173]. All cells harbour a set of DNA repair enzymes cap-
able of repairing different DNA lesions to a certain degree. The O6-alkylguanine
alkyltransferase (AGT), also known as O6-methylguanine-DNA methyltransferase
(MGMT), removes alkyl adducts from the O6 position of guanidine, effectively re-
pairing these lesions and preventing the alkylating agent triggered cell death (Fig-
ure 1.5 iii) (Shiraishi, Sakumi and Sekiguchi [247]). The protein acts by facilitating
the transfer of the alkyl group to a cysteine residue in its active site, thereby get-
ting inactivated and rapidly degraded by the proteasome (Pegg and Byers [214]).
Consequently, the initial repair capacity of a cell is determined by its constitutive
levels of MGMT. As such, cancer cells expressing high MGMT protein levels show
resistance to alkylating agents, while those lacking the MGMT protein seem to be
more susceptible. In some glioma cases, epigenetic silencing of the MGMT gene
through promoter methylation prevents the synthesis of the enzyme, consequen-
tially making such tumours more sensitive to TMZ. Therefore, the assessment of
the MGMT promoter methylation status can predict the response of patients to
therapy with alkylating agents. It has been shown that TMZ treatment results in
improved survival in patients with a hyper-methylated MGMT gene compared to
patients in which the MGMT promoter was unmethylated, independent of tumour
grade (Hegi et al. [106]).
Mutations in DNA mismatch repair
Mutations in MMR genes have been identified and shown to be involved in various
cancer types (Boyer et al. [19] and Peltomäki [215]). In non-malignant cells the
MMR pathway corrects DNA mismatches generated during DNA replication, and
plays a critical role in cell cycle arrest and programmed cell death in response to
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certain types of DNA damage. Thus the MMR pathway prevents mutations from
becoming permanent in the next cell generations and prevents cells with DNA
damage from dividing (Li [159]). The core of the MMR pathway consists of six
proteins, MutS homolog 2 (MSH2), MutS homolog 6 (MSH6), MutL homolog 1
(MLH1), MutL homolog 3 (MLH3), postmeiotic segregation increased homolog 1
(PMS1) and postmeiotic segregation increased homolog 2 (PMS2). These pro-
teins work together as heterodimers forming MutS and MutL homologues, and
the choice of subunit partner dictates substrate specificity (lesion type) and cellu-
lar function.
For the repair of base-base mismatches, MutSౖ (MSH2-MSH6) recognises
the lesion and recruits heterodimer MutLౖ (MLH1-PMS2). Possessing endonuc-
lease activity localised to the PMS2 subunit, MutLౖ introduces nicks at sites span-
ning the mismatch. Subsequent loading of exonuclease 1 (EXO1) at the 6༚side of
the mismatch leads to activation of its 6༚ to 4༚ exonuclease activity resulting in re-
moval of the incorrect DNA-fragment. The remaining single-stranded gap is filled
by polymerase delta (POLౙ) and its cofactors; proliferation cell nuclear antigene
(PCNA) and replication factor C (RFC). The repair process is completed when the
remaining nick is sealed by DNA ligase I. The cytotoxicity of O6-meG induced by
TMZ, is mainly due to recognition of O6-meG/T (or C) mismatches by the MMR
system and the induction of unsuccessful repair cycles, which ultimately result in
cytotoxic double-strand breaks leading to apoptosis (Figure 1.5ii).
Germline mutations in the MMR pathway are the cause of Lynch syndrome,
also known as Hereditary cancer-predisposing syndrome (HCPS), which is an
autosomal dominant condition in which mutations in MLH1, MSH2, MSH6 and
PMS2 are linked to an increased risk of developing multiple adult-onset cancers,
especially those of the colon, uterus and ovaries. The offspring of couples in
which both parents suffer from HCPS have a 25% chance to inherit both faulty
copies, leading to a rare condition called Constitutional Mismatch Repair Defi-
ciency (CMMRD), which is associated with a high risk of early-onset cancers,
including cancers of the brain and blood. Mutations in the MMR system have not
been linked to the development of GBM in adults, but are involved in a hyper-
mutation phenotype after TMZ treatment. MSH6 was first found to be mutated in
two recurrent GBM cases treated with TMZ in a large-scale sequencing analysis
(Louis [166]). MSH6 mutations were shown to confer tolerant cell growth under
cytotoxic doses of alkylating agents in vitro (Levati et al. [156]). The direct role
of MSH6 in chemo-resistance was confirmed when it was found that the reintro-
duction of wild type MSH6 could re-sensitise the MSH6 mutant harbouring cells to
alkylating drugs (Yip et al. [302]). Treatment of MGMT-deficient GBMs with alkylat-
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ing therapy introduces a strong selective pressure to lose MMR function, causing
resistance to the killing effects of TMZ, but not to the mutagenic effect, causing
an increase in the mutational rate in these tumours (Figure 1.5 iv) (Drabløs et al.
[54], Cancer Genome Atlas Research Network [31] and Li [159]). Loss of MHS6
occurs in a subset of post-treatment (Radiotherapy and TMZ) recurrent tumours
and is associated with alkylator resistance (Hunter et al. [122]); however, there
is also evidence that MSH6 mutations may be present before alkylator therapy
(Nguyen et al. [194]).
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Figure 1.5 | The action of TMZ and the development of a hypermutator phenotype.
i) TMZ introduces alkyl groups at the backbone of the DNA, specifically at O-6 positions of guanine
residues. ii) Patients with MGMT promoter methylation are more sensitive to TMZ treatment.
Without functioning MGMT present the DNA polymerase pairs methylated guanines with thymine
during replication. The MMR complex MSH6-MSH2 (MutSౖ) recognises the base pair mismatch
and recruits MutLౖ. The MLH1-PMS2 complex then introduces double strand breaks to correct
the putative error leading to futile cycles of DNA repair until the cell undergoes apoptosis. iii)
Functioning MGMT protein removes alkyl groups from the DNA, leading to degradation of MGMT-
CH3 and the escape of tumour cells from TMZ treatment. iv) MGMT promoter methylation and
loss of function of the MMR system causes accumulation of alkyl groups at guanines. In the
process of replication alkylated guanine will be recognised as adenine and paired with thymine
instead of cytosine leading to the accumulation of C?T and G?A transitions.
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Glioma-CpG island methylator phenotype
A genome-wide methylation profiling of gliomas identified a subgroup of gliomas
with an unusual high and very specific methylation pattern termed glioma-CpG is-
land methylator phenotype (G-CIMP) which correlates significantly with IDH muta-
tions and was also found to be associated with young age and prolonged survival
(Noushmehr et al. [200] and Christensen et al. [41]). A link between a genome
wide DNA hypermethylation and IDH mutation was found in AML by Figueroa and
colleagues who suggested that the hypermethylation might be caused by the in-
hibition of the oncogene family member tet methylcytosine dioxygenase 2 (TET2)
(Figueroa et al. [65]). TET2 is an ౖ-KG-dependent dioxygenase catalysing the
conversion of 5-methylcytosine to 5-hydroxymethylcytosine and thereby demethyl-
ating DNA. It was shown that 2-HG is a competitive inhibitor of ౖ-KG-dependent
dioxygenases ([301]). Hence, decreased levels of ౖ-KG and increased levels of
2-HG caused by IDH mutations could block the demethylation of DNA, leading to
global epigenetic changes and driving cells into a malignant fate.
1.2.3 EGFR amplification, variants and point mutations
RTKs are a class of mitogenic signalling proteins including EGFR, platelet-derived
growth factor receptor A (PDGFRA), and MET, that are widely implicated in onco-
genesis (1.1.2 (Sustaining proliferative signalling). Amplifications of these recept-
ors are especially prevalent in GBM, with a high level amplification of the EGFR
locus occurring in 35 to 45% of all cases. PDGFRA (10 to 15%) and MET (ap-
proximately 4%) are also frequently amplified in GBM (Brennan et al. [25], Cancer
Genome Atlas Research Network [31] and Frederick et al. [70]). In the case of
EGFR, the amplification is often associated with intra-genic rearrangements of the
EGFR gene, or point mutations in the extracellular domain. The most common
amplified variant of EGFR in GBM is the EGFR variant III (EGFRvIII) with a 287-
amino acid in-frame deletion of exons 2 to 7 in the EGFR extracellular domain
(Sugawa et al. [261]). This deletion enables the receptor to form homodimers, or
heterodimeric complexes with either wild-type EGFR or other erbB family mem-
bers ligand-independently, leading to constant growth promoting signalling and
showing highly oncogenic potential (Gan, Kaye and Luwor [76]). EGFR variant II
(EGFRvII), another ectodomain variant with only a small 83-amino acid deletion
of exons 14 and 15, is often found in association with vIII, but shows less onco-
genic potential (Humphrey et al. [121] and Francis et al. [69]). In EGFR variant V
(EGFRvV) the extracellular part of the receptor is unchanged, while a part of the
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intracellular domain responsible for internalisation and degradation of the receptor
is C-terminally truncated (C-958 COOH-terminal truncation).
While EGFRvII and EGFRvV account for around 10% of all EGFR amplifica-
tions, other variants which have been identified seem to play an even minor role
in gliomagenesis. Apart from the intergenic rearrangements in the EGFR gene,
GBM often carries EGFR with point mutations in the extracellular domains of the
receptor compared to other cancers, in which EGFR kinase domain mutations
appear to be more relevant (Lynch et al. [178], Marie et al. [181] and Lee et al.
[153]). The most common amino acid changes of EGFR in GBM are R108K,
T263P, A289V, and G598V, which are associated with EGFR amplification in ap-
proximately 60% of the analysed GBM cases (Frederick et al. [70] and Idbaih
et al. [123]). EGFR ectodomain mutations occur independently of EGFRvIII and
were shown to be tumourigenic when stably transfected into NIH-3T3 cells and
subcutaneously injected into the flanks of nude mice. Furthermore, these EGFR
ectodomain mutants showed ligand-independent basal tyrosine phosphorylation
and were responsive to exogenous EGF. The general structure and a summary of
common EGFR variants and mutants in GBM can be found in Figure 1.6.
Most importantly, the composition of altered RTKs reflects the heterogeneous
characteristic of GBM, with a tumour either harbouring multiple populations of
clones with different RTKs being amplified, or populations of clones with under-
lying EGFR amplification and the expression of different EGFR variants in sub-
clones ([69]). These findings suggest that combining different targeting drugs,
e.g. multiple EGFR inhibitors acting through different mechanisms on the receptor




Figure 1.6 | EGFR in GBM: variants and point mutations
A| Schematic overview of the EGF receptor in the cell membrane. Extracellular Domain (ECD)
with the ligand-binding regions (I, III) and cysteine-rich regions (II, IV), Intracellular Domain (ICD),
Transmembrane (TM), Tyrosine Kinase (TK) and Regulatory Domain (RD). Y891-Y1173 indicate
tyrosine phosphorylation sites.
B| A schematic overview of the most common EGFR alterations in GBM located throughout the
28 exons of the receptor. Point mutations R108K, A289V and G598V are all located in the ECD.
In-frame deletions of exons 2-7 (EGFRvIII) and exons 14 and 15 (EGFRvII) also affect the ECD,




Despite all efforts to treat GBM and to prevent relapse, tumours mostly recur six
to eight months after the first surgery, usually within 2 to 3 cm from their original
site (Gaspar et al. [79] and Lee et al. [155]). However, a growing body of liter-
ature shows that about one third of recurrences occur remotely to the primary
lesion in patients with a complete resection of enhancing disease at initial surgery
(Brandes et al. [21], De Bonis et al. [48] and Tejada et al. [266]). Treatment op-
tions for recurrent GBM are mainly determined by the specific clinical situation;
however, patients with recurrent GBM often gain only minimal or modest bene-
fit from conventional treatments like TMZ. One of the pivotal questions regarding
recurrence is the process by which it develops, particularly in light of the highly
heterogeneous nature of GBM. For instance, what sort of clones may or may not
drive recurrence? Are they already present in the original tumour with low or high
abundance, or are they a newly evolved species?
Exome sequencing on 23 paired WHO grade II and matching recurrent
samples of every grade showed that in 43% of the cases the majority of the muta-
tions in the initial tumour were undetected at recurrence, indicating that recurrence
is often driven by cells derived from a very early stage of tumour development
(Johnson et al. [135]). This result is similar to the observations of Wang et al.,
which showed that the mutations occurring in only one of a patients two GBM
samples (primary and recurrent) outnumbered the shared mutations in more than
half of all patients (Wang et al. [284]). Johnson and colleagues observed that ini-
tial and recurrent gliomas display a broad spectrum of genetic relatedness; Some
extreme cases in this patient cohort showed a clear pattern of linear evolution
with more than 75% of mutations retained at recurrence while others showed
branched evolution with less than 25% of the mutations in the initial tumour found
in the recurrent sample.
In one example of branched evolution initial and recurrent disease only shared
an IDH1 mutation, which furthermore was the only shared mutation found in all
IDH1 mutated patients illustrating the importance of IDH1 mutations as a thera-
peutic target especially in lower-grade disease and its progression. It was shown
that other key driver mutations such as TP53 and ATRX mutations can be lost
at recurrence, but can evolve at distinct base pairs through convergent evolution
caused by strong enduring selection for the loss of these genes (Johnson et al.
[135]). This convergent switch was supported by Wang et al., who found that 11%
(10/93) of patients with recurrent GBM had clonal replacements in the key driver
genes EGFR, TP53, and PDGFRA (Wang et al. [284]).
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Similar results on GBM phylogeny were obtained on ten paired primary GBM
and recurrent samples supporting both linear and branched model of disease
progression in gliomas (Kim et al. [141]). In cases in which primary and recurrent
tumours only share a small subset of clonal mutations, recurrence has most likely
evolved from refractory ancestral cells leading to a highly different mutational pat-
tern in the recurrent sample. In paired samples showing a high degree of overlap
between clonal mutations and a general absence of primary-specific mutations,
the recurrent tumour has most likely evolved from the residual disease and expan-
ded. In both studies, however, the majority of patients showed mutational patterns
which made it impossible to group the tumour progression into either evolutionary
model. The analysis of sequential recurrent samples of single patients provided
evidence that particular patterns of clonal evolution are not intrinsic properties of
the tumour, as the different recurrences followed different patterns of evolution
(Johnson et al. [135] and Favero et al. [63]).
Nearly all recurrent samples are treated with TMZ, a drug known to be muta-
genic, which is clearly reflected in the distinct mutational signature in a high num-
ber of recurrent samples; this signature consists of a massive increase in muta-
tions (hypermutation) most of which are C?T0G?A transitions predominantly oc-
curring at CpC and CpT dinucleotides (Johnson et al. [135] and Cancer Genome
Atlas Research Network [31]). This finding is interesting because it reveals TMZ
treatment as a possible positive selection pressure for resistant clones leading
to a highly malignant progression of lower grade tumours. Hypermutation would
provide opportunities for facilitated mutation of known GBM drivers such as muta-
tions in the RB and Akt-mTOR (protein kinase B (PKB) (AKT), mechanistic Target
of Rapamycin (mTOR)) signalling pathways (Johnson et al. [135]). A possible ex-
planation for this are dysfunctions in the MMR pathway which cause resistance to
TMZ and can result in hypermutation as explained in the previous Section 1.2.2
(Mutations in DNA mismatch repair) on page 30.(Hunter et al. [122], Cahill et al.
[29], Cancer Genome Atlas Research Network [31] and Yip et al. [302]). The fact
that the mutations in MMR were only found in the recurrence but were absent in
the initial tumour raises the question of clonality and ITH. MMR mutations may
have been present at an undetectable level or may have been restricted to an
unsampled portion of the tumour, such as residual cells left after surgery.
With the statistical power conferred by 93 paired primary and recurrent
samples from three different centres, Wang et al. observed the following signific-
ant associations that were exclusive to GBM recurrence: co-occurrence of MGMT
promoter methylation and hypermutation, co-deletion of RB1 and PTEN and co-
mutation of NF1 and TP53 (Wang et al. [284]). Furthermore, they found four
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genes, latent transforming growth factor beta binding protein 4 (LTBP4), MSH6,
PR/SET Domain 2 (PRDM2) and insulin-like growth factor 1 receptor (IGF1R)
mutated and expressed exclusively in recurrent tumours (Wang et al. [284]).
In a single case study on multiple regions of three longitudinal samples histo-
pathologic analysis revealed that the primary tumour consisted of a grade II and
a grade IV component and that the clonal pattern of the samples indicated that
the grade II region gave rise to the grade IV region, while the recurrence evolved
directly from the grade IV part (Favero et al. [63]). Even though most studies
describe IDH1 mutations as stable within the tumour and throughout tumour pro-
gression, the IDH1 mutation in this case got lost in the recurrent tumour in favour
of the macro-evolution of a DM chromosome carrying multiple oncogenic com-
ponents of the PI3K pathway (e.g. PDGFRA and KIT amplification), which seem
mutually exclusive with IDH1 mutations.
Lee et al. looked at four different tumour sample types to study tumour het-
erogeneity and the diversity in recurrence: locally adjacent samples (samples of
the same surgery and same tumour mass), multifocal samples (samples from
the same surgery, but from remote tumour masses), longitudinal local samples
(samples recurring at the original site) and longitudinal distant samples (samples
recurring remote to the original site) (Lee et al. [154]). As expected, genetic di-
versity was greater in locally remote samples than in locally adjacent samples,
in distant recurrences than in local recurrences and in long-term recurrence than
short term recurrences (Lee et al. [154]). While this would seem self-evident, it
stands in contrast to other cancers, where tumours expand to other sites sud-
denly and all at once, resulting in genetically similar but spatially distinct tumours.
In gliomas, tumours at other sites result from clones formed at an early stage in
the tumour evolution (Lee et al. [154]). Their results showed an enrichment of
PIK3CA mutations in multifocal tumours suggesting a role in GBM multipotency
based on its involvement in multipotency of mammary tumours (Lee et al. [154]).
In contrast to other studies, they identified EGFR amplification and PTEN deletion
as private events and not as trunk alterations (Lee et al. [154]).
Taken together these findings support the importance of re-characterising glio-
mas at recurrence, including the re-analysis of variants assumed to be early driver
mutations, and question the use of TMZ in lower grade tumours. The results also
show that multifocal and remote recurrences need to be treated as different en-
tities compared to single focal and local recurrences. A clear statement about
clonal evolution in recurrent tumours is difficult and a predictive model for glioma
progression has yet to be developed. Nevertheless, these studies show that the
evolution of gliomas can vary hugely depending on tumour grade and pre-existing
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mutations and that treatment can act as selective pressure driving recurrence in
different directions.
1.3 Aims
Much progress has been made in understanding the clonal evolution from primary
to recurrent gliomas, however many of the conclusions lack clarity and have lim-
ited clinical utility. Retrospective studies on patient cohorts investigate the causes
of disease and are used to establish links between risk factors and health out-
comes. These studies give a broad picture; they are able to determine, for in-
stance, common traits of GBM, such as shared genomic alterations or shared
histopathological features, and help to divide patients into groups that potentially
benefit more than others from certain treatments or groups with different pro-
gnoses and outcomes. However, each patient, and each cancer, is unique. Gen-
omes, life histories and treatment modulate the development and progression of
the disease in ways that cannot be replicated. Therefore, while identifying com-
mon traits and grouping patients clearly is important for the finding of new targets
and the development of novel drugs or other treatment options, these studies are
often superficial, generalising and do not give a full picture of a complicated med-
ical situation. Case reports can help to test current hypothesis and develop new
ones and can provide a level of detail and understanding that is often lost or over-
looked in studies using big cohorts, but which can improve outcomes for individual
patients.
In this thesis I present my work on the evolution of a single GBM from the
original treatment naïve tumour over its first TMZ and radiation treated recurrence,
to its TMZ-treated second recurrence. Cases of primary GBM which undergo
resection of two consecutive recurrences are rare in Europe due to health policies
that prioritise quality of life, and which advise against re-operating if the risks
outweigh the benefits. This study aims to give a thorough analysis of the complex
nature of GBM biology, a detailed assessment of the tumour development under
multimodal therapy and to explore the disease beyond the data gathered from the
patient by integrating experiments which place our findings in the context of the
most recent GBM research.
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2 | Materials and Methods
2.1 Glioblastoma sample collection
Patient informed consent was obtained through our research clinic. Tissue collec-
tion protocols were compliant with the UK Human Tissue Act 2004 and approved
by the Local Regional Ethics Committee (LREC ref. 04/Q0108/60).
2.2 DNA, RNA and protein isolation from brain tu-
mour tissue
DNA, RNA and protein were isolated from tissue pieces using the AllPrep
DNA/RNA Mini Kit (Qiagen) according to the manufacturers protocol.
Tissue homogenisation
Approximately 30 mg of fresh frozen brain tumour was transferred into 2 ml
Lysing Matrix D tubes containing 600 µl of RLT buffer (containing 10% of ౗-
mercaptoethanol) and immediately run 2x 5,000 15s on a FastPrep-24™ homo-
geniser (MP Biomedicals) to homogenise the tissue. Samples were then trans-
ferred into 1.5 mL tubes and centrifuged at top speed for 3 min to pellet out tis-
sue debris. The lysate was then carefully transferred into the AllPrep DNA spin
columns (purple). The columns were centrifuged at 10,000 G for 30 s to pass the
liquid trough the filter into the collection tube. Then the AllPrep DNA spin columns
were placed into a new 2 ml collection tube and stored at room temperature until
ready for the DNA purification steps. The liquid that had passed through the filter
was then used for the RNA purification steps as follows.
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2.2.1 RNA isolation
430 µl of 70% EtOH were added to the flow-through of the AllPrep DNA spin
column and mixed well by pipetting. 700 µl of the sample were transferred into
a RNeasy spin column (pink) and centrifuged for 15 s at 10,000 G. The protein
containing flow-through was transferred into a 2 ml tube for protein purification
and stored on ice. The remaining sample was loaded onto the same column and
centrifuged at 10,000 G for 15 s and the protein containing flow-through added
to the already collected sample. 700 µl of buffer RW1 were added to the column
and centrifuged for 15 s at 10,000 G. The flow-through was discarded. 500 µl
buffer RPE were added to the column. The columns were centrifuged at 10,000
G and the flow-through liquid discarded. The last step was repeated and after
discarding the flow-through the column was placed in a new 2 ml collection tube
and centrifuged at full speed for 1 min. To elute the RNA 40 µl of RNase-free
water were directly pipetted to the centre of the column and the column was then
centrifuged for 1 min at 10,000 G. RNA samples were stored at -80҅C until use.
2.2.2 Protein precipitation
600 µl of APP buffer were added to each protein containing flow-through, vigor-
ously mixed by shaking and incubated at room temperature for 10 min to precip-
itate protein. Samples were then centrifuged at full speed for 10 min, and the
supernatant discarded. The protein pellets were washed with 500 µl 70% EtOH,
centrifuged at full speed for 1 min and the supernatant discarded. The protein
pellet was dried for 5 to 10 min at room temperature and the samples then stored
at -80҅C until further use.
2.2.3 Genomic DNA purification
Buffer EB or DNase free water was pre-heated to 70҅C using a heat block. 500 µl
of buffer AW1 were added to the DNA containing AllPrep DNA spin column and
the columns were centrifuged for 15 s at 10,000 G. Then 500 µl buffer AW2 was
added to each column and the columns were centrifuged at full speed for 2 min.
The genomic DNA was eluted using either a 100 µl buffer EB (3-Peater) or 100 µl
of DNase free water (other samples) and centrifuging for 1 min at 10,000 G. DNA
samples were stored at -20҅C until further use.
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2.3 Sequencing
2.3.1 Library preparation and whole genome sequencing
DNA quality was assessed using NanoDrop (Thermo) and the DNA was quantified
using Qubit (Thermo). To achieve a fragment size of 350 bp DNA was sonicated
using a Bioruptor Sonicator (Diagenode) with appropriate settings (8 cycles, 30 s
on/90 s off). For library preparations the TruSeq DNA PCR-Free Library Prep kit
(Illumina) was used exactly according to the manufacturers protocol. The library
was quantified using the KAPA Library Quantification Kit (Illumina) according to
the manufacturers protocol (KR0505-v6.14).Whole genome sequencing was per-
formed by the Genomics Core of the CRUK Cambridge Institute using HiSeq4000,
long paired-end reads at 50x genome coverage.
2.3.2 10X Genomics Chromium linked-read sequencing
For 10X Genomics Chromium linked-read sequencing DNA was isolated using
the MagAttract high molecular weight (HMW) DNA Kit (Qiagen) according to the
manufacturer’s protocol and DNA quality was assessed by agarose gel electro-
phoresis. DNA concentration was measured using Qubit and 1 ng per sample
was used as an input for library preparations. Library preps and sequencing were
performed by the Genomics Core of the CRUK Cambridge Institute.
2.3.3 RNAseq
The RNA was submitted randomised and in triplicate to the Genomics Core of the
CRUK Cambridge Institute. The libraries for sequencing were generated by the
core using the TruSeq Stranded mRNA library preparation kit from Illumina and
sequenced.
2.3.4 Methylation
DNA was submitted in triplicate to the Pathology Department of Cambridge Uni-
versity and the methylation raw data were generated using an Infinium Methylation
EPIC array. This technology interrogates individual Cs at >850,000 known methyl-
ations sites and determines the frequency of methylation in the sample using a
two colour system.
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2.4 DNA Isolation from patient derived cell lines
DNA isolation from patient derived cell lines was performed using the Wizard ©
Genomic DNA Purification kit (Promega) according to the manufacturers protocol.
DNA quality was assessed by agerose gel electrophoresis and DNA was further
processed as described in 2.3.1.
2.4.1 Whole exome library preparation
Libraries for whole exome sequencing were generated with the TrueSeq DNA
Exome kit (Illumina) according to the manufacturer’s protocol including quality
controls. DNA of six samples was pooled together for sequencing.
2.5 PCR: double minute breakpoint validation
Primers to validate the DM breakpoints were designed using the UCSC gen-
ome browser, Primer 3 and Basic Local Alignment Search Tool (BLAST) (https:
//blast.ncbi.nlm.nih.gov/Blast.cgi) based on the genomic location obtained from
the 10X sequencing data (see Table 2.1). The PCR was performed using the Phu-
sion High-Fidelity PCR Master Mix with the standard Phusion PCR programme.
Samples were then purified for Sanger Sequencing using the QIAquick PCR Puri-
fication Kit (Qiagen) and sent to GATC Biotech (now Eurofins Scientific) according
to the LightRun requirements.
Table 2.1 Primers designed for DM breakpoint validation
Oligo Name Length Tm҅ GC % Sequence
F1 MERTKr Pl (A) 20 62.8 55 ACTGGTGGAGTTATGGAGGG
F1 MERTKr Pr (B) 20 66.0 55 TTCTTAACCCCTTCGACCCC
F2 lAQP1 Pl (C) 20 63.5 50 ACGATTTACTGAGGAGGGCA
F2 lAQP1 Pr (D) 20 67.1 50 CACCATGCATTTTCCAGCCT
F2 AQP1r Pl (E) 21 63.5 42.8 TGTTCCGCTGTACACAATTTG
F2 AQP1r Pr (F) 20 63.2 45 AAACACTCCAAGGCACATGA
F3 lEGFR Pl (G) 20 65.1 55 ACCTTGGGAATTAGGGCTAA
F3 lEGFR Pr (H) 20 63.8 55 GAAACAGGACTCAAGCTGGG
F1 lMERTK Pl (I) 21 66.0 52.3 GAGCTTCTCATTCCTGGCATG
F1 lMERTK Pr (J) 20 61.4 50 ATCAGGTCTCACAAGCAGGT
F3 EGFRr Pl (K) 20 68.5 55 CAGGCCCATGGTTCAATTCC
F3 EGFRr Pr (L) 20 65.7 50 AAGCAGGTGTGGGAAAAGGA
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2.6 Western blot
For protein preparation from cell pellets, 2৘217 cells were washed with PBS and
spun down at 1,200 rpm for 4 min and stored at -80҅C until lysis. For cell lysis and
protein preparation cell pellets were thawed and 150 µL cOmpleteTM, EDTA-freel
lysis-M buffer with protease inhibitor (Roche) was added to each pellet and pipet-
ted up and down. Samples were then incubated 10 min at RT and centrifuged at
13,000 rpm for 5 min. Supernatant was collected and frozen down at -20҅ until
BCA based protein concentration determination. For re-solving pellets obtained
from tissue (see 2.2.2), the protein pellet was thawed and 200 µL lysis-M buffer
was added. As samples did not re-solve easily SDS was added to a final con-
centration of 5 %. Samples were then stored over a week in the fridge, vortexed
every two of days and finally heated for 10 min at 95҅C. In order to assess the pro-
tein concentration of protein lysates, a BCA test was carried out with the BCA kit
from Thermo Scientific. The method was carried out according to the accompa-
nying protocol (BCA kit, Thermo Scientific). Samples where then prepared at the
desired concentration with LDS Sample Buffer (4X, life technologies, NuPAGE),
Sample Reducing Agent (10X, life technologies, NuPAGE) and water. For west-
ern blot experiments the XCell SureLock ™ Mini-Cell Electrophoresis System was
used together with Mops Running buffer (life technologies, NuPage) and 4-12%
Bis-Tris gels (life technologies, NuPAGE). The samples were run for 1.5 hours at
120V and transferred for 2 hours on ice at 30V with the XCell II ™ Blot Module onto
either the Hybond ecl nitrocellulose membrane or Low Fluorescence PVDF West-
ern Membrane from abcam. Afterwards, the membranes were blocked for 1h at
room temperature. The blocking solution varied, depending on the antibody used
downstream. In general, the blocking agent used was either dried milk dissolved
in TBS, BSA dissolved in TBS or LI-COR Odyssey®Blocking Buffer (TBS). After
blocking, membranes were incubated with the primary antibody diluted in the equi-
valent blocking solution with 0.1% Tween20 at room temperature for several hours
or at 4҅C overnight depending on the antibody. After incubation, the membranes
were washed with TBST for 30 min. The washing solution was changed every 10
min. Following washing, membranes were incubated with the secondary antibody
diluted in the appropriate blocking solution for 1 hour at room temperature. Next,
membranes were washed in TBST for 30 min and rinsed with ddH2O. Finally, the
antigen of interest was detected using the LI-COR Odyssey CLx Infrared Imaging
System. Results were analysed with ImageStudio.
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Table 2.2 Antibodies used in western blot
Antibody Company Host species Dilution Blocking agent
Anti-EGFR (PA1-1110) Thermo rabbit, polyclonal 1:1000 5% milk
Anti-AQP1 (AB3272-50UL) Milipore rabbit, polyclonal 1:1000 5% BSA
Anti-MSH2 (ab52266) abcam mouse, monoclonal 1:1000 5% milk
Anti-MSH2 (D24B5) Cell Signaling rabbit monoclonal 1:1000 1x Odyssee TBS
Anti-MSH6 (ab92471) abcam rabbit, monoclonal 1:1000 5% milk
Anti-SEC61ౘ (PA5-21384) Invitrogen rabbit, polyclonal 1:1000 1x Odyssee TBS
Anti-b-actin (ab8224) abcam mouse, monoclonal 1:1000 5% milk or1x Odyssee TBS
Anti-mouse IRDye 680RD








2.7.1 Derivation of primary glioblastoma cell lines
In order to derive cell lines from glioblastoma specimen, I used the following pro-
tocol devised by Talal Al-Mayhani in 2009 during the course of his PhD. Tissue
samples were obtained in accordance with local ethical guidelines. The tumour
tissue was mechanically minced using sterile razor blades, followed by enzymatic
digestion with accutase (Sigma, UK) for 60 min at 37҅C. The digested tissue was
then washed with Hank’s Balanced Salt Solution (HBSS) and single cells were
isolated by filtration through a 40 ţm filter (Falcon, UK). The cells were centri-
fuged for 5 min at 1200 RPM and subsequently incubated with 2-3 ml red blood
cell lysis buffer for 5 min. Cells were then washed with HBSS, spun down and
seeded at a standard density of 15,000 cells/ cm2 in Neurobasal-A media (Gibco,
UK) containing 2 mM l-glutamine, 1% (v/v) PSF, 20 ng/ml hEGF (Sigma, UK), 20
ng/ml hFGF (Tissue Culture, Cambridge), 1% (v/v) B27 (Invitrogen, UK) and 1%
N2 (Gibco, UK) and incubated at 37҅C in 5% CO2. The cells were allowed to
form primary aggregates and the medium was changed three days after deriv-
ation. Primary aggregates were collected and plated, without dissociation, onto
extracellular matrix (ECM)-coated flasks (ECM 1:50 dilution, Sigma, UK) and al-
lowed to form a primary monolayer. When the primary monolayer formed the
confluent cells were dissociated by incubation with accutase at 37҅C and washed
with HBSS. The cells were reseeded onto ECM-coated flasks at a density of 150
cells/cm2 to generate the secondary monolayer and passaged further once con-
fluence was reached.
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2.7.2 Maintenance and passaging of patient-derived cell lines
Patient-derived cell lines (PDCLs) were grown as monolayers or tumour-sphere
cultures. If grown as monolayer, cells were passaged upon confluence. For
tumour-sphere cultures, cell lines were passaged when most of the spheres had
reached a diameter of 500 µm, to avoid cell death in the core of the spheres.
Medium was changed once a week or more often depending on cell density. The
time it took for the cells to attain confluence differed from line to line, but in general
cells could be split every 4-14 days. To detach cells from the ECM-coated bottom
of the flask, the medium was discarded and cells were washed once with HBSS or
PBS to remove any dead cells or debris and to avoid interference of the medium
with the enzymatic activity of Accutase. Then, 1 or 2 ml of Accutase was added,
depending on the flask size. Next, the cell lines were incubated at 37҅C for at least
5 min to detach the adherent cells and disrupt cell aggregates. Flask were then
carefully rinsed with 10 ml of HBSS and the cell suspension was transferred to a
15 ml Falcon tube. Next, the suspension was pelleted at 1200 G for 5 min and
the supernatant was discarded. Afterwards, the cells were resuspended in 1 ml of
medium and the number of cells was determined with a haemocytometer. Cells
were then seeded onto new flasks at the appropriate density for the down-stream
experiment.
2.7.3 Freezing and thawing of cells
In order to generate a patient derived cell line bank that included multiple lines
from one patient, cell lines were frozen down and stored in liquid nitrogen upon
reaching a stable passage (cell line dependent). First, the medium was removed
from the flasks, the cells were detached with Accutase at 37҅C for 5-10 min at a
volume of 1 to 2 ml, depending on flask size. Flasks were then rinsed with 10
ml HBSS and the cell suspension was transferred to a 15 ml Falcon tube. Cells
were pelleted at 1200G for 5 min. Subsequently, the supernatant was discarded
and the cells were resuspended in sterile freezing medium (SFM +10% SDS).
Following, cell lines were stored overnight in the rate controlled freezing module
at -80҅C and transferred to cryogenic storage the day after.
In order to re-establish cell lines from frozen populations, the pellet was first
thawed quickly at 37҅C. Once the ice around the edges of the pellet was thawed,
the pellet and the already liquid components were transferred to a 15 ml Falcon
tube containing 10 ml HBSS, in order to dilute the cytotoxic DMSO. Next, cells
were pelleted at 1200G for 5 min and afterwards washed, resuspended in SFM
and cultivated at 37҅C, 5% CO2. 24 hours later, cells were pelleted and medium
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was changed again, in order to remove dead cells. After a couple of days the cells
were plated onto ECM-coated 12cm2 or 24cm2 flasks and left to reach confluence
for their use in downstream applications.
2.8 Metaphase spreads
For metaphase spreads flasks with a 70-90% confluency were picked and 0.01 µL
Colcemid (Gibco, UK) per mL cell culture was added and incubated for 1h at 37҅C.
The culture was then pelleted at 500 x g for 10 min. Supernatant was removed
and 10 ml prewarmed hypotonic solution added (1:1 % (w/v) sodium citrate: 0.56
% (w/v) (0.075M) KCl). The cells were then incubated at 37҅C for ten minutes.
For pre-fixation 2 mL freshly made fixative (3+1 v/v methanol/ glacial acetic acid)
was added on top of the hypotonic suspension, and mixed carefully by inverting
the tube. After 10 min at RT the suspension was pelleted by centrifugation at 500
x g for 10 min. Supernatant was removed, but leaving 1mL for resuspension of
the cells. Then 10 mL fixative were slowly added while agitating gently. Washing
and fixation was repeated 3 times. After the third time, supernatant was removed
completely and 1mL fresh fixative was added until a milky suspension of cells was
formed without clumps. Microscope slides were made moist by breath and slides
were placed horizontally at a 45 degree angle and a 10 µL of cell suspension was
dropped onto the slide using a pipette. The slide was dried vertically. The mitotic
index and the spreading of the chromosomes was assessed by viewing under a
low power phase contrast microscope.
2.9 FISH
Fluorescent in situ hybridisation was either performed on metaphase spreads or
tissue sections cut from paraffin blocks. The gene specific probes used were
EGFR-orange 5-TAMRA-dUTP (Empire Genomics), AQP1-aqua (custom made,
Empire Genomics) and the chromosome control probes used were CHR02-
orange, CHR07-green and CHR08-aqua. Metaphases were either used imme-
diately for FISH or stored at -20҅C. Prior to applying the FISH probes, slides were
dehydrated for 2 min each in 60%, 80% and 100%, respectively. Residual eth-
anol was shaken off the slides and 2 µL probe were mixed with Hi-buffer to a final
volume of 10 µL per reaction. 10µL of Hi-buffer/probe mix were added to a cov-
erslip and the slide with the area of interest put onto the coverslip. The coverslip
was then fixed with Marabu fixo gum all round the edges of the coverslip and air
48
2. Materials and Methods
dried for 5 min. Denaturation was done at 72҅C for 2 min on a hybridiser. The
slides were then put horizontally in a small microscopy slide box containing wet
tissue and the box was left floating with closed lid over night in a 37҅C water bath.
After at least 16h of hybridisation, the fixo gum and the coverslip were removed
carefully and the slides were washed for 2 min in a coplin jar containing 0.4X
saline-sodium citrate (SSC) buffer with 0.3% Tween20 heated to 73҅C. A second
wash was done for 2 min in 2X SSC buffer with 0.1% Tween20 at room temper-
ature. The slides were then dried by touching the edges on a tissue paper. 10
µL gold anti-fade Dapi mount were applied on a coverslip and the slide was put
with the area of interested onto the coverslip. The slide was then taken between
two layers of tissue and pressure was applied carefully to remove access liquid.
Slides were then left to dry.
2.10 Immunofluorescence staining
Cells for immunofluorescence (IF) stainings were grown in microscopy µ-Slide 8
Well (Ibidi) (20,000 cells per well) for two days and then fixed with paraformalde-
hyde (PFA) as following: cells were prefixed for 2 min by adding 1 volume 4% PFA
in PBS to the growth medium and subsequently fixed for 8 min in 3% PFA in PBS.
Cells were then washed 3x in PBS and incubated for 10 min with PBS containing
0.1% Triton X-100. Then cells were blocked for 1h in PBS containing 1% BSA, 5%
normal goat serum and 0.1% Tween20. Primary antibodies were diluted in PBS
containing 1% BSA and 0.1% Tween20 according to Table 2.3 and cells were in-
cubated at 4҅C over night with the diluted primary antibodies. The next day, cells
were washed 3x with PBS and incubated with the secondary antibodies diluted in
PBS containing 1% BSA and 0.1% Tween20 for 2h in the dark according to Table
2.3. Cells were then washed 3x with PBS, incubated with DAPI (1 µg/ml) in PBS
for 10 min in the dark and then washed twice more with PBS before imaging.
Table 2.3 Antibodies used in immunofluorescence (IF)
Antibody Company Host species Dilution
Anti-Vimentin (ab8978) abcam mouse, monoclonal 1:500
Anti-GFAP (ab7260) abcam rabbit, polyclonal 1:500
Anti-rabbit IgG AlexaFluor594 (ab150080) abcam goat, preadsorbed 1:750
Anti-mouse IgG AlexaFluor488 (ab150113) abcam goat, preadsorbed 1:750
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2.11 TMZ dose-dependent survival assay using
MTT
The MTT assay is a colorimetric assay for assessing cell metabolic activ-
ity. NAD(P)H dependent cellular oxidoreductase enzymes may, under defined
conditions, reflect the number of viable cells present. These enzymes are
capable of reducing the tetrazolium dye MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide to its insoluble formazan, which has a purple color.
Cells were seeded at a density of 4,000 cells per well and grown for two days
under normal cell culture conditions. Cells were then treated with TMZ every two
days for six days with a serial concentration of TMZ (0, 100, 300, 500, 700, 900
µM) and then analysed performing a MTT assay as follows. The MTT powder was
diluted in Neurobasal medium at a 10x stock concentration of 5 mg/ml. The stock
concentration was added to the wells to reach a final concentration of 0.5 g/ml and
the plates were incubated under cell culture conditions for 3h. After the incuba-
tion time, cells appeared as purple crystals under the microscope. The medium
was fully removed and the purple formazan was solubilised in 70 µl DMSO by
thoroughly pipetting up and down. The assay was then measured in a microplate
reader at a wavelength of 570 nm.
2.12 CRISPR-Cas9 knockout of MSH2 and MSH6
2.12.1 CRISPR guides
CRISPR guides were designed by the gene editing core in the CRUK CI. Three
guides were designed for each gene, MSH2 and MSH6 respectively, that were
able to cut all transcript variants of the genes with minimum predicted off target
effects. All guides were cloned into the PX459 plasmid V2 using the BbsI sites.
The sequences of the guides can be found in Table 2.4.
Table 2.4 CRISPR guides designed for MSH2 and MSH6 knockout
Target Gene Species Editing Type Plasmid Name Sequence
MSH2 Human KO PX459 93F GGTTTTACACTTATTCAGCA
MSH2 Human KO PX459 94F AATAAGTGTAAAACCCCTCA
MSH2 Human KO PX459 95F GACAAAGACTTGTTAACCAG
MSH6 Human KO PX459 96F TGACATTCTAATAGGCTGTG
MSH6 Human KO PX459 97F TGTTACTGGACCAAATATGG
MSH6 Human KO PX459 98F GTTACTGGACCAAATATGGG
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2.12.2 Transfection
GBM cell lines were transfected by electroporation using the Amaxa™ 4D-
Nucleofector™ technology and the Primary Cell Nucleofector™ Kit (Lonza) with
buffer P2 and programme F2. This combination resulted in the highest trans-
fection efficiency and viability compared to other buffers and programmes, but
also compared to other methods such as lipid transfection and nonliposomal cal-
cium phosphate-based methods. The transfection was performed according to the
manufacturer’s protocol using 2৘217 cells per transfection with 4 µg plasmid. Cells
were then incubated in supplemented Neurobasal for 24h under normal growing
conditions (37҅C in 5% CO2).
2.13 In vivo work
For all mouse work performed in this study we used the immunosuppressed
mouse model NOD SCID (NOD.CB17-Prkdcscid/NCrCrl) purchased from Charles
River. The non-obese diabetic (NOD) animals carry a homozygous mutation in
the X-linked severe combined immunodeficiency (SCID) gene and thus have im-
paired T and B cell lymphocyte development. The NOD background additionally
results in deficient natural killer (NK) cell function. This immunodeficiency makes
this model most suitable to perform human xenografts and study tumour develop-
ment.
2.13.1 Stereotactic orthotopic xenograft injections into the
mouse brain
Cell suspensions were prepared with supplemented Neurobasal in the lab for all
animals injected in one day and kept on ice until used. Before each surgery a
Hamilton syringe was prepared by rising in 70% Ethanol and then sterile PBS.
300.000 cells in 3 µL were carefully drawn in the Hamilton syringe, avoiding
bubbles. The syringe was then positioned in the stereotactic device. The animals
were anaesthetised with isoflurane and an analgesic was given for pain relief. The
head was shaved with clippers and the mouse’s eyes were protected by coating
with sterile ocular lubricant. The animal was then fitted into a stereotactic frame
for small animals. Once the mouse was positioned correctly the ear holders were
tightened until firm. The skull was cleaned with a sterile cotton swab soaked in
ethanol and a 1 cm sagittal incision in the mouse’s scalp from the front to the
back was made. When the bregma suture was identified a hole 2.5 mm left and
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1 mm anterior to the bregma suture was drilled. The needle was then lowered 4
mm into the brain and then raised 1 mm. 3 µL of cells were slowly injected over
a time course of 10 min. After 5 min of not touching the needle, the needle was
slowly removed from the mouse’s brain over a time course of 10 min. The cut was
carefully cleaned with a bud soaked in sterile PBS to remove drilling chips. The
cut was then closed with forceps and medical glue was applied. The mouse was
then removed from the stereotaxic device and recovered under observation for 1
h.
2.13.2 Tumourigenicity
All animal procedures were performed according to the Home Office UK
guidelines. To test the tumourigenicity of the cell lines used for my work cell lines
JR2M, A112, AW20S1, AW10S4, A25C and A25M were injected into the mouse
brain as described in 2.13.1. The animals were weighed before the procedure
and every three days starting two weeks after surgery to detect any weight loss
associated with tumour growth. The animals were furthermore observed for other
symptoms such as circular pacing, decreased food and water intake, aggressive
behaviour or any other visual signs of illness. If a mouse lost more than 15%
bodyweight within 72 h it had to be sacrificed. The brain was removed from the
scull and immediately incubated in 10% neutral buffered formalin solution for 24
h. After fixation the brain was transferred to 70% EtOH for a maximum of three
days before it was cut sagittally and embedded in paraffin blocks for sectioning.
2.14 Pulsed-field gel electrophoresis
For pulsed-field gel electrophoresis, HMW DNA was isolated using the MagAttract
HMW DNA Kit (Qiagen) according to the manufacturer’s protocol and DNA quality
was assessed by agarose gel electrophoresis. 200 ng DNA was run alongside
agarose strings of Lambda ladder (Promega) in a 1% agarose gel prepared with
SeaKem® Gold Agarose. The CHEF-DR® III variable angle system was used
with 0.5X TAE under the following running conditions: Block1: 9҅C (temperature),
6 V/cm (voltage), 1 s (initial switch time), 6 s (final switch time), 7.5 h (run time)
and 120҅C (angle). Block2 : 9҅C (temperature), 6 V/cm (voltage), 60 s (initial
switch time), 120 s (final switch time), 12 h (run time) and 120҅C (angle). After
the run was complete the gel was removed from the platform and stained for 30
min in a 0.5 µg/ml ethidium bromide solution in water. The gel was destained in
distilled water for 2 h and then visualised on a UV transilluminator.
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2.15 Hybridisation based isolation of the DM
To enrich DM DNA we designed six biotinylated oligo probes (Sigma) for the
MERTK sequence (chr2:112711719-112731563) on the DM. This region was
divided into six parts of approximately 2,700 bp length and three 75-82 bp
long sequences per region were picked and tested for MERTK specificity us-
ing BLAST. Promising candidates were run through the Berkley Oligo Calculator
(http://mcb.berkeley.edu/labs/krantz/tools/oligocalc.html) and selected based on
melting temperature (around 75҅C) and GC content (around 50%). Table 2.5
shows the final oligos. Hybridisation reactions were set up using leftover parts
of the TruSeq Rapid exome Library preparation kit (Document 1000000000753
v00) as follows. 500 ng DNA (6 µL of R2A) (84 ng/µl) was used and resuspen-
sion buffer was added to a final volume of 38 µL. 2 µL of each oligo was added,
the reaction well mixed and briefly centrifuged. 125 µL sample purification beads
were added and mixed by pipetting up and down. The reaction was incubated for
10 min at room temperature, centrifuged briefly and then left on a magnetic stand
for 2 min. The supernatant was discarded and the beads carefully washed twice
with 80% EtOH. Beads were then air-dried on a magnetic stand for 10 min. 7.7
µL enrichment buffer 1 were added and the reaction mixed thoroughly. The tube
was removed from the magnetic stand, incubated at room temperature for 2 min
and then centrifuged briefly. The tube was placed back on the magnetic stand
until the liquid appeared clear. 7.5 µL supernatant were transferred to new PCR
tube, 2.5 µL enrichment buffer 2 were added and mixed thoroughly and the tube
was briefly centrifuged. The reaction was then placed on a thermal cycler and run
with the preheated lid option for 10 min at 95҅C (denaturation) and then for 30 min
at 58҅C (hybridisation). The hybridisation probes were then captured as follows.
The sample was centrifuged briefly and transferred into a new 1.5 mL tube. 250
µL Streptavidin beads were added and mixed thoroughly by pipetting. The mix
was incubated at room temperature for 15 min, centrifuged briefly and put on a
magnetic stand. After the liquid appeared clear the supernatant was removed and
discarded. The tube was removed from the magnetic stand and 200 µL enhanced
enrichment wash solution was added and the reaction was mixed. The mix was
incubated for 30 min on a heat block at 50 ҅C and subsequently placed on a mag-
netic stand until the liquid appeared clear. The supernatant was discarded and
the mix was once more washed with the enhanced enrichment wash solution and
incubated on the heat block. Elution premix was prepared and 23 µL added to the
capture reaction reaction. The reaction was mixed, incubated for 2 min at room
temperature and centrifuged briefly. The tube was placed on the magnetic stand
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until the liquid appeared clear and 21 µL supernatant were transferred to a new
tube. 4 µL elute target buffer 2 were added, mixed thoroughly and centrifuged.
5 µL resuspension buffer were added, the reaction was mixed thoroughly and
briefly centrifuged. The captured DNA was then tested for enrichment of MERTK
using the TaqMan® Copy Number Assay HS00081049_cn specifically targeting
the region of MERTK present on the DM.
Table 2.5 Oligos designed for DM capture
Oligo Name Length Tm҅ GC % Sequence
Oligo 1 80 75 45 TAAATAAAGCAGTGAGTGTTCCCAGGGGACGCCATTCTATCTGAAATTGACCCCTAAGTAAACTTTGCCGACCCCTTCTA
Oligo 2 76 73 41 CCCCCTGAAAATGTGAGCTCTATAAGGGTGGGGATCTTGGTTTTATTCATGGATATATCCCAAGTTTCTGGAAAAA
Oligo 3 81 75 46 ACTGGGGATAATACAGTGATTTCCCATAAACCCCACCCCCACTTTCCCCTATCGTTAGCATTTTACATTGGTGTGGTGCAT
Oligo 4 79 75 44 GGATCAGGTGAGCCTCAGAACCCACTTTCCTTGATATTGGGGCTAGCGATTTGCAGTAAAAATCTAAATGATCCTGCTT
Oligo 5 78 75 45 CAAAGGTCTCCTCATTTCATTAGTGAATAGGAAAGTGGGTCTGCGTTCACTTCTTTGGCCCTTCACTGGAAGACTTCT
Oligo 6 78 77 50 GTTTAAGGATTTTTCTTCCTTCCAAGGATGGGCATGGAGGGCATTTCTCCATCTCTGTACAGAGTCCCCTGACCTCCC
2.16 Bioinformatic data analysis
This project was performed in collaboration with computational analysts in the
Computational Biology lab at the Cancer Research UK Cambridge Institute. In
particular, read mapping, somatic mutation calling and copy number calling was
performed by Lawrence Bower and Ginny Devonshire using the ICGC oesopha-
geal adenocarinoma pipeline established by Secrier et al. (Secrier et al. [242]).
Downstream analysis of the variants, as well as RNA-seq and EPIC methylation
array analysis was performed by Dr Juliane Perner and Dr Andy Lynch as indic-
ated in the text.
2.16.1 WGS analysis
For the WGS analysis a blood sample of the patient was used as a germline
reference.
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Read alignment
The reference genome used for the alignment of the WGS data is the Homo sapi-
ens (human) genome assembly GRCh37_g1k (hg19). Alignment was performed
using BWA MEM and duplicated reads were discarded using Picard.
Somatic mutation and indel calling
Somatic mutations and indels were called using Strelka 1.0.13 (Saunders et al.
[234]). SNVs were filtered using the same filters as in Secrier et al. (Supplement
Table 11). Variants were annotated using the Variant Effect Predictor (VEP re-
lease 75). The following VEP annotations were used to categorise SNVs as non-
synonymous: missense, nonsense, stop_gained, stop_lost, splice_donor_variant,
splice_acceptor_variant, splice_region_variant and initiator_codon_variant.
Variant allele frequency re-estimation
SNVs detected in the different samples were merged and the variant al-
lele frequency was re-estimated using the ReadCountWalker in the gatk-tools
(https://github.com/crukci-bioinformatics/gatk-tools). The minimum mapping qual-
ity was set to 10 and the minimum base quality to 30. For all down-stream analysis
a position with at least one variant supporting read was counted as a SNV unless
otherwise stated.
Mutational signature proportions
The contribution of predefined mutational signatures to the observed spec-
trum of mutations was estimated in R. The SomaticSignatures and the BSgen-
ome.Hsapiens.UCSC.hg19 packages were used to calculate the trinucleotide fre-
quencies. The contribution each signature in the cosmic database was calculated
using the deconstructSigs package (using the package’s signature definition).
Copy number and loss of heterozygosity analysis
Read counts at heterozygous single nucleotide polymorphisms positions were es-
timated using GATK 3.2-2 (McKenna et al. [186]) and used in the somatic absolute
copy number calling. ASCAT-NGS v2.1 (Loo et al. [164]) was used to estimate tu-
mour cellularity and absolute genome copy number after correction for estimated
normal-cell contamination.
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2.16.2 RNAseq analysis
Expression quantification
Fastq-files of multiple technical replicates were combined and transcript expres-
sion was quantified using salmon 0.8.2 and the Ensembl GRCh37 (90) transcript
index. Transcript expression was summarised to gene-level using tximport in R
and the so-defined abundance measured in transcript per million (TPM) was used
in downstream analysis.
Estimation of immune cell infiltration
The Tref definition of immune cell markers defined in the R package EPIC (Racle
et al. [220]) was used to estimate the proportion of RNA derived from CD8+ T-
cells, CD4+ T-cells, B-cells, Macrophages, NK-cells, CAFs and endothelial cells.
The estimated proportion of other cells was used to estimate the non-immune cell
content, e.g. tumour content.
2.16.3 Methylation
The minfi package (Aryee et al. [6]) was used to process the EPIC methylation
array data. Minfi’s estimateCellCounts function with parameters composite cell
type DLPFC and cell types NeuN_neg and NeuN_pos was used to estimate the
proportion of neurons from the methylation signal.
2.17 Analysis performed by Dr A. Lynch
2.17.1 Tumour content estimates with Crambled
For an improved estimate of the tumour content Dr Lynch used his tool Crambled
(Lynch [177]).
2.17.2 Clonality/Phylogenetic analysis
The following analysis was performed by Dr Lynch based on the output files of
Dr Juliane Perner. In total, 445,927 sites were called as SNVs from the 9 tumour
samples. A matrix of allele fractions for all samples at the 445,927 sites was as-
sembled to investigate. This was done in R using Rsamtools pileup. The exact
procedure is documented in a markdown documents which can be found in the
the Supplementary Material. In this analysis Dr Lynch used the Illumina index
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labels as the names of the samples. The key is as follows: PA=A014, PB=A016,
PC=A018, R1A=AOO2, R1B=A004, R1C=A013, R2A=A005, R2B=A007 and
R2C=A012.
2.17.3 DM phylogeny supported by 10X Genomics data
Rsamtools scanBam was used to obtain the read sequences, alignments and 10X
tags for each read from the provided 10X bams. Only reads with "perfect" cigars
were used so that genotypes could be extracted lazily. Reads not matching the
two expected alleles at a site were discarded. An explanation of the further pro-
cedure is given within the results chapter "The phylogeny of the DM" on page 98.
2.17.4 RNAseq for DM analysis
RNA reads were trimmed using Trim Galore! and aligned using hisat2-2.0.5.
"Coverage" as a surrogate for expression in the plots was calculated as the num-
ber of well-mapped reads starting in a 100 bp window. Reads linking different
segments of the DM were identified by read-names in the bam files. Plots were






In 2012 a 50-year old female presented with a 3-week history of increasingly
severe frontal/orbital headaches accompanied with vomiting in the final week. Ini-
tial MRI scans revealed a 4.5 cm, well-defined, heterogeneously enhancing mass
in the lateral right frontal lobe with moderate edema, consistent with a HGG (Fig-
ure A.1 on page 159 in the Supplementary Material). The patient underwent
5-ALA fluorescence-guided subtotal resection with a 27x12 mm area of enhan-
cing tumour left behind, seen at the posterior margin on postoperative imaging
(Figure A.1). Histopathological analysis confirmed a diagnosis of GBM (Figure
3.1A-F) by demonstrating endothelial proliferation (Figure 3.1C), palisading nec-
rosis (Figure 3.1D), and a MiB-11 of 20%. (Figure 3.1E). The pathological samples
tested positive for TP53 (Figure 3.1F) and MGMT gene promoter methylation and
tested negative for IDH1 mutations (data not shown). The patient completed a
full course of radiotherapy (60 Gy in 30 fractions) with concomitant TMZ. Three
cycles of adjuvant TMZ were given prior to halting therapy due to myelosuppres-
sion (3rd cycle given at dose-reduction of 150 mg/m3). Almost two years after
the first surgery, significant progressive disease was found on MRI with tumour
extending across the corpus callosum and into the right internal and external cap-
sules (Figure A.1). The patient underwent a second 5-ALA fluorescence-guided
subtotal tumour resection in an attempt to improve treatment effect and to main-
tain her good performance status. The patient was rechallenged with nine cycles
of TMZ and the tumour showed excellent response. The first cycle was at stand-
ard dose of 200 mg/m3, but the remaining cycles were reduced to a dose of 100
mg/m3 due to intermittent episodes of thrombocytopenia. Follow-up imaging 16
months later showed significant progression of the left frontotemporal GBM with
a large area of enhancement of the right frontal operculum and anterior tem-
poral lobe extending to orbital gyri inferiorly and periventricularly and the sub-
ependymal zone of the right lateral ventricle more superiorly (Figure A.1). Ima-
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ging also demonstrated mass effect with effacement of the frontal horn of the right
lateral ventricle and some subfalcine herniation. A third 5-ALA guided debulk-
ing was performed, but residual disease was left in situ around exposed middle
cerebral vessels. Post-operatively, the patient suffered from an acute right middle
cerebral artery stroke causing left hemiparesis and slurred speech. The patient
received further care from a Stroke and Palliative Care Unit. No further oncolo-
gical treatment was recommended and the patient passed away two months later.
Figure 3.2A gives a detailed overview of the patient, her surgeries and treatment
timeline. Figure 3.2B illustrates how the samples were taken and processed. Dur-
ing each surgery (P=Primary, R1=first recurrence, R2=second recurrence) three
fluorescent samples (A, B and C) at least 1 cm apart were collected, cut into
smaller pieces, and frozen. A cell line (R2CL) was derived from a sample of the
second recurrence. One piece of each sample was processed with the AllPrep
DNA/RNA/Protein mini kit to ensure all downstream applications were spatially
identical: WGS, EPIC methylation, RNAseq and western blot. Based on the WGS
results and the sample quality, an additional piece from each of PC, R1B, R2A and
DNA from R2CL was chosen for 10X Genomics Chromium linked-read sequen-
cing. Primary samples were treatment naïve and samples from the recurrences
treated with TMZ and radiation (R1) or only TMZ (R2) as depicted in the patient
timeline. DNA extracted from blood was used as the germline reference.
1Molecular immunology Borstel (MiB) is an antibody used to label Ki67 protein only expressed
in the active G(1)-,S-,G(2) and M-phase of cells. Ki67 serves as a marker for dividing cells and is
used to determine the proliferating fraction of a cell population.
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Figure 3.1 Histopathological stainings of the primary GBM.
A| Two H&E stained tumour sections from the same tissue piece showing areas with high tumour
(left) and low tumour cell density (right). B| H&E staining showing high tumour cell density 40x.
C| H&E staining showing low tumour cell density and microvascular proliferation. D| H&E staining




Figure 3.2 | Patient details, sample information and general workflow
A| The timeline displays patient details, surgery dates and the treatment course.
B| Samples were taken under 5-ALA fluorescence guided surgery. During each surgery
(P=Primary, R1=Recurrent1 and R2=Recurrent2) three spatially distinct samples (A, B and C)
were collected and frozen for further analysis. A sample of the third surgery was taken to derive
a cell line (R2CL). All tissue pieces were processed with the AllPrep DNA/RNA/Protein mini kit.
Whole-genome sequencing, EPIC methylation, RNAseq and some proteomics were performed.
For 10X Genomics Chromium linked-read sequencing three samples and the cell line R2CL were




Solid malignant tumours consist not only of cancer cells, but also harbour normal,
tumour-associated epithelial cells, stromal cells, immune cells and vascular cells.
The purity of a tumour sample affects the quality of the downstream analysis; it
may interfere with analysis of the tumour cells involved, but may also give addi-
tional insight into the tumour and its environment. The use of 5-ALA-induced tu-
mour fluorescence to distinguish normal brain tissue from highly malignant tissue
not only helps the surgeon to achieve a significantly higher rate of complete resec-
tion, but also helps to collect samples of high tumour cell density (Hadjipanayis,
Widhalm and Stummer [97]). Nevertheless, false positive fluorescence has been
reported in rare cases (Tonn [268] and Hadjipanayis, Widhalm and Stummer [97]).
To ascertain the level of cellular heterogeneity in the tumour analysis, ASCAT
(Loo et al. [165]) was used to calculate tumour content (Figure 3.3, top panel).
The samples of the primary tumour (P) showed a particularly low tumour content:
24% (A), 26% (B) and 24% (C). The samples of the first recurrent tumour (R1)
showed the greatest divergence between samples of the same surgery; R1A’s
tumour content was only 26%, whereas R1B and R1C had a tumour content of
93% and 87%, respectively. All samples obtained from the second recurrence
(R2) showed a high tumour content: 90% (A), 71% (B) and 85% (C).
To identify the other cell types in the samples we made use of the RNAseq
and DNA methylation data. By running EPIC (Racle et al. [220]) on the RNAseq
data we estimated the immune and stromal cell content of all samples (Figure
3.3, middle panel). This tool estimates how many immune cells are present in
a sample by comparing the expression pattern of known immune cell markers to
the expression signature in our sample set. The samples with the lowest tumour
content (all samples from P and R1A) showed the highest stromal and immune
cell infiltration with a fractional estimate over 25%, whereas all other samples were
below a 25% stromal and immune cell fraction. For P1A, the estimate of stromal
and immune cell infiltration was 60%, the highest of all samples. Furthermore,
we estimated the neuronal content of the samples by applying the minfi package
(Aryee et al. [6]) on the Infinium Methylation EPIC array data (Figure 3.3, bottom
panel). Samples with the highest tumour cell content (R1B and C and all samples
of R2) showed the lowest evidence of a neuronal methylation signature, with the
exception of R1A. Despite the low tumour content estimate, this sample also had
a low score for a neuronal methylation pattern, which supports the finding that
this sample contains mainly other cells such as stromal or immune cells. The low
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Figure 3.3 | Tumour purity and cellular heterogeneity.
Top panel: Tumour purity estimated by ASCAT using WGS data.
Middle panel: Immune and stromal cell infiltration estimated by EPIC using bulk RNAseq data.
Bottom panel: Neuronal cell content estimated by minfi using Infinium Methylation EPIC array
data.
tumour cell density of all P samples and R1A must be taken into consideration
when assessing the following analysis.
As will be seen, two samples, PB and R1A, showed anomalies in the fol-
lowing analysis, which are explainable if we assume an overestimation of cellu-
larity by ASCAT. Therefore in the last few weeks, we reanalysed the cellularity
using Crambled (Lynch [177]). Assessed by Crambled, the tumour content of the
primary tumour is generally lower (<20%) than estimated by ASCAT, and for PB
and R1A Crambled estimated the tumour content as only approximately 6% which
indeed explains the difficulties with these samples in the analysis (Table A.1 on
page 159 in the Supplementary material).
3.3 The mutational landscape of the tumour
3.3.1 Single Nucleotide Variants (SNV)
Analysis of the WGS data revealed a much higher mutational burden (hypermuta-
tion) of the samples of the second recurrence compared to blood (Figure 3.4A).
The number of mutations found in all samples of the primary and the first recurrent
tumour was below 15,000, whereas all samples of the second recurrence showed
a massive increase in the number of mutations detected. R2A and R2C both
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had over 300,000 mutations per sample, while sample R2B had half as many
(150,000) mutations detected. As there is an expected high false negative rate
when calling mutations in samples with low tumour purity, we made use of the
fact that all samples are from the same patient and hence related. When calling
SNVs lower quality reads were included if found in at least one other sample. The
difference between confidently called mutations and mutations included based
on information from other samples is visualised as darker hues on the bottom of
the bars (confidently called) and lighter hues on the top of the bar (low quality call
supported by other samples) (Figure 3.4A). Especially for primary tumour and first
recurrence samples, this analysis had a big influence on the SNV count, which
emphasises the advantage of multiple sampling during surgery.
To get a first impression of the evolution of the tumour we looked into which
mutations were unique in every sample, which mutations were shared with at
least one other sample of the same surgery, which mutations were shared with at
least one sample of another surgery and which mutations were shared amongst
all samples (Figure 3.4B). Sample B of the primary tumour (PB) and sample A
of the first recurrence (R1A) showed the highest fraction of unique mutations and
the lowest fraction of overall shared mutations within their surgeries. Sample A
and C of the hypermutated second recurrence (R2A and R2C) had a very high
proportion of mutations shared within their surgery, but only a very low propor-
tion of unique mutations. For R2C the proportion of unique mutations was under
1%. In contrast, sample R2B was the most divergent sample compared to all
other samples with almost 60% of its mutations being unique. To determine which
sample most closely resembles the cell line derived from the second recurrence,
we compared the SNVs of the cell line to the SNVs of the tumour samples. With
a Jaccard index2 of approximately 0.4 the cell line R2CL is most closely related to
sample R2B (Figure 3.4C).
3.3.2 The mutational pattern
The hypermutation detected in the second recurrence of the patient is a known
event in recurrent GBM. It was first described in recurrent GBM in 2006 by Hunter
et al. and has been linked to TMZ treatment (Hunter et al. [122]). To test if
the hypermutation detected in the second recurrence of our patient shows the
same pattern as hypermutation induced by TMZ we looked at the fraction of each
2The Jaccard index is a statistic used to measure the similarity or diversity between two sample
sets. It is calculated as follows: Jaccard index=(number of mutations in both sets)/(number of
mutations in either set). The closer to 1, the more similarity between the two sample sets tested.
Example: ঱)ষ 2- হ3প঳* > }ষ 2 Җ হ3প঳}0}ষ 2 җ হ3প঳}
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Figure 3.4 | Genetic variation between samples based on SNVs.
A| Hypermutation of the second recurrence. Shown are the number of SNVs detected in each
sample. The darker hues on the bottom of each bar represent the number of mutations confidently
called in each sample whereas the lighter hues on top show mutations with lower quality calls but
with support from other samples. This analysis accounts for the relatedness of the samples.
B| Fraction of shared mutations between spatial and longitudinal samples.
C| Jaccard similarity index for R2CL to all samples.
type of base pair changes in all samples (Figure 3.5A). The majority of basepair
changes found in all samples were C?T transitions. Comparing the fraction of
C?T transitions between the samples from different time points, there was a clear
increase of this type of mutation in the second recurrence, which was also retained
in the cell line. Looking at the base pair context in which these C?T transitions
occurred there was also a clear change from transitions mostly happening in an
NpCpG context in the primary and first recurrent tumour to transitions in a NpCpC
and NpCpT context in the second recurrence and the cell line (Figure 3.5B). The
full mutational pattern for all samples can be found in the Supplementary Material
(Figure A.2) on page 160.
A comparison of base pair changes in their base pair context for all samples
of the second recurrence and the cell line showed slight differences in their muta-
tional patten (Figure 3.6). R2B and the cell line both showed more C?T transitions
in a CpCpN context than samples R2A and R2C.
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Figure 3.5 | Characterisation of mutations.
A| Proportion of base pair changes by type in all samples.
B| C?T transitions in their base pair context for one representative sample of each surgery and
the cell line.
Figure 3.6 | Differences in the mutational pattern of the second recurrence.
Shown are the base pair changes in their base pair context for all samples of the second recur-
rence and the cell line.
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3.3.3 The mismatch repair (MMR) system
Treatment of brain tumours with TMZ does not always lead to hypermutation of
the recurrent tumour. The reason only some tumours hypermutate under TMZ
treatment is not known. In our case, hypermutation of the tumour only happened
after the resection of the first recurrence, when the tumour was treated a second
time with TMZ.
As deficiencies in MMR are linked to hypermutation of GBM under TMZ treat-
ment, we looked at the non-synonymous, somatic mutation status of the tumour
samples compared to the blood reference of the following MMR genes: MSH2,
MSH6, MSH3, PMS1, PMS2, MLH1, and MLH3. Out of these seven genes, four
genes (MLH1, MSH2, MSH6 and PMS2) were found to be altered, but only in the
samples of the second recurrence and the cell line, R2CL, derived from it (Figure
3.7). No mutations in these genes were found in the samples of the primary and
the first recurrent tumour. We found one mutation each in MLH1 and MSH2, five
different mutations in MSH6 and two different mutations in PMS2. All mutations
detected were either C?T transitions (six out of nine mutations) or G?A transitions
(three out of nine mutations) and thus could possibly be induced by the drug it-
self. Samples R2B and R2CL only showed mutations in MSH6, whereas R2A
and R2C showed mutations in all four genes. The cell line, most closely related to
sample R2B, only had two MSH6 mutations. If a deficiency in the MMR system is
responsible for the development of a hypermutation phenotype under TMZ treat-
ment, then this difference in mutations in the MMR system between R2B and the
other two samples of the second recurrence would further support the hypothesis
that the hypermutation has evolved twice in our patient.
Searching for these mutations in ClinVar (https://www.ncbi.nlm.nih.gov/
clinvar/) I found six out of nine mutations annotated (Table 3.1). Of the remaining
three mutations two were intronic (the MLH1 mutation and one MSH6 mutation).
All MSH2 and exonic MSH6 mutations were reported in connection with either
Lynch Syndrome or other Hereditary Cancer Predisposition Syndromes (HCPS).
The mutations’ significance was uncertain in all cases except MSH6 C?T trans-
ition at chr2:48033352, which was classified as "likely pathogenic".
To test if the protein expression levels of MSH2 and MSH6 were influenced by
the mutations found in the second recurrence, I performed western blot analysis
on all samples of the patient and the cell line (Figure 3.8A). The protein expres-
sion levels of MSH2 and MSH6 did not seem connected to the mutational status
of the genes, which was not surprising as none of these mutations led to a new
stop codon. The low tumour purity in the primary tumour and the sample R1A de-
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Figure 3.7 | Mutations in the MMR system
Shown are the mutations found in the MMR system (MSH2, MSH6, MSH3, PMS1, PMS2, MLH1,
and MLH3). Genomic regions are based on Homo sapiens (human) genome assembly GRCh37
(hg19).)
Table 3.1 MMR mutations found in R2 and R2CL
Genomic regions are based on Homo sapiens (human) genome assembly GRCh37 (hg19)
Gene location transition aa change significance conditions
MLH1 chr3:37038791 G?A intronic n/a n/a
MSH2 chr2:47703695 C?T T732I uncertain HCPS
MSH6 chr2:48033352 C?T T1219I uncertainlikely pathogenic Lynch syndromeHCPS
MSH6 chr2:48032167 G?A intronic n/a na
MSH6 chr2:48028082 C?T T987I uncertain HCPS
MSH6 chr2:48027463 C?T P781S uncertain Lynch syndrome
MSH6 chr2:48026135 G?A R338G no literature no literature
PMS2 chr7:6043632 C?T G74A uncertain not specified
PMS2 chr7:6027065 C?T R338S no literature no literature
creases the informative value of an expression level comparison of these samples
to the other tumour samples. Sample R1B showed the highest expression of both
proteins compared to all other samples, with the exception of the cell line. The
expression of MSH2 in R2CL was much higher than in any other sample.
We also looked at the mRNA expression of the whole MMR pathway and
also included POLD (encoding POLౙ), POLE (encoding DNA polymerase epsilon
(POL౰)) , MPG (encoding N-methylpurine DNA glycosylase (MPG)) and MGMT in
our analysis (Figure 3.8B). Both polymerases are involved in DNA repair and are
linked to cancers with high mutational burden (Jansen et al. [128] and Chalmers et
al. [35]), whereas MGMT and MPG are enzymes which remove alkylation lesions.
The expression levels of MSH2 and MSH6 mRNA roughly reflected their protein
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expression levels. MSH3 showed the lowest mRNA expression in all samples,
whereas MPG was expressed at relatively high levels in all samples. POLD and
POLE both showed high expression in the samples with high tumour purity and
varying expression levels in samples with lower tumour purity. As opposed to
MPG, the expression of MGMT mRNA was low. Notably, MGMT expression was
even lower in the samples with higher tumour purity compared to samples with
lower tumour purity. This is concordant with the MGMT promoter methylation
status of the tumour, which leads to a lower expression of MGMT in malignant
tissue. Sample R1B showed particularly low MGMT expression.
Figure 3.8 | Expression levels of proteins and mRNA in the MMR system.
A| Protein expression of MSH2 (left) and MSH6 (right) normalised to b-actin.
B| RNA expression levels of all players in the MMR system (left) and POLE, POLD, MPG and
MGMT (right).
To test if any mutated MMR genes were expressed, we searched for mutant
mRNA versions of MLH1, MSH2, MSH6 and PMS2 in the RNAseq data of the
second recurrence. All MMR mutations, except of the MLH1, were confirmed and
shown to be expressed at the mRNA level (Figure 3.9). Mutant MMR genes were
only expressed in the samples where they have been detected by WGS.
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Taking all results of the MMR pathway analysis together, this suggest that
no single somatic alteration of the pathway is responsible for the development
of a hypermutation phenotype under TMZ treatment; rather an accumulation of
mutations in these genes is responsible for the phenotype. We hypothesise that
every mutation impairs the functions of the affected protein slightly, leading to
the breakdown of the MMR pathway as a whole. R2B, which has only half as
many mutations as R2A and C, only showed mutations in MSH6, leading us to
postulate that the number of mutations, or the number of affected genes, in the
MMR pathway may correlate with the rate at which the hypermutation develops.
Figure 3.9 | RNA expression levels of MMR mutants.
Shown are the expression levels of the identified MMR mutants compared to the expression of the
unaltered mRNA at the respective locus. Genomic regions are based on Homo sapiens (human)
genome assembly GRCh37 (hg19).
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3.4 Mutational pattern in cell culture
3.4.1 Strategy to induce hypermutation in vitro
The effect of hypermutation on tumour growth and aggressiveness is not well
understood. The cell line R2CL, derived from a sample of the second recurrence,
has maintained the hypermutation and mutational pattern detected in R2B, but as
there is no matching cell line derived from the primary or first recurrent tumour
to compare it to, studying the hypermutation phenotype of this cell line is limited.
Therefore, instead of using R2CL, I developed a strategy to induce hypermutation
in cell culture (Figure 3.10), keeping the unaltered original cell line as a negative
control.
As described in Figure 1.5 on page 33, the impact of TMZ on the tumour
depends on the MGMT promoter methylation status and the presence of a func-
tional MMR system. Therefore, I chose two GBM cell lines derived from patients
with positive MGMT gene promoter methylation test results (JR2M and AW20S1),
which were not hypermutated and were TMZ naïve. In these I knocked out MSH2
or MSH6 using the CRISPR-Cas9 system (with assistance from the CRISPR core
in designing the guides)(Figure 3.10A). The cell lines were transfected, using elec-
troporation, with plasmids carrying the Cas9 system containing either one of three
different guide RNAs targeting MSH2 (F93, F94, F95) or one of three different
guide RNAs targeting MSH6 (F96, F97, F98). Information about the guide RNAs
can be found in Table 2.4 on page 50 in Materials and Methods. The cells were
then left to recover and proliferate, resulting in a heterogeneous mixture of cells
with a knockout in either MSH2 or MSH6 and unaltered cells. As the freshly
transfected cells were very weak and a knockout in MSH2 or MSH6 leads to res-
istance against TMZ treatment, we decided against antibiotic selection of trans-
fected cells. Selection of MSH2 or MSH6 knockout cells by TMZ treatment of this
heterogeneous cell population in the experiment would be analogous to selection
in a patient (Figure 3.10B). A validation of the MSH2 or MSH6 knockout at the pro-
tein level can be seen in Figure 3.11. Figure 3.10C shows the treatment plan to
induce hypermutation in the MSH2 and MSH6 knockout cell lines. The treatment
plan was developed based on western blot analysis and TMZ dose-dependent
survival assays described in the following section.
Protein samples for analysis were taken after the recovery period following
the transfection, thus Figure 3.11 shows the bulk expression of MSH2 and MSH6
in the heterogeneous, unselected knockout cell lines normalised to the cell line
transfected with the control construct. In JR2M there is a clear reduction in the
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Figure 3.10 | Strategy to induce hypermutation in GBM cell lines.
A| GBM cell lines were transfected with the MSH2 or MSH6 ko constructs using electroporation.
In transfected cells a DSB is introduced by the Cas9 system in the target region of the gene and
repair via NHEJ leads to indels, a frameshift, and potentially, the formation of a stop codon. The
heterogeneous mixture of edited and non-edited cells was then left to recover and expand.
B| Treatment of the heterogeneous mixture of edited and non-edited cells with TMZ selects cells
where a MSH2 or MSH6 ko was successful.
C| Transfected cells were treated for nine weeks every Monday and Wednesday with TMZ or
DMSO. Five weeks of this treatment was given at a dose of 300 µM and the remaining four weeks
were given at a lower dose of 150 µM. Medium was changed every Friday and cells were split if
they reached confluence.
overall expression of both proteins with all constructs (Figure 3.11A). I observed
that when knocking out MSH2 (F93, F94, F95) there is not only a reduction in
the expression of MSH2, but also a reduction of MSH6 and vice versa. This is
consistent with the literature, which shows that the proteins stabilise each other
when forming a heterodimer (Marra et al. [182] and de Wind et al. [49]). The
reduction of MSH2 and MSH6 protein levels in AW20S1 was less pronounced,
which was probably the result of a lower transfection efficiency in this cell line
compared to JR2M (Figure 3.11B).
In order to find a suitable concentration of TMZ to select edited cells and to
induce hypermutation, the MSH2 and MSH6 knockout cell lines of JR2M were
treated with TMZ every two days for six days with a serial concentration of TMZ (0,
100, 300, 500, 700, 900 µM) and then analysed using an MTT assay which meas-
ures cell viability (Figure 3.12). All MSH2 or MSH6 knockout cell lines tested in
this experiment showed a higher resistance to the treatment compared to control
cell lines (untransfected cell line and cell line transfected with control construct).
For the hypermutation of MSH2 or MSH6 knockout cells, I was looking for a con-
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Figure 3.11 | Knockout of MSH2 and MSH6 at the protein level.
Protein level of MSH2 and MSH6 in cell lines JR2M and AW20S1 transfected with MSH2 knock-
out constructs (F93, F94, F95), MSH6 knockout constructs (F96, F97, F98) or both (F93/F97,
F94/F98). Transfected cell lines have not been selected after transfection.
A| Protein level of MSH2 (left) and MSH6 (right) in cell line JR2M.
B| Protein level of MSH2 (left) and MSH6 (right) in cell line AW20S1.
centration which would kill the non-edited cells quickly, but would allow the edited
cells to survive. As 100 µM TMZ only had an effect on two of the four knockout
cell lines tested, I decided on the next higher concentration (300 µM) as the ini-
tial treatment concentration to induce hypermutation. I started treating the cells
with 300 µM TMZ or DMSO without TMZ twice a week with a medium change
before the weekend. Cells transfected with the same construct but not containing
guide RNAs did poorly and died after only three weeks of treatment, in contrast to
the knockout cell lines, which were not proliferating, but alive. This confirmed the
knockout-mediated resistance against TMZ, but in order to produce hypermuta-
tion, replication of the alkylated DNA must occur (see Figure 1.5 on page 33). To
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Figure 3.12 | Effect of MSH2 and MSH6 knockout on TMZ sensitivity.
MTT assay of TMZ-treated cell line JR2M with MSH2 or MSH6 knockout. The six cell lines indic-
ated above were seeded on 96-well plates and treated with a serial concentration of TMZ for six
days. Medium containing TMZ was changed every two days. The results are presented as the
mean ±SD of three technical replicates and are expressed relative to DMSO treated control cells.
give the cells the chance to proliferate, I halved the dose of TMZ after five weeks
and treated the cells for an additional four weeks. Knockout cell lines treated with
DMSO proliferated normally with either dose of DMSO and had to be split once a
week. After nine weeks of treatment I waited for the cell lines to recover (between
two and four weeks) and then isolated DNA for sequencing.
3.4.2 Induced hypermutation after MSH6 knockout
To test if the TMZ treatment regime in combination with the MSH2 or MSH6 knock-
out induced hypermutation, we performed shallow WGS (average depth 5X) on
the unaltered JR2M cell line, the cell line transfected with empty vector and the cell
line transfected with the MSH6 knockout construct F97 untreated, DMSO-treated
and TMZ-treated. As we did not have a blood sample as a germline reference,
variants were filtered to exclude all variants appearing in the 1000 Genome data
set (Durbin et al. [55]) in order to remove likely germline variants. The sequencing
results confirmed an indel in MSH6 at the position expected for the F97 knockout
construct (Figure A.3 page 161). No off-target effects could be detected at the
three most likely off-target effect locations. The number of mutations found in the
four control samples was approximately 100,000, whereas the TMZ-treated MSH6
knockout cell line showed approximately 525,000 mutations (Figure 3.13A). To
test if the hypermutation induced by TMZ showed the same mutational pattern as
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the samples of the second recurrence of our patient, we looked at the fraction of
each type of base pair change in all cell samples (Figure 3.13B). The majority of
base pair changes found in all control samples were C?T (25%) and T?C (25%)
transitions, whereas the C?T transitions exceed 80% of base pair changes in the
TMZ-treated MSH6 knockout cell line. Looking at the base pair context in which
these C?T transitions occur there is a clear change from transitions mostly hap-
pening in an ApCpG context in all controls to transitions in an NpCpC and NpCpT
context in the TMZ-treated MSH6 knockout cell line (Figure 3.13C). The full muta-
tional pattern for all samples can be found in the Supplementary Material (Figure
A.4) on page 162.
We also analysed JR2M with the MSH2 knockout construct F93 by exome
sequencing. In spite of using only exome sequencing, it was clear that knock-
ing out MSH2 produced results that are almost identical to MSH6. The number
of mutations rose six fold compared to controls with most mutations being C?T
transitions (see Figure A.5 on page 163 in the Supplementary Material). Further
whole exome analysis will be performed on other patient derived GBM cell lines
and a double knockout of MSH2 and MSH6. This result is similar to what we
observed in the patient samples. Thus I have demonstrated, as a novel result,
that TMZ-induced hypermutation in patients can be reproduced in cell culture by
knocking out MSH2 or MSH6 in patient derived MGMT promoter methylated cell
lines and TMZ treatment.
In order to determine if the hypermutations in the 3-Peater and the cell line
were the result of the same mutations in the MMR, we compared all the muta-
tions found in both. The results have to be interpreted with care, however, as
the median target coverage for the cell line was only 5X and some mutations are
supported by <10 reads. In the 3-Peater we found nine MMR mutations, all in
the hypermutated second recurrence, whereas we found a total of 39 mutations
in the cell line. All mutations found were C?T and G?A transitions. 38 of the cell
line mutations were found in the hypermutated, TMZ-treated cell line, of which
three were also found in some of the control samples (one MLH1 and two MSH2
mutations). One mutation (PMS2 chr7:6017902 G?A) was detected in all control
samples, but not in the TMZ-treated cell line. As the cell lines were not analysed
against a germline reference and we did not sequence a tumour sample of the
patient from which the cell line originated, it is not clear if the mutations which
were found in all control samples were germline mutations, somatic mutations or
cell culture artefacts. None of the MMR mutations detected in the 3-Peater were
detected in the cell lines.
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Figure 3.13 | Mutational landscape of JR2M with MSH6 knockout after treatment with TMZ.
Controls are JR2M unaltered, JR2M with control construct eV, JR2M F97, JR2M F97 DMSO
treated.
A| Hypermutation of the TMZ-treated JRM2 line with MSH6 ko (F97). Shown are the number of
SNVs in thousands detected in each sample
B| Fraction of base pair changes in all samples.
C| C>T transitions in their base pair context for JR2M cells with F97 construct untreated, DMSO
treated and TMZ-treated.
The fact that the number of mutations found in the MMR system of the cell
line is 4-fold higher than in the patient could be due to a harsher TMZ treatment
in the experiment compared to the treatment of the patient. There are several
factors that distinguish treatment of cells in culture and treatment of cells in the
patient which render it impossible to give a physiologically comparable dose of
TMZ. Firstly, TMZ is an oral prodrug, which decomposes into its effective meta-
bolite at a pH >7, but is stable under acidic condition. The pH-dependent bio-
transformation of TMZ has significant variability between organ, tissue, or cell
compartments; thus conditions in cell culture may be very different from the con-
ditions the drug is exposed to when taken by a patient. Secondly, only 20% of
the AUC (concentration-time curve) plasma was shown to penetrate into the CSF
(Ostermann et al. [209]). Thirdly, the cells in culture are not protected from the sur-
rounding medium by anything other than their cell membrane, whereas the cells
77
3. Results
in the brain are separated from the circulating blood by an additional, highly se-
lective, semipermeable border; the BBB. Therefore, rather than designing my ex-
periment based on physiological TMZ dosages, I determined the treatment dose
for the cells empirically based on the viability results of the MTT assays.
Figure 3.14 | Mutations in the MMR system of JR2M
Shown are the mutations found in the MMR system (MSH2, MSH6, MSH3, PMS1, PMS2, MLH1,
and MLH3). Genomic regions are based on Homo sapiens (human) genome assembly GRCh37
(hg19).
3.4.3 No hypermutation phenotype development in a MGMT
unmethylated cell line
Having established a strategy to reproduce TMZ-induced hypermutation in a pa-
tient derived GBM cell line, we wanted to test if the same results can be obtained
in a MGMT promoter unmethylated cell line. We performed WES on the MGMT
promoter methylated cell line AW20 with MSH2 or MSH6 knocked out, on JR2M
with MSH2 knocked out and on the MGMT promoter unmethylated cell line J3T6
with MSH2 or MSH6 knocked out. The knockout at the protein level was success-
ful in all cell lines (Figure 3.11 for AW20 and JR2M and A.6 on page 164 for J3T6).
TMZ treatment of the cell lines AW20 and JR2M with the MSH2 or MSH6 knock-
out resulted in hypermutation (Figure 3.15). Cell lines without the gene knockout
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died during TMZ treatment. The number of mutations increased from approx-
imately 5,000 mutations in the DMSO treated controls to approximately 35,000
mutations in the TMZ treated MSH2 knockouts of JR2M and AW20 and to ap-
proximately 25,000 mutations in the MSH6 knockout of AW20 (Figure 3.15A). In
the MGMT promoter methylated cell line J3T6, controls and TMZ treated MSH2
and MSH6 knockouts all showed approximately 5,000 mutations (Figure 3.15A).
No hypermutation was detected. In the hypermutated cell lines a increase of C>T
transitions was observed compared to controls (Figure 3.15B) in the for TMZ typ-
ical base pair context of NpCpC and NpCpT (data not shown).
Figure 3.15 | The hypermutation phenotype cannot be induced in the MGMT promoter un-
methylated cell line J3T6
A| Hypermutation of the TMZ-treated, MGMT promoter methylated cell lines JR2M and AW20
with MSH2 (F93 and F94) or MSH6 knockout (F98). No increase in mutations of the TMZ-treated,
MGMT promoter unmethylated cell line J3T6. Shown are the number of SNVs in thousands de-
tected in each sample.
B| Fraction of base pair changes in all samples.
3.4.4 Hypermutation "onset" without preceding MMR knock-
out
In our patient there was no evidence for a mutation or structural variance in MSH2
or MSH6 until the second recurrence. We wanted to test if it is possible to induce
hypermutation in a patient derived cell line without altering the MMR pathway prior
to treatment. As all control cell lines in the knockout experiment died with the high
dose of TMZ used in the knockout experiment, we treated the original JR2M cell
line with low concentrations of TMZ over nine weeks. The cell line treated with the
lowest dose (1 µM twice a week for nine weeks) survived and was analysed by
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WES after a recovery phase of three weeks. Treatment of JR2M with this low dose
of TMZ (sample JR2M TMZ) led to double the number of mutations compared to
the control cell line not treated with TMZ (Figure 3.16A). Looking at the nature
of the gained mutations showed an increase in C>T transitions (Figure 3.16B) in
the NpCpC and NpCpT context (Figure 3.16C). Listing all the mutations detec-
ted in the MMR system of JR2M showed that mutations exclusive to TMZ treated
samples are all C>T or G>A transitions, which are possibly caused by TMZ (Figure
3.16D). As JR2M treated with a low dose of TMZ showed an onset of the hyper-
mutation phenotype without an introduced MMR impairment prior to treatment we
looked at the allele fraction, the consequence, the impact, the clinical significance
and the PolyPhen estimate of each MMR mutation (Table 3.2). The three PMS2
mutations detected in JR2M TMZ were not of C>T or G>A nature and were either
found in all samples analysed (chr7:6013049, C>G) or in the empty vector control
JR2M eV (chr7:6031660, T>C and chr7:6031658, T>C). These mutations were
either found in very low allele fraction (0.013 for chr7:6031660, T>C and 0.016
for chr7:6031658, T>C) or classified as benign (chr7:6013049, C>G). One of the
three MSH6 mutations (chr2:48027886, C>T) leads to a premature stop codon
and was the only MMR mutation classified as pathogenic.
Table 3.2 MMR mutations in JR2M after low dose of TMZ treatment
Genomic regions are based on Homo sapiens (human) genome assembly GRCh37 (hg19)
Gene location allele fraction consequence impact clinical significance PolyPhen
MLH1 chr3:37083774, C>T 0.012 synonymous variant LOW n/a n/a
MSH6 chr2:48033358, C>T 0.021 missense variant MODERATE uncertain benign
MSH6 chr2:48027886, C>T 0.133 stop gained HIGH pathogenic n/a
MSH6 chr2:48026021, G>A 0.053 missense variant MODERATE n/a probably damaging
PMS2 chr7:6031660, T>C 0.405 missense variant MODERATE benign benign
PMS2 chr7:6031658, T>C 0.013 missense variant MODERATE uncertain benign
PMS2 chr7:6013049, C>G 0.016 missense variant MODERATE n/a probably damaging
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Figure 3.16 | Onset of the hypermutation phenotype without preceding MMR gene knockout
A| Increased number of mutations in JR2M after nine weeks of low dose TMZ treatment (JR2M
TMZ). Shown are the number of SNVs in thousands detected in each sample.
B| Fraction of base pair changes in all samples showing an increase in C>T transitions in JR2M
TMZ compared to the untreated control.
C| C>T transitions in their base pair context for unaltered JR2M cells treated with a low dose of
TMZ compared to the untreated cell line, the hypermutated MSH2 (F93) cell line and the DMSO
treated F93 cell line.




In the first section of the results, I focused on the point mutations detected in
the tumour, but we also found structural changes involved in the pathology of the
tumour and its recurrences. Figure 3.17A shows what percent of the genome
was affected by copy number aberrations. With two exceptions (PB and R1A),
we found that approximately 16% of the genome was altered in its copy number
status. R2B, which was the most divergent sample of the second recurrence
based on SNVs, only differed by <1% of the genome being affected by CNAs
from the other samples of the same surgery. For samples PB and R1A ASCAT,
had problems detecting any CNAs. In these samples only 1% of the genome
was found to be affected by CNAs. These samples were also the samples with
the lowest number of point mutations called with high confidence amongst all the
samples with low tumour purity. The cell line R2CL showed a much higher CN
change than the tumour samples. Before taking a DNA sample for sequencing,
the cell line had been in culture for several months and was in passage six when
the DNA was isolated. Aneuploidy in long term cell culture is a frequent event,
and classified as a cell culture artefact. Looking into the sunrise plot of the DNA
analysis confirmed that the cell line was tetraploid at the time of analysis (see
Figure A.7 on page 165 in the Supplementary Material).
Copy number changes are highly conserved among all tumour samples (Fig-
ure 3.17B), as opposed to the single point mutations of which only around 50%
(samples of the primary tumour and first recurrence) or below 10% (second re-
currence) were shared. Over 95% of CNAs are shared between all samples.
Exceptions to this finding were PB and R1A, which showed a high proportion of
unique CNAs. These results suggest that CNAs were an early event in the tumour
and stayed mostly stable throughout tumour progression compared to the muta-
tions. Figure 3.17C shows the CNAs of the cell line R2CL compared to all tumour
samples. R2B, which shares the highest number of SNVs with R2CL, also shares
a marginally higher proportion of CNAs with R2CL compared to all other samples.
The low similarity of the cell line to the tumour samples can be explained by the
tetraploidy gained in culture.
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Figure 3.17 | Genetic variation between samples based on CNA found by ASCAT.
The ploidy of all tumour samples is 2 and the ploidy of the cell line is 4.
A| Fraction of CNA events in all samples. A deletion is detected when a segment shows a CN <
ploidy and an amplification when a segment shows a CN > ploidy. Note that PB and R1A showed
a tumour purity of under 6% which made this analysis uninformative for these samples.
B| Fraction of shared CNA regions between spatial and longitudinal samples. Each base falling
into a region with altered copy number was tested if unique, shared with a sample of the same
surgery, shared with a sample of another surgery or shared between all samples. The number
of bases was then added together. The cell line R2CL was excluded from this graph due to its
tetraploidy.
C| Jaccard similarity index of CNAs for R2CL to all samples.
3.5.1 Chromosome rearrangements in detail
To get an overview of which parts of the genome are affected by CNA, the chromo-
somes of each sample were mapped as a circos plot (Fig 3.18) and the bound-
aries of the most obvious shared gains or losses were taken from the ASCAT
results. We found amplification of chromosome 7 (4 copies), with a high focal
amplification of two sections at p11.2 and p14.3, both of which showed up to 100
copies per sample. Another high focal amplification in a similar CN range was
found on chromosome 2 at q13. Amplification of parts of chromosome 19 and 20
were also found. LOH was detected on chromosome 9p, 10 and 22q and smaller
parts of chromosome 6 and 1 (p36.32-p33). A homozygous deletion was found at
chromosome 9p21.3, including CDKN2A/B, and a homozygous deletion of tumour
suppressor Protein Tyrosine Phosphatase, Receptor Type D (PTPRD) (Ortiz et al.
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[206]). Further losses and gains of genes involved in brain tumours based on the
130 Heidelberg gene panel (Sahm et al. [230]) can be found on page 165 (Figure
































Figure 3.18 | Overview of copy number changes in all samples
Shown are CNA in all chromosomes of all samples of the 3-Peater. The inner rings depict samples
of the primary tumour, the middle three show the first recurrence and the outer circles show
samples of the second recurrence. Light red depicts amplifications, dark red depicts amplifications
of more than five copies. Light blue shows LOH with copy number change to 1, while purple shows
copy-neutral LOH. Dark blue depicts homozygous deletions.
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Because chromosome 2 and 7 showed such high levels of regional amplific-
ation we looked at their structural rearrangement in more detail (Figure 3.19 and
3.20). The CN profile at each time point is represented by one sample of each
surgery (PC, R1C and R2A) and the break points were determined by combining
all read pairs from all samples at each time point. The cell line was also included.
Only those chromosome rearrangements were considered which were not detec-
ted in the blood reference and thresholds for read-pairs were chosen to make the
plots clearer, maximise consistency across time points and allow for differing pur-
ities and numbers of samples, as indicated in the figure caption. Due to the low
tumour cell content in the primary tumour (and also stringent filtering), sample PC
showed the lowest level of structural rearrangement in both chromosomes (Figure
3.19 and 3.20). Despite its low power, this primary sample showed more internal
rearrangements of chromosome 2 than samples from the recurrences (Figure
3.19). The high focal amplification at chromosome 2 was shared between all lon-
gitudinal samples of the tumour and was part of several rearrangements involving
chromosomes 7 and 15 (in all tumour samples), 6 and 12 (in both recurrences)
and 18 (only detected in R1C). This high focal amplification and its associated
rearrangement vanished in the cell line, whereas almost all other rearrangements
affecting chromosome 2 were retained.
Chromosome 7 showed two highly amplified regions in all tumour samples,
which, like the high amplification in chromosome 2, were not detected in the cell
line (Figure 3.20). The two amplified regions were inter-connected in all samples
and showed further connections to other chromosomes. In the primary sample
one of the highly amplified regions connected to chromosome 19, whereas the
other highly amplified region connected to chromosome 4. These two connections
were retained in the recurrences. In the recurrences the highly amplified regions
gained further connections to chromosomes 5, 10, 11, 12, 14 and 15. While the
rearrangements associated with high amplification in chromosome 2 and chro-
mosome 7 vanished in the cell line, R2CL gained additional rearrangements in
chromosome 2 involving chromosome 12. Both highly amplified regions of chro-
mosome 7 showed involvement with the highly amplified region of chromosome 2
and all three pieces were shown to be connected, forming a potential ring struc-
ture. All three highly amplified regions showed several breakpoints, suggesting
high instability around these loci, but for each amplified region, two breakpoints
were supported by a particular high number of reads.
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Figure 3.19 | Structural rearrangements in chromosome 2
Linear presentation of chromosome 2. The red arcs (intra-chromosomal rearrangements) and the
blue peaks (inter-chromosomal rearrangements) are based on clustering discordant read pairs.
The height and thickness of the arcs and spikes are related to the number of supporting read
pairs (log-scale). Rearrangements are only included in the figure if they reach a given threshold of
read pairs. The threshold for each read pair is set independently depending on sample numbers
and purity. Read pair thresholds for PC are 20 (spikes) and 14 (arcs), for R1C, 30 and 30, for R2C
40 and 20 and for R2CL 40 and 20.
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Figure 3.20 | Structural rearrangements in chromosome 7
Linear presentation of chromosome 7. The red arcs (intra-chromosomal rearrangements) and the
blue peaks (inter-chromosomal rearrangements) are based on clustering discordant read pairs.
The height and thickness of the arcs and spikes are related to the number of supporting read
pairs (log-scale). Rearrangements are only included in the figure if they reach a given threshold of
read pairs. The threshold for each read pair is set independently depending on sample numbers
and purity. Read pair thresholds for PC are 30 (spikes) and 20 (arcs), for R1C, 50 and 30, for R2C
60 and 30 and for R2CL 30 and 20.
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3.5.2 The double minute
In order to validate that the three highly amplified regions form a ring, and to bet-
ter resolve the sequence, we sent one sample per surgery and the cell line for
linked-read sequencing by 10X Genomics. The three most supported fragments
were chr2:112711719-112731563 (fragment 1), chr7:30729854-30996592 (frag-
ment 2) and chr7:54787033-55286374 (fragment 3), which form an extrachromo-
somal ring structure (double minute (DM)) comprising 785,923 base pairs. The
fusion regions of these fragments were also validated using Sanger Sequencing
of PCR fragments spanning the fusions. The validation results can be found in
the Supplementary Material on page 91 in Figure 3.22. Fragment 1 only carries
part of MER Proto-Oncogene, Tyrosine Kinase (MERTK ) (intron 4, exon 5, in-
tron 5, exon 6 and part of intron 6). Fragment 2 contains the promoter region
of Corticotropin Releasing Hormone Receptor 2 (CRHR2), and the full sequence
of Indolethylamine N-Methyltransferase (INMT ), Family With Sequence Similarity
188 Member B (FAM188B) and AQP1. Fragment 3 contains the full sequences of
EGFR and Sec61 Translocon Gamma Subunit (SEC61G).
Figure 3.21 shows the DM with its boundaries defined by the 10X data. Blue,
red and green lines show points connected by read-pairs within the boundaries of
the DM, based on the WGS data, demonstrating the genomic instability around
these loci. Despite low power in the primary tumour, there were additional strongly
supported junctions, especially connecting the fragments of chromosome 7 (red
lines), but also a highly supported connection between MERTK (fragment 1) and
EGFR (fragment 3) (blue lines). All these highly supported connections vanished
in the recurrences, which showed more rearrangements, mostly between the frag-
ments of chromosome 7, but with fewer reads supporting them.
The detection of other highly supported junctions in the primary tumour sug-
gests that several possible versions of a DM might have existed before surgery
and treatment, for instance a DM not containing AQP1. As DMs segregate un-
equally to the daughter cells during cell division, their evolution is independent
of the clonal evolution of the cell population in which they reside. In the blood
reference, where we did not detect any high amplification of the DM fragments,
five connecting reads in total could be found to support the junctions of the DM,
but none of the junctions could be validated by PCR (Figure 3.22), suggesting
sequencing errors, such as index swapping, rather than the presence of the DM
in the reference sample. As the general trend suggests that there is more hetero-
geneity in the DM earlier on, it is also possible that we are looking for the wrong
junctions when looking for the DM in the germline DNA.
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In the cell line, R2CL, we detected more reads connecting fragments 1 and 3
with each other, than reads connecting the other two fragments. All DM junctions
in the cell line were also detected by PCR (Figure 3.22). Together with the finding
that the high amplification of the DM fragments vanished in cell culture, this sug-
gests that the selective pressure on the DM was lost in cell culture, but that this
did not affect the selection of the fusion between fragments 1 and 3. The loss of
the DM in cell culture is supported by FISH analysis of R2CL metaphase spreads,




Figure 3.21 | Fusion of breakpoints between the three fragments of the DM
Fragment 1 with part of MERTK (yellow). Fragment 2 with CRHR2 promoter, full sequence of
INMT, FAM188B and AQP1 (dark purple). Fragment 3 full sequences of EGFR and SEC61G (light
purple). White boxes represent genes (not only coding regions). Arrows indicate the transcription
orientation of the genes. Green lines are WGS reads spanning fragments 1 and 2, red lines span
fragments 2 and 3 and blue lines span fragments 3 and 1. The number of reads spanning the
different fragments are indicated on the left side of each sample. The size of the fragments and
genes are not to scale.90
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Figure 3.22 DM breakpoint validation
DM breakpoint validation primers were designed using the UCSC genome browser, Primer 3 and
BLAST, based on the genomic location obtained from the 10X sequencing data (see Table 2.1).
All three fusions of breakpoints involved in the DM were validated in all tumour samples and the
cell line R2CL, but not in a random DNA control (human DNA from Millipore) or the blood of the
patient.
A| Validation of fragment 1 fusion with fragment 2. Primer pairs AB and CD spanning the break-
points on the original chromosomes. Primer pair AD spans the fusion.
B| Validation of fragment 2 fusion with fragment 3. Primer pairs EF and GH spanning the break-
points on the original chromosomes. Primer pair EG spans the fusion.
C| Validation of fragment 3 fusion with fragment 1. Primer pairs TJ and KL spanning the break-
points on the original chromosomes. Primer pair JL spans the fusion.
D| Validation of all three fusions in the cell line R2CL.
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The expression of genes on the DM
DMs are frequently observed in GBM and many other cancer types. Most stud-
ies focus on the exact sequence and formation of this type of ecDNA structure,
but not much is known about its functionality in cancer and its progression. Hav-
ing determined the sequence of the most abundant DM we plotted the relative
mRNA expression levels of all annotated genes which appeared on the DM (Fig-
ure 3.23A). SEC61G, FAM188B, INMT, EGFR and AQP1 were present as full
genes, whereas only parts of MERTK and only the promoter of CRHR2 were
present on the extrachromosomal structure. As INMT-FAM188B is an annotated
fusion gene and has also been found in our fusion gene analysis, its expression
was also included, but only showed a medium expression level in R2C and almost
no expression in the other samples. Due to the low cellularity of the P samples
and R1A, the gene expression levels in these samples are not reliable and do
not reflect tumour expression levels. These are also the samples with the lowest
DM copy number detected. The genes with the highest expression in all other
samples are SEC61G, EGFR and AQP1.
The expression of MERTK mRNA is at a similar level in all samples. MERTK
expression cannot be attributed to the DM as the DM only contains a part of in-
tron 4, intron 5, part of intron 6 and the full sequence of exons 5 and 6. Both of
these exons fall within the extracellular domain of MERTK, which has two im-
munoglobulin (Ig) domains and two fibronectin type III (FNIII) domains (http://
atlasgeneticsoncology.org/Genes/MERTKID41339ch2q13.html). The Ig domains
are encoded by exons 2-5 and the FNIII domains are encoded by exons 6-9 (Gal
et al. [74]), which means that it is unlikely that exons 5 and 6 alone could be func-
tionally active. Adjacent to these exons on the DM are the promoter of CRHR2,
but in the inverse direction to MERTK transcription, and SEC61G, in the same
orientation as MERTK.
To test the protein levels of the most highly transcribed genes I performed
western blots for EGFR, AQP1 (Figure 3.23B) and SEC61ౘ (Figure A.10). The
expression levels of AQP1 and EGFR were similar; with low protein detection in
the samples of the primary tumour, high expression levels in the first recurrence
(except in R1A) and medium protein expression in the samples of the second re-
currence. EGFR expression is highest in sample R1B, whereas AQP1 expression
is highest in sample R1C. The expression of both proteins is very low in the cell
line R2CL and matches the expression of samples with low tumour purity (P and
R1A), which further supports the loss of the DM in cell culture. The results of
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the SEC61ౘ expression were inconclusive and are shown and discussed in the
Supplementary Material on page 167.
Figure 3.23 | Expression levels of genes found on the DM.
A| RNA expression levels of genes found on the DM.
B| Protein expression of EGFR (left) and AQP1 (right) normalised to b-actin.
A better representation of the mRNA expression potentially originating from
the DM can be found in Figure 3.24, which also includes the possible expression
of gene fusions in the DM. To achieve this we plotted the RNAseq fragments which
map to the DM and included transcripts spanning the different fragments depicted
as green, blue and red lines. The genes with the highest mRNA expression in all
samples were AQP1, SEC61G and EGFR, while the exons of MERTK showed
the lowest expression. INMT and FAM188B showed medium expression, except
in two samples with low tumour purity (PB and R1A), which showed almost no
expression of INMT and FAM188B. In samples of the primary tumour and R1A,
only two fragment-connecting reads could be found; in PA there is support for a
fusion between AQP1 and SEC61G and in PC we found a read connecting the
breakpoints of fragments 2 and 3. Three other samples, R1B, R1C and R2A, also
showed fusions between AQP1 and SEC61G. Fusions between fragments 2 and
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3 were also found between AQP1 and EGFR and fusions around the breakpoints
of fragment 2 and 3 were detected in samples R1B and R1C, and with less sup-
port, in the samples of the third surgery. Fusions involving the part of MERTK on
fragment 1 were only found in sample R1C, R2B, and R2C. R1C and R1B showed
connections of the exons of MERTK to a location adjacent to INMT on fragment
2, whereas R2B showed fusion of of the exons of MERTK to SEC61G.
Figure 3.24 | RNA expression and fusion transcripts of the DM
The DM is plotted based on the breakpoints found by the analysis of the 10X Genomics data of
R1A. Gene names can be found in Figure 3.21 on page 90. Green lines are mRNA transcript reads
spanning fragments 1 and 2, red lines span fragments 2 and 3 and blue lines span fragments 3
and 1. The red peaks around the DM show the number of mRNA reads mapping to the DM, which
can be seen as a proxy for expression. Dashed black lines show where the expression peaks had




Amplification of EGFR is a common alteration in GBM. It is also very com-
mon for the amplified receptor to carry a mutation or truncation, which leads to
ligand-independent activation and constant growth-promoting signalling (Lee et
al. [153]). We therefore analysed the samples for variants of EGFR and tested
if any of these mutations fall into the highly amplified region of the DM. While
we did not find any versions leading to a truncated protein, we found seven non-
synonymous mutations (Figure 3.25). Four of these mutations, all either C?T or
G?A transition, are only found in the samples of the second recurrence and could
be caused by TMZ treatment. One mutation, chr7:55233043 G?T, leading to a
glycine to valine change in the ectodomain of the receptor at position 598, was
found in all samples of the tumour. Lee at al. showed that this amino acid change
confers baseline activation of the receptor without binding of the EGF ligand (Lee
et al. [153]). A second ectodomain mutation (chr7:55221822 C?T, leading to an
amino acid change from alanine to valine at position 289) found in the same study,
also confers ligand-independent baseline activation (Lee et al. [153]). We detec-
ted this EGFR variant in two primary samples of the tumour (PA and PB), but
not in any other samples, suggesting it has been lost in progression. The cell
line R2CL has lost all other EGFR mutations apart from the G598V ectoderm
mutation. Four of the seven mutations found in EGFR in the analysed samples
are annotated in the COSMIC database (https://cancer.sanger.ac.uk/cosmic) and
were classified as pathogenic (Table 3.3).
Figure 3.25 | Non-synonymous EGFR mutations
Non-synonymous mutations found in EGFR. Mutation chr7:55233043 leads to a amino acid
change from glycine (G) to valine (V) at position 598 in the EGFR protein. Genomic regions
are based on Homo sapiens (human) genome assembly GRCh37 (hg19).
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Table 3.3 Mutations found in EGFR
Genomic regions are based on Homo sapiens (human) genome assembly GRCh37 (hg19),
*amino acid (aa)
location transition aa* change significance conditions citation
chr7:55323947 G?A not exonic n/a n/a n/a
chr7:55268974 G?A D1014N pathogenic Lung cancer Wu et al. [299]
chr7:55249130 G?A G810S pathogenic Lung cancer Tsao et al. [271]
chr7:55240752 C?T L666F n/a n/a n/a
chr7:55233043 G?T G598V pathogenic Lung cancer, GBM Lee et al. [153]
chr7:55221822 C?T A289V pathogenic Lung cancer, GBM Lee et al. [153]
chr7:55219010 C?T P195S n/a n/a n/a
To test if any of the EGFR mutations were expressed we looked for mutated
EGFR mRNA in the RNAseq data compared to EGFR wild type mRNA and
confirmed all mutations were expressed. EGFR mutation chr7:55233043 G?U
(A598V), shown to be present on the DM, was expressed in all samples apart
from P1B. In all samples with high tumour purity more than 80% of EGFR mRNA
expressed carried the G?U transition at this position. The second ectodomain
mutation (chr7:55221822 C?T, A289V) found in the DNA of samples PA and PB
was only detected in PA at the mRNA level, but not in PB, and its expression was
undetectable in the recurrences (R1 and R2). Mutations chr7:55268974 G?A,
chr7:55240752 C?T and chr7:55219010 C?T only show negligible expression
compared to the wild type mRNA. chr7:55323947 .
96
3. Results
Figure 3.26 | RNA expression levels of EGFR mutants
Shown are the expression levels of the identified EGFR mutants compared to the expression of the
unaltered mRNA at the respective locus. Genomic regions are based on Homo sapiens (human)
genome assembly GRCh37 (hg19).
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3.5.3 The phylogeny of the DM: making use of the 10X Gen-
omics data
The evolution of DMs happens independently from the evolution of the chromo-
somes. In the primary tumour, and the first recurrence, the DM only carried three
mutations. In the second recurrence, the DM underwent TMZ-induced hyper-
mutation. The DM is found at a CN greater than 80 in all samples of the second
recurrence. In order to determine the phylogeny of the mutations on the DM, the
allele fraction of mutations on the DM shared in samples R2A and R2C, were
plotted against each other (Figure 3.28). Plotted this way, the allele fractions of
the mutations on the DM appear to cluster in groups and are suggestive of sub-
clones (3.28A). Dr Lynch used the 10x data to refine these clusters and validate
the grouping (3.28B). A simplified example of how the 10x data was used is il-
lustrated in Figure 3.27. 10X Genomics Chromium linked-read sequencing is a
relatively novel sequencing technique. HMW DNA is segregated into droplets in
an oil suspension, such that each droplet contains a single molecule. The mo-
lecule is then digested and a tag containing an identification index and a universal
primer-binding site is ligated. The tagged fragments are then put through stand-
ard Illumina library prep and sequencing. Reads are aligned and all reads with
the same tag can be presumed to come from the same molecule.
Figure 3.27 | Simplified explanation of cluster refinement using 10X linked reads
In the WGS the mutations 1 to 6 cluster together based on their similar allele fraction in samples
R2A and R2C. X (grey) symbolises the presence of a mutation. The 10x data is consulted for
reads which cover two mutation regions. Reads covering only one mutation region (red reads)
are discarded. Mutation 4 does not appear in all reads covering mutation regions 3 and 5. Reads
carrying mutation 3 or 5, that do not carry the mutation in region 4 are called "discordant" reads
(blue reads) and disprove that mutation 4 belongs to the same cluster as mutations 1-3 and 5.
Mutation 4 was gained after the mutations of the cluster and occurred in only a subset of the DMs
carrying 1,2,3 and 5. DM A developed from DM B. For mutation 6 we only see discordant reads




Cluster 1 (C1) is a solitary mutation, present in almost every read and has
been ubiquitous since the primary tumour (Figure 3.28). Cluster 2 (C2) consists
of two mutations. We know they have to be on the same copies of the DM, as
the fraction of both of these mutations is over 50% and, naturally, these are a
subset of the copies containing the C1 mutation. For the further groups we used
the 10X data, to validate the fraction groups. In C3 we have 148 10x linked-read
sets, each of which covers two of the 21 mutation regions. Only around 10% of
these reads were discordant (0-1) which might be an indication that there is one
or two mutations in the group forming a different subgroup, but it seems equally
likely that we have 10X tag, or genotype-calling, issues. The remaining 134 linked
reads are split into 65 reads covering two mutation regions with no mutations (0-
0) and 69 reads covering two mutation regions with both mutations (1-1). This
means C3 is present in about half of the linked reads, which is consistent with
the frequency of it’s mutations and means that C3 is a subset of the DM copies
carrying C1 and C2 (with a fraction of approximately 50% (Figure 3.28A)). To give
an example of a cluster that was disproved by the 10X data we can look at C4. By
eye, C4 is not necessarily one group (Figure 3.28A), and this is confirmed by the
discordant check: reads 0-0 = 2, reads 0-1 = 23, reads 1-1 = 0. As 23 out of 25
reads fall into the discordant read group, the 10X data disprove this cluster. Reas-
signing one mutation to C5 removes all evidence of discrepancy within C4 (Figure
3.28B). After sorting clusters internally with the discordant read check, clusters
were then compared to each other to distinguish linear from branched phylogeny.
As there is a high agreement in the mutations of C3 and C4, C4 developed in a
subset of the DM carrying C3 (and therefore C2 and C1). So far the evolution
of the DM happened linearly, gaining one cluster after another. C5 contains 33
mutations and is internally concordant based on the 10X data. A comparison with
C3 showed many distinct mutations, other than the mutations from C1 and C2.
C5 is therefore in a different subset of the DMs than C3 (and C4), but shares the
mutations of CC1 and C2, meaning that the evolution of the DM branched after
C3. Proceeding with this method, Dr Lynch was able to recapitulate the phylo-
geny of the DM (Figure 3.29). Further along the phylogenetic tree, it becomes
more difficult to resolve the clusters and determine the order in which the muta-
tion clusters appeared. The small numbers and low mutation frequencies limit the
analysis, resulting in some clusters which can not be integrated properly, such as
C12, C11, and C13, which may have appeared under C6 or C16.
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Figure 3.28 | Fractions of mutations on the DM based on samples R2A and R2C
A| Clusters defined and coloured by eye. Clusters 1,2 and 3 are clear, but C4 and C5 are very
close to each other and it is uncertain to which cluster the mutation marked with a question mark
belongs. Grey circled clusters are other clusters which look well defined, but were disproved by
the "discordant check" based on the 10x linked-reads.
B| Clusters defined by 10X Genomics data doing a "discordant read check".
Figure 3.29 | DM phylogeny
While we can infer 14 different forms of the DM just from R2A, R2C and the 10X data (these 13
and one involving C11), two of them (in white) we really dont expect to see in great number (e.g.
seeing C2 without C3 or C5 being present would seem to be rare although it might be present in
different samples of the tumour). The low-allele-fraction mutations will create more variants and
of course R2B has others, as (to a lesser extent) do the other time points.
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3.6 Characterisation of R2CL
What do we know so far about R2CL? Based on the sunrise plot in the Sup-
plementary Material on page 165, the FISH image of R2CL metaphase spreads
(page 166) and the WGS analysis, the cell line is tetraploid and the DM has been
lost, or at least its number decreased across the cell population to a point where
a detection proves difficult. The WGS revealed that the hypermutation of the
second recurrence was retained in R2CL which most closely resembles sample
R2B. Here I describe the growth pattern, phenotype and behaviour of R2CL in
culture. In order to elucidate the special characteristics of R2CL, I performed an
in vivo experiment: intracranial injection in mouse brains.
3.6.1 Phenotype of R2CL
As there is no matching cell line from the primary tumour or the first recurrence I
chose a cell line in the same passage, but derived from the primary tumour of a
different patient, as a control (JR2M). Figure 3.30A shows images of R2CL and
JR2M captured by brightfield microscopy. R2CL cells were round, and due to
their voluminous shape, difficult to focus. JR2M showed different types of shapes
being either bipolar or symmetric, but were attached flat to the ECM surface and
easy to focus. Focusing through the cell body, R2CL gave the impression of mul-
tiple nuclei in the cell, leading to the bigger round shape of the cell body. To test
if R2CL cells were indeed multinucleated, I stained cells from both cultures with
DAPI, to visualise the nuclei, and used cell type markers glial fibrillary acidic pro-
tein (GFAP) and vimentin, to visualise the cell bodies and protrusions making it
possible to determine cell boarders (Figure 3.30B). Both cell lines co-expressed
GFAP and vimentin, but differed in the number of nuclei per cell. JR2M cells were
mostly mononucleated, whereas R2CL showed a high percentage of cells with
more than three nuclei and up to ten nuclei in the same cell (dotted white circles)
(Figure 3.30B). Multinucleation in cancer cells is not unusual, but harbouring up
to ten nuclei is uncommon. In GBM such a phenotype is only found in giant cell
GBM, which is defined as its own category in the WHO grade IV class and only
makes up 5% of GBMs. Such giant multinucleated cells had not been detected
in the pathological stainings of the primary tumour (Figure 3.1) or its first recur-
rence and the tumour was not classified as giant cell GBM. In the time between
R2CL derivation until the current passage (12) the growth rate of the culture de-
clined and the number of multinucleated cells in R2CL increased to a point where
working with this cell line became impossible, for instance making it difficult to
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get metaphase spreads. The decision to study the 3-Peater was not made dir-
ectly after the third surgery, but almost a year later, thus the cell line has was
not closely monitored in the beginning. Vials of R2CL which were frozen down
in earlier passages might have undergone a selection process with the freeze-
thawing cycle given the hypermutation. Moreover, pathological slides or paraffin
embedded tissue of the third surgery do not exist, thus a statement about the
presence of this multinucleated cell phenotype in the patient cannot be made and
it cannot be ruled out that the phenotype only emerged in cell culture.
3.6.2 Growth pattern of R2CL in vivo
In order to test the aggressiveness of R2CL in vivo I injected R2CL cells into the
caudate putamen of the left hemisphere of five immunosuppressed mice. Figure
3.31 shows the growth pattern of the tumour represented by histological stain-
ings of one exemplary mouse brain. The injection of R2CL was part of a bigger
cohort of mice, testing the tumourigenicity of eight different cell lines in a collab-
oration with Alexandra Vaideanu, a PhD student working on nanoparticle based
treatment in the Engineering Department. The first mice (injected with A25M)
became symptomatic (15% weight loss within 24h) six to seven weeks after injec-
tion and had to be sacrificed. In the following weeks mice injected with other cell
lines developed symptoms and also had to be sacrificed. Apart from one mouse,
which developed a mouse lymphoma, mice injected with R2CL did not show any
symptoms after four months and were sacrificed due to the end of the experiment.
The growth pattern of the tumours varied greatly between cell lines. One cell line
produced solid tumours with defined boarders (JR2M), others only grew in the
meninges and the corpus callosum (A25M, A25C and J3T3) and one cell line did
not show any tumour growth in mice (AW10). R2CL did not produce a solid tu-
mour, but showed infiltrating tumour cells around the injection site and infiltration
into the corpus callosum (Figure 3.31A). Many of these cells were positive for the
proliferation marker Ki67 (Figure 3.31B). Single Ki67 positive cells also travelled
into the corpus callosum of the right hemisphere (Figure 3.31B, B1.1 and B1.2).
As no cell line had been derived from the primary tumour and the first recurrence,
a qualitative comparison of the aggressiveness between a hypermutated and a
non-hypermutated tumour cannot be made, but R2CL, which did not form solid
tumours and did not cause any symptoms four months after injection, was (after
AW10) the least aggressive cell line tested in this experiment. Its invasive capa-
city, however, was remarkable and letting the cell line grow in the mouse brain for
longer could prove interesting.
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Figure 3.30 Phenotype of R2CL. Brightfield imaging and immunofluorescent staining of R2CL.
A| Brightfield image of R2Cl and JR2M. The scale bar is 100 µm
B| Immunofluorescent images of R2CL and JRM2. The nuclei are stained with DAPI (blue), GFAP
is shown in red and vimentin in green. The top two panels were captured with a 20X objective
(scale bar= 20 µm) and the bottom two panels with a 60X objective (scale bar= 20 µm). The dotted
circles in the top panel highlight cells with more than three nuclei.
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Figure 3.31 Growth pattern of R2CL in the brain of immunosuppressed mice
Histology of mouse brains orthotopically injected with R2CL. Injection site: 2.5 mm left to the
bregma, 1 mm anterior and 3 mm deep into the left hemisphere.
A| H&E staining of the left hemisphere.
B| Human Ki67 staining of both hemispheres. B1.1 and B1.2 zoom into the right hemisphere.




In this work I studied the evolution of a single GBM from the original treatment
naïve tumour over its first TMZ and radiation treated recurrence, to its TMZ-
treated second recurrence. During the last three years the work by others in
the field of GBM has paralleled my own work, and provided validation for find-
ings which seemed, at first, remarkable when observed in only one patient. This
study provides novel insights into the genomics of GBM and our ability to study
hypermutation in an in vitro system.
4.1 Heterogeneity
4.1.1 Purity
Despite using 5-ALA to distinguish highly malignant tissue from normal tissue,
the tumour purity in the primary samples was low, with the result that we were
not able to extract some of the information we wanted from the data on these
samples. False positive fluorescence has been reported in rare cases (Tonn [268]
and Hadjipanayis, Widhalm and Stummer [97]), a more likely explanation of the
low purity is that the infiltrative nature of GBM leaves the strength of fluorescence
subjective to the surgeon. Only highly malignant glioma cells will accumulate
PpIX and appear pink under UV light with the right filters. In the infiltration zone,
the intensity of this pink fluorescence will gradually decrease with the decreasing
density of tumour cells. If there is no highly fluorescent tissue around, malignant
tissue infiltrated with immune cells might seem highly fluorescent even if it is not,
and a surgeon might mistake it for a pure sample. A standard practise to ensure
high tumour purity is consulting a pathologist, who evaluates H&E stainings for
high cellularity. Even this cannot ensure high purity of a sample, as tissue pieces
of high cellularity can reside in close proximity to pieces of low cellularity as shown
in Figure 3.1A, B and C. Analysing multiple samples can help to improve the re-
liability of the results. Nevertheless, samples of low tumour purity can provide
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information on the microenvironment of the tumour, for instance, about immune
cell infiltration or inflammation. Looking at the purity scores in other studies com-
paring primary and matching recurrent tumours, there was high variability in purity
amongst all samples and no correlation between purity and tumour type (initial vs
recurrent samples) (Kim et al. [141] and Wang et al. [284]).
In our case the low tumour purity, especially in the samples of the primary tu-
mour, made confident statements about the CN status, protein and mRNA expres-
sion levels, and about the phylogeny of the tumour impossible for these samples.
The information we gained for these low purity samples reflects a mixture of tu-
mour, stromal, neuronal and immune cells as seen in the analysis testing for ex-
pression patterns of known immune cell markers and a neuronal methylation pat-
tern. The higher immune cell infiltration means these samples could give valuable
information about the composition of this immune environment.
4.2 Hypermutation
Hypermutation in TMZ-treated recurrent GBM was first described in a study se-
quencing kinase domains in malignant gliomas (Hunter et al. [122]). Based on the
involvement of MSH6 mutations in hypermutated childhood gliomas they looked
at MSH6 mutations/deletions in their samples and found them only in the recur-
rent hypermutated samples, but not in the matching treatment naïve samples or
any other primary glioma analysed. Later, other studies focusing not only on
MSH6 alterations, but alterations in all genes of the MMR system, showed that
all hypermutated recurrences had alterations in this pathway, but that these alter-
ations were not limited to MSH6. For instance, Yip et al. re-analysed matching
primary and hypermutated recurrent GBMs and found one recurrent tumour with
a higher degree of hypermutation that, additionally to MSH6 mutations, also har-
boured somatic mutations in two other mismatch repair genes, MSH2 and MLH1.
They hypothesised that these additional alterations in the MMR pathway could
account for the larger number of mutations in this case compared to the other
hypermutated cases (Yip et al. [302]).
This hypothesis is in agreement with our finding that the two hypermutated
clones in the second recurrence differ significantly in their number of mutations.
R2A and R2C, which had around 300,000 mutations, showed additional mutations
in MLH1, MSH2 and PMS2, whereas R2B with 150,000 mutations, only showed
MSH6 mutations. As the MMR system does not show any overlapping mutations
in these clones, we can assume the hypermutation in the second recurrence has
evolved twice. Even though R2A and C share C?T and G?A transitions with
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R2B in other genes, this can be explained by a higher probability of mutations
hitting the same location due to the high mutational rate and the specific sequence
context in which TMZ induced mutations occur. This subclonality of hypermutation
has also been detected by Kim et al., where they analysed two samples of a
hypermutated recurrent tumour and also did not find any overlapping mutations
in the MMR system. Notably, the only MMR gene mutated in both samples was
MSH6 (Kim et al. [141]) as was the case in our second recurrence samples.
An involvement of MGMT in the development of the hypermutation phenotype
had been controversial, but in a study looking at 93 matched primary and recur-
rent cases (reporting 17 hypermutated cases) Wang et al. found co-occurrence
of MGMT promoter methylation and hypermutation (Wang et al. [284]). Our pa-
tient tested positive for MGMT promoter methylation in the original prognostic
analysis, but later our sequencing analysis showed a deletion of the gene and
exhibited very low MGMT RNA expression. This lack of MGMT expression may
have facilitated the development of the hypermutation as lower levels of MGMT
result in inefficient removal of alkyl adducts from the DNA, such as the ones added
by TMZ. Van Thuijl et al. observed a consistent increase of the MGMT promoter
methylation level from non-hypermutated LGGs to their matching hypermutated
recurrent GBMs (van Thuijl et al. [276]) and thus hypothesised that a positive
selection of MGMT promoter methylated cells under TMZ treatment and a cor-
responding decrease in MGMT expression may predispose a cell to TMZ-induced
mutations, which eventually affect the MMR system. This in turn might then en-
able hypermutation from subsequent rounds of TMZ treatment (van Thuijl et al.
[276]). In our patient a decrease in MGMT mRNA expression can be observed
from the primary to the first recurrent tumour, but this could be better explained
by the lower tumour cell content in the samples of the primary tumour, than by a
selective process, as the lowest expression levels were measured in a sample of
the first recurrence, which has been treated with fewer rounds of TMZ than the
second recurrent tumour.
The first question which struck us was why TMZ treatment did not lead to
a hypermutation in the first recurrence, but evolved only in the second recur-
rence. The most obvious explanation would be the treatment duration and the
TMZ dosage. The primary tumour was treated with the standard Stupp protocol
for GBM (1.2.1, Stupp et al. [260]), but the patient did not complete the adjuvant
TMZ treatment. She only completed three cycles consisting of 200 mg/m3 for the
first cycle and 150 mg/m3 for the other two cycles, instead of full six cycles con-
sisting of 150-200 mg/m3. The patient only developed the hypermutation when
treated a second time with TMZ for the first recurrence. This time she completed
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nine cycles of treatment, with one cycle at 200 mg/m3 and the remaining eight
cycles at 100 mg/m3. At first the tumour showed excellent response, but then
showed significant progression after 16 months. This behaviour was reflected by
the hypermutation induction experiment in cell culture, in which non-resistant cells
died during the course of the treatment and resistant cells stayed dormant. Only
after several treatment-free weeks did the resistant populations start to proliferate,
but then expanded very quickly.
Another possibility is that patients who develop a hypermutation phenotype
after TMZ treatment might already have a predisposition in a MMR gene or other
genes involved in base pair repair, such as POLD or POLE, or yet unknown play-
ers. This could include germline deletions or germline mutations in MMR genes,
as in the case of Lynch Syndrome. We are currently investigating if such an alter-
ation was present in our patient. As all MMR genes known to be involved in the
repair of TMZ-induced lesions show expression on the mRNA level, a complete
knockout of any of these genes, no matter if of germline or somatic origin, can be
excluded.
TMZ-induced hypermutation in gliomas has received increasing attention, but
with the focus on LGG. While the impact of hypermutation on the malignancy of
GBM is unclear (Kim et al. [141]), there is evidence that the hypermutation pheno-
type in LGG gliomas drives rapid malignant transformation to GBM (Johnson et al.
[135]). This study by Johnson et al. showed that, in six out of ten patients treated
with TMZ the tumour recurred hypermutated and immediately progressed to GBM.
The authors attributed this immediate progression to disruptive mutations in the
RB and Akt-mTOR signalling pathways, which were gained with the hypermuta-
tion and which are associated with HGGs (Johnson et al. [135]). The duration of
the treatment varied and did not seem to be connected with the development of a
hypermutation phenotype in this small cohort and the dosages given were not part
of the clinical data made available for the reader. Moreover, the initiation of TMZ
treatment and radiographic progression to a hypermutated tumour ranged from
12 to 90 months and a statement about a potential hypermutation "latency" could
not be made (Johnson et al. [135] and Choi et al. [40]). In a study looking at 21
primary GBM/recurrent pairs, four cases were hypermutated, but the clinical data
on these patients provided by the authors was limited (Kim et al. [141]). The au-
thors state that three of these cases were treated with concomitant and adjuvant
TMZ, but the duration and dosage was not provided. In a study by Wang et al.,
including six hypermutated recurrences of primary GBM cases (wild-type IDH1),
their median survival time of 24 months corresponded to a slight increase in com-
108
4. Discussion
parison to other patients with GBM having wild-type IDH1 (18 months) (Wang et
al. [284]).
The limited number of hypermutated cases derived from primary GBM means
it is not possible to confirm that a high level of mutation is associated with aggress-
ive disease progression at statistically significant levels. In contrast to a worse
prognosis for hypermutated LGGs, other hypermutated cancers, although not
treatment related, have improved outcomes and better prognosis. For instance,
patients with MMR-deficient hypermutated sporadic colorectal cancer (Careth-
ers and Jung [33]) and patients with hypermutated uterine serous carcinomas
with somatic mutations in MMR genes and POLE, exhibit significantly better pro-
gnoses compared to patients with their non-hypermutated counterparts (Santin
et al. [233]). In MMR-deficient hypermutated sporadic colorectal cancer this bet-
ter prognosis is attributed to a stronger anti-tumour immune response (Carethers
and Jung [33]). Both in GBM and LGG questions about the reasons for the devel-
opment of a hypermutation phenotype in some cases but not others remain. Ac-
curate collection and linked clinical data, such as treatment duration and dosage
with combined information about biological factors, such as genetic or epigenetic
features, could help to answer this question. For each patient, the risk or benefit
of TMZ treatment needs to be calculated individually and the possible develop-
ment of a hypermutation phenotype must be taken into consideration. Circulating
tumour DNA (ctDNA) extracted from liquid biopsies, in which detached tumour
cells, and cell free DNA are extracted primarily from blood, but also from urine, or
CSF (in the case of CNS tumours), is under investigation for the early detection of
cancer. This approach could also prove useful as a non-invasive method to mon-
itor patients during treatment and could provide clinicians with information about
the development of a hypermutation phenotype in real time, provided that robust
biomarkers for hypermutation can be discovered.
Hypermutation, an advantage in immunotherapy?
While for LGGs hypermutation coupled with the immediate transformation to a
HGG may not be desirable, a hypermutated GBM could prove a better target for
immunotherapy than a non-hypermutated GBM. The radically altered genomes
lead to a higher abundance of neoantigens, which can then be more efficiently
detected by tumour infiltrating lymphocytes (TILs) (Dolcetti et al. [53] and Le et
al. [151]). In two recent studies, both an adult patient with a hypermutated GBM
secondary to a germline POLE mutation (Johanns et al. [134]), as well as two
paediatric patients with GBM due to Biallelic mismatch repair deficiency (bMMRD)
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(Bouffet et al. [18]), showed strong responses to anti-PD-1 therapy, after having
progressed on standard of care treatment.
With the abundance of more neoantigens, one would expect an increasing
expression of PD-L1 in recurrent tumours to protect themselves from a stronger
immune response, but the opposite was found in a study comparing the expres-
sion of PD-L1 in primary and recurrent GBM (Heynckes et al. [110]). Heynckes
et al. showed a significant downregulation of PD-L1 in recurrent GBM at both
the mRNA and protein level, compared to matching primary samples, and valid-
ated their results in a bigger cohort of non-matching samples. Of note, no differ-
ence was made between hypermutated and non-hypermutated cases. Recurrent
samples which had received an extended TMZ therapy (> 6 cycles, 17 patients)
beyond the classical Stupp-protocol showed even less PD-L1 expression, which
might be caused by the immune modulating effect of TMZ therapy, such as lymph-
openia and an increase in regulatory, immunosuppressive T-cells (Fadul et al. [62]
and Sengupta et al. [243]). A reduction in PD-L1 would make recurrent GBM a
worse target for PD-L1 blockers (Heynckes et al. [110]), but PD-L1 occurrence
and the therapeutic effect of PD-L1/PD-1 therapy are not necessarily connected
in all patients. In some cases of non-small-cell lung carcinoma patients with PD-
L1 negative tumours also showed some treatment benefit (Borghaei et al. [17])
and the robustness of PD-L1 expression as a prognostic biomarker for immune
response is controversial due to its variability across histologies and inconsist-
ency in immunohistochemical stainings (Herbst et al. [109] and Gandini, Massi
and Mandalà [77]).
Although the immunosuppressive effects of the PD pathway have been shown
in preclinical studies of GBM (Wainwright et al. [283] and Zeng et al. [303]), the
correlation between elevated pretreatment levels of PD-L1 and patient prognosis
is very unclear (Filley, Henriquez and Dey [66]), with some studies finding a worse
prognosis (Nduom et al. [191]) and others in which no prognostic value was found
(Berghoff et al. [12]). When looking at PD-L1 expression or TILs density in re-
current cases, no one has so far stratified recurrence into hypermutated and non-
hypermutated tumours (Berghoff et al. [12] and Heynckes et al. [110]). Hodges
et al. evaluated tumour mutation load (TML) as a biomarker in glioma looking for
correlations with PD-L1/PD-1 expression and CD8+ TILs (Hodges et al. [113]).
No correlation of TML, PD-L1/PD-1 expression and TILs was found, but they did
show an association between TML and mutations of, and loss of expression in,
MMR genes MLH1, PMS2, MSH6 and MSH2 (Hodges et al. [113]).As hypermuta-
tion seems to be a subclonal event (our data and Kim et al. [141]) the relationship
between ITH and antitumour immunity must be considered. In nonsmall cell lung
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cancer and melanoma cytotoxic chemotherapy-induced subclonal neoantigens,
contributing to an increased mutational load, were enriched in certain poor re-
sponders, suggesting that neoantigen heterogeneity may influence immune sur-
veillance (McGranahan et al. [185]).
Encouraged by high success rates with PD pathway inhibition in melanoma
and nonsmall cell lung cancer, there are now an increasing number of clinical tri-
als in GBM using different set ups with different drugs and drug combinations (a
table of ongoing clinical trials can be found in a review by Filley, Henriquez and
Dey [66]). So far, however, striking success seems to be missing as PD pathway
inhibition failed to improve survival in newly diagnosed or recurrent glioblastoma
in several studies (Lamberti, Franceschi and Brandes [148]). Future studies will
have to take TMZ-induced hypermutation as a possible advantage for immuno-
therapy into account and more work needs to be done to understand the immune
environment in the brain, especially in respect to the changes occurring with GBM
pathology.
4.2.1 Hypermutation induced in cell culture
In this thesis I have demonstrated that it is possible to reproduce in vitro the hy-
permutation and mutational pattern seen in GBM as a result of TMZ treatment.
By knocking out the MMR genes MSH6 or MSH2 in a subset of cells of a patient
derived GBM cell line and subsequent TMZ treatment I have produced cells which
are resistant to TMZ. Subsequently these cells are selected for under the applied
TMZ treatment regime. This approach to creating hypermutated GBM cell lines
as a model system could help to shed light on the aggressiveness of hypermuta-
tion in HGGs. Hypermutated cell lines and their non-hypermutated control cell
lines could be injected subcutaneously, or orthotopically, into mice and the de-
velopment of the tumours could be monitored and compared. In our experiment
we used electroporation as a transfection method to deliver the CRISPR-Cas9
system with the MSH6 or MSH2 knockout guide RNA. As we did not select trans-
fected cells and the transfection efficiency in test runs with a GFP construct was
below 80%, not all cells will be depleted for MSH6 or MSH2. Without TMZ treat-
ment the depletion did not confer any advantage to the cells in culture and thus
cells with the MSH6 or MSH2 indels did not get selected.
As Wang et al. found a strong association of co-occurrence of MGMT pro-
moter methylation and hypermutation (Wang et al. [284]), we also analysed a
MGMT non-promoter methylated cell line (J3T6), which has been depleted for
MSH6 or MSH2 and treated with TMZ. TMZ treatment did not lead to hypermuta-
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tion in the J3T6 cell line, with neither a MSH6 nor a MSH2 knockout. J3T6 showed
a high resistance to TMZ even when unaltered, so that there was no selection ad-
vantage for MMR deficient cells. When functional MGMT is present in a cell line,
alkyl groups added by TMZ will be removed, therefore no mismatch will be pro-
duced during replication and cells will not be driven into apoptosis. There is no
selection advantage for MMR deficient cells.
To test if the hypermutation phenotype can be induced without a preceding
gene alteration in the MMR system, I treated the MGMT promoter methylated cell
line JR2M with a low dose of TMZ over nine weeks. We observed a doubling of
the mutations compared to the non treated control that may reflect the onset of
the TMZ induced hypermutation. Newly gained mutations were C>T transitions in
the base pair context typically for TMZ. Three of the four mutations gained in the
MMR system were MSH6 mutations of which one proved to be deleterious and
was classified as pathogenic. This was also the C>T mutation with the highest
allele fraction. A question arising is if the clone with this mutation would have been
the dominant clone driving the hypermutation. Due to the low allele fractions we
cannot infer clonality and do not know if the other mutations in the MMR pathway
are in cells with the deleterious mutation or if they are in different cells.
While the patient we analysed did not exhibit a complete knockout of any MMR
gene, Wang et al. detected deleterious mutations in genes of the MMR system
in hypermutated recurrences in their cohort (Wang et al. [284]). Moreover, they
found MSH6 mutations were almost exclusive to hypermutated recurrences (8
out of 17 hypermutated cases) (Wang et al. [284]). In one case, however, a non-
synonymous MSH6 mutation could already be detected in the primary lesion with
a variant allele frequency (VAF) of 2%, but no validation had been performed.
Taking the results from all studies dealing with TMZ-induced hypermutation to-
gether, MSH6 seems to play a leading, but not exclusive, role in the development
of this phenotype (Hunter et al. [122], Johnson et al. [135], Kim et al. [141] and
Wang et al. [284]). Other genes, such as POLD and POLE, which are not directly
counted as genes of the MMR pathway, also need to be included in the analysis,
given their roles in the development of hypermutation in GBM and other cancers
(Bouffet et al. [18] and Jansen et al. [128]).




Figure 4.1 Models of TMZ-induced hypermutation
GBMs with different pre-conditions get resected and then treated with a varying number (X) cycles
of TMZ that kills a subpopulation of cells, but the remaining cells can lead to a TMZ-induced,
hypermutated phenotype at recurrence.
A| Treatment with TMZ leads to TMZ-induced mutations in key amino acids of MMR genes. Once
the MMR system is impaired more TMZ-induced mutations accumulate as the killing effect of TMZ
relies on a functioning MMR system. The tumour recurs hypermutated.
B| The tumour already has a somatic MMR impairment (SNVs, deletions, epigenetic silencing...).
These cells will get selected for during TMZ treatment and further mutate under the treatment.
The tumour recurs hypermutated. This scenario could not be confirmed as to date no somatic
lesions in the MMR have been identified before the hypermutation.
C| The patient carries a germline mutation in the MMR system which leads to a higher mutational
burden without TMZ treatment. TMZ treatment accelerates the mutation rate and the tumour
recurs hypermutated. This scenario can be found in cases of bMMRD or HCPS.
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4.3 Double minute chromosome
The emergence of DMs and neochromosomes is a common phenomenon in can-
cer, especially in GBM. While other studies focus on the formation of DMs, my
work focuses on the development of a DM over time and through treatment. DMs
and neochromosomes carry oncogenes and other genes which are presumably
hitchhiking with the oncogenes. In our case the DM comprises three fragments
from two different chromosomes (2 and 7) and is of medium complexity com-
pared to DMs found in other studies, which either originated from one chromo-
some (Schneider et al. [237]) or were composed of several different chromosome
fragments (Coquelle et al. [43] and L’Abbate et al. [145]). Our DM carries five
genes in full sequence (INMT, FAM188B, AQP1, EGFR, SEC61G), the promoter
region of CRHR2 and three introns and two exons of MERTK. Three of the genes,
AQP1 (on fragment 2), EGFR and SEC61G (both on fragment 3), showed high
expression at the mRNA level and EGFR and AQP1 were also expressed at the
protein level. The protein expression analysis of SEC61ౘ will need to be repeated
with a different antibody. All three genes were shown to be upregulated in GBM
and to play a role in GBM pathology (Gullick [96], Saadoun et al. [229] and Lu
et al. [174]).
4.3.1 EGFR, a well known oncogene
EGFR (described in detail in Section 1.2.3) on the DM carries the ectodomain
mutation G598V, which confers ligand-independent basal phosphorylation of the
mutant EGF receptor and thus allows cells expressing this variant to grow in the
absence of exogenous EGF (Lee et al. [153]). In one sample of the primary tu-
mour (PA) we found another EGFR ectodomain mutant, A289V, which got lost in
the evolution of the tumour, while G598V seemed to be selected for and to drive
the disease. Lee et al. showed that G598V had a higher basal phosphoryla-
tion activity than A289V, which would explain a preferential positive selection of
this variant (Lee et al. [153]). In our patient EGFR G598V was the only non-
synonymous mutation detected in all samples, however, because of the low tu-
mour purity in the primary tumour this result has to be taken with care. There
exists the possibility that it was the only mutation detected due to its high CN,
which increased the probability that it would be confidently called even in low tu-
mour purity samples. Other mutations present at low frequencies may exist in all
samples but would be underestimated.
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4.3.2 SECG61G, a potential oncogene?
As well as EGFR, fragment 3 also carried a gene adjacent to EGFR on chr7p
11.2; SEC61G. EGFR is a well studied oncogene, but not much is known about
SEC61G and its potential oncogenic characteristics. SEC61ౘ is one of three sub-
units (ౖ, ౗ and ౘ) forming the SEC61 translocon, a heterotrimeric protein channel
in the endoplasmic reticulum (ER) and the ER-Golgi intermediate compartment
(Greenfield and High [91]). The SEC61 complex forms a transmembrane pore for
the translocation of newly synthesised precursor polypeptides into the ER lumen,
as well as the integration of transmembrane proteins into the ER bilayer (Osborne,
Rapoport and van den Berg [207] and Linxweiler, Schick and Zimmermann [163]).
The main functions of the ER are the folding of protein molecules and their trans-
port in vesicles to the Golgi apparatus. Disturbances in redox regulation, calcium
regulation, glucose deprivation, viral infection or the over-expression of proteins
can lead to a condition, termed ER stress, under which the homeostasis of pro-
tein synthesis, folding and transport at the ER is disturbed and unfolded proteins
accumulate (Linxweiler, Schick and Zimmermann [163]). Under ER stress, activ-
ation of the Unfolded Protein Response (UPR) occurs, which aims at restoring
the normal cell function by suppressing translational processes, degrading unfol-
ded and misfolded proteins and by activating signalling pathways that increase
chaperone expression, which are necessary for the correct folding of proteins. If
this response is not successful in restoring order and the stress situation remains,
UPR leads to apoptosis.
In a study using qPCR analysis of genomic DNA extracted from 43 primary
GBMs to identify EGFR and SEC61G copy number, co-amplification with a high
copy number gain (>4-fold) of EGFR and SEC61G was shown to occur in 40%
of the samples (Lu et al. [174]). A high copy number gain of SEC61G alone was
only detected in three samples, whereas a high copy number gain of EGFR was
never detected without a corresponding SEC61G high copy number gain (Lu et al.
[174]). SEC61G was not only shown to be highly amplified in GBM, but was also
shown to be overexpressed in 77% of the GBM cases compared to healthy brain
tissue. Neither SEC61A1 nor SEC61B (coding for the other two subunits of the
translocation channel) showed comparably high expression levels, only a tend-
ency to an elevated expression in these samples (Lu et al. [174]). Upon silencing
of SEC61G by siRNA mediated knockdown in the human glioblastoma cell line
H80, Lu et al. observed reduced cell viability with an increased rate of apoptosis.
Induction of ER stress by treating H80 and HeLa cells with tunicamycin (an inhib-
itor of N-linked glycosylation) led to an increase in SEC61ౘ expression (Lu et al.
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[174]). An upregulation of SEC61ౘ expression in GBM may counteract ER stress
by increasing ER capacity. This could be a mechanism to survive ER stress (e.g.
glucose deprivation) which interferes with N-linked protein glycosylation.
Lu et al. found that SEC61ౘ expression correlated with tumour grade; none of
the 8 WHO grade I and II samples exhibited SEC61ౘ overexpression, whereas
2 of 11 (18%) Grade III samples and 14 of 19 (82%) GBM samples overex-
pressed SEC61ౘ(Lu et al. [174]). In light of the frequent co-amplification of other
genes within a genomic region, such as PDGFRA co-amplification with KIT and
KDR (4q12), and DDX1 co-amplification with N-Myc (2p24), Lu et al. propose
a possible synergistic effect on neoplastic pathogenesis for these types of co-
amplification (Lu et al. [174]).
RNAseq analysis of 164 GBM TCGA samples showed evidence of transcribed
SEC61G-EGFR fusions (n = 4) as part of focal gains, but neither the expression
of this fusion at the protein level nor its functionality was tested (Brennan et al.
[25]). When we searched for gene fusions we focused on genes residing on
two different fragments of the DM and found strong evidence for fusions between
AQP1 and SEC61G, but further analysis is needed to confirm this result and test
its functionality.
4.3.3 AQP1, another potential oncogene?
AQPs are water-selective membrane channels, which allow the regulated in- and
efflux of water in cells and permit a higher water flow than by simple diffusion
through the semi-permeable plasma membrane. The movement of water through
AQPs is bidirectional and driven by osmotic gradients. Thirteen water channels
(AQP0-AQP12), which differ in their intrinsic water permeability, have been identi-
fied in mammals and show a unique tissue distribution. A subset of these AQPs,
called aquaglyceroporins, also transport glycerol. AQPs are found in cells in
which the diffusion rate of water through the cell membrane cannot satisfy the
demand. For instance, fluid secretion and absorption across epithelial cell layers,
such as in kidney tubules and exocrine glands, requires high, aquaporin-facilitated
transepithelial water permeability. AQPs are also found in the brain, where a high
water permeability facilitates water movement between blood and brain paren-
chyma across the bloodbrain barrier (Verkman [278]). AQP4 is the most abund-
ant water channel in the brain, followed by AQP1, and is expressed in astrocytes
and ependymal cells. It is implicated in brain oedema formation/resolution and in
clearance of K+ released during neuronal activity (Saadoun et al. [228]). AQP1
can be found in the ventricular-facing cell plasma membrane of choroid plexus
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epithelial cells and plays a role in CSF production and secretion (Nielsen et al.
[196] and Oshio et al. [208]). AQP1 is also expressed in vascular endothelial cells
throughout the body but is notably absent in the cerebrovascular endothelium, ex-
cept in the circumventricular organs (Wilson et al. [297]) and in malignant brain
tumours when the BBB is disrupted (Saadoun et al. [229]).
Saadoun et al. detected AQP1 expression in astrocytomas, which increased
with the grade of malignancy, but was absent in neoplastic cells of metastatic car-
cinomas, where AQP1 positive staining was only found in microvessel endothe-
lium and reactive astrocytes (Saadoun et al. [229]). Saadoun et al. hypothesise
that AQP1 may contribute to the flow of oedema fluid through the tissue and they
suggest AQP1 channel blockers as possible, potent anti-brain-tumour-oedema
agents.
Elevated AQP1 expression also upregulates the migratory ability of tumour
cells (Saadoun et al. [227] and McCoy and Sontheimer [183]). McCoy and Son-
theimer et al. tested AQP expression in frequently used glioma cell lines, as well
as patient derived lines and tissue biopsies by PCR, WB and IHC. They found
expression of AQP1, AQP4 and, in some cases, expression of AQP5, predomin-
antly in the tumour biopsies (McCoy and Sontheimer [183]). Only AQP1 expres-
sion was maintained in cultured cells, but at lower levels and not in all cell lines.
Stable transfection of AQP1 or AQP4 into these cells was sufficient to restore
water permeability, but only AQP1 enhanced cell growth and migration, whereas
AQP4 enhanced cell adhesion suggesting differential biological roles for AQP1
and AQP4 in glioma cell biology (McCoy and Sontheimer [183]).
As the expression of some AQPs, including AQP1, were shown to be regu-
lated via osmotic response elements in the gene’s promoter region it is hypothes-
ised that cells not stimulated by constant changes in osmolarity may selectively
downregulate AQP1 expression (Jenq et al. [130], Umenishi and Schrier [273]
and McCoy and Sontheimer [183]). Lack of AQP1 in mice (AQP1-null mice) led to
a slower development of subcutaneous tumours after melanoma cell injection and
a markedly lower density of microvessels as seen by IHC (Saadoun et al. [227]).
AQP1-negative endothelial cells derived from the aorta of the same mouse model
showed decreased migration capacities and slower wound healing in scratch as-
says compared to endothelial cells derived from control mice, providing a mech-
anistic link between the involvement of AQP1 in endothelial cell migration and
impaired angiogenesis in AQP1 deficiency in vivo (Saadoun et al. [227]). Stable
transfection of non-endothelial cells with AQP1 accelerated cell migration and in
vitro wound healing, indicating that AQP-facilitated cell migration is a general phe-
nomenon, not limited to endothelial cells (Saadoun et al. [227]). This was suppor-
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ted by the finding that AQP1 expression also accelerates the migration of cancer
cell lines, such as mouse melanoma B16F10 cells, breast cancer 4T1 cells and
HT20 human colon cancer cells, in vitro (Hu and Verkman [117] and Jiang [131]).
Upon tail vein injection, HT20 cells cell line also showed increased extravasation
in nude mice when over-expressing AQP1 (Jiang [131]).
Based on the findings that motile AQP-expressing cells show AQP polarisation
to lamellipodia and increased lamellipodial dynamics, Verkman et al. proposed
a mechanism for AQP-dependent cell migration in which AQPs facilitate rapid
water influx after ion uptake at the tip of lamellipodia resulting in an increase of
local hydrostatic pressure and the formation of cell protrusions in the direction of
cell migration (Saadoun et al. [227], Hara-Chikuma and Verkman [102], Verkman
[279] and Schwab et al. [239]). AQPs might not only accelerate cell migration by
facilitating the rapid turnover of cell membrane protrusions at the leading edge,
but might also allow a rapid change in cell shape and volume enabling cells to
migrate through narrow spaces, such as the brain parenchyma.
As the creation of an osmotic gradient is necessary for water flow through
AQPs, ion channels are a prerequisite for AQP-facilitated migration. Like AQPs,
ion channels are also polarised to lamellipodia at the leading edges of motile
cells and work together with components of the cytoskeleton to make migration
possible. The finding that AQP1 interacts with beta-catenin through Lin-7, thereby
affecting the organisation of the cytoskeleton, gives evidence that the function of
water channels might go beyond the function of water transport (Monzani et al.
[187]).
A possible mechanism for the upregulation of AQP1 expression was proposed
by Hayashi and colleagues, who observed an increase of AQP1 expression in 9L
rat glioblastoma cells under hypoxic cell culture conditions and who showed that
increasing medium D-glucose or fructose and decreasing O2 levels correlate with
the level of glycolysis (Hayashi et al. [103]). Based on these findings and the
presence of an E-Box/ChoRE transcriptional element in the AQP1 promoter they
proposed a model in which hypoxia induced glycolysis produces lactic acid and
enhances AQP1 transcription through E-Box/ChoRE. To counteract the resulting
intracellular acidosis tumour cells need to shuttle the excess H+ to the extracellular
space, which may involve the reaction of H+ and HCOH3
- catalysed by the cystolic
carbonic anhydrases. This reaction results in H2O and CO2. To prevent cell
swelling, water gets released quickly through the up-regulated AQP1 channels
(Hayashi et al. [103]).
With the examples given above, a picture starts to emerge of the ways in which
expression of AQP1 can be beneficial to GBM cells. Allowing them to survive and
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escape the hypoxic environment in the tumour by protecting the cell from acidosis,
by facilitating migration and, in light of epithelial AQP1 expression, by aiding in
blood vessel formation. The presence and high expression of the AQP1 gene on
the DM in our patient thus supports the hypothesis that the fragment carrying the
gene was under positive selective pressure. The primary tumour appears to carry
a version of the DM which did not include AQP1, which raises the question of
whether the change in the environment due to treatment made the version with
AQP1 more valuable for the tumour.
AQP1 is shown to be over-expressed in multiple human cancers including that
of biliary duct, bladder, brain, breast, cervix, colon, lung and prostate, but no one
to date has reported the gene to be amplified (Endo et al. [59], Saadoun et al.
[229], Hoque et al. [115], Moon et al. [188], Chen et al. [39] and Papadopoulos
and Saadoun [211]). In all these studies, except the study by Hoque et al., no
one actually tested for how AQP1 was over-expressed. Hoque et al. found over-
expression of AQP1 in lung cancer and performed FISH to test for AQP1 gene
amplification in tissue samples, but could only detect it in normal copy number.
4.3.4 Fragment 1, the fragment of MERTK
Fragments 2 and 3 both carry highly expressed oncogenes and thus confer a
growth advantage to the cells carrying the DMs, whereas fragment 1 contains
only parts of a gene, including two exons (5 and 6) which code for extracellular
components of the c-mer proto-oncogene tyrosine kinase (MERTK). The extracel-
lular part of the MERTK receptor contains two Ig domains (exons 2-5: aa 112-186
for domain 1 and aa 197-280 for domain 2) and two FNIII domains (exons 6-9:
aa 284-378 for domain 1 and 386-478 for domain 2) (Linger et al. [162]). These
four domains define MERTK as part of the TAM family of RTK (MERTK, AXL and
Tyro-3), which are involved in a broad variety of cell functions including cell prolif-
eration/survival, cell adhesion and migration, blood clot stabilisation, and regula-
tion of inflammatory cytokine release (Linger et al. [162]). Within the intracellular
region, exons 13-19 encode the tyrosine kinase domain (Gal et al. [74]). The ex-
tracellular domain of MERTK serves as the ligand binding region for the ligands
GAS6 (Chen, Carey and Godowski [37]) and Protein S (Prasad et al. [218]).
Looking at the expression levels of the fragment of MERTK on the DM, ex-
ons 5 and 6 are expressed, but the expression level is dwarfed by the expression
of EGFR, SEC61G and AQP1. Taking the DNA sequence of exon 5 and 6 of
MERTK using Ensemble (Transcript: MERTK-201 ENST00000295408.8), trans-
lating it with Prosite (ExPASy) into amino acids and comparing it to the amino acid
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sequence of the Ig-like C2-type 2 domain and FNIII 1 domain (as found on Uni-
ProtKB Q12866 (MERTK-HUMAN)), it shows that the sequence on the DM does
not comprise a full sequence of any of those two domains. The sequence neither
contains a promoter for transcription, nor does the amino acid sequence carry
start or stop codons for translation. If there is any functionality of this sequence, it
must be fused to transcripts originating from the neighbouring fragments, or read
in the inverse direction from the promoter region of CRHR2. There is only some
evidence for fusion transcripts between fragment 1 and fragment 2 in R1C and
R2C, connecting the exons of MERTK to a region next to INMT, and for fusion
transcripts connecting fragment 1 and 3 in R2B, connecting the exons of MERTK
to AQP1. In the primary tumour the fragment of MERTK not only connected to
the edges (defined by the 10X data) of the other fragments but also showed high
evidence for a connection to EGFR. The question of whether this fragment is func-
tional as part of a fusion transcript or fusion protein, or if it just confers stability to
the ring structure of the DM remains unclear, but will be further investigated (see
Section 4.6.2 (Future work)).
4.3.5 The development of the DM over time
DM biology has gained increasing attention over recent years and a variety of
bioinformatic techniques are used to detect and reconstruct these extra chromo-
somal structures. For instance, Sanborn et al. detected DMs in GBM by using
high-depth WGS data (Sanborn et al. [232]). They focused on the breakpoints
that were part of highly amplified regions in the tumour and then reconstructed
the amplicons by walking a breakpoint graph. Also focusing on highly amplified
regions, Turner et al. developed the tool AmpliconArchitect, which searches for
and constructs circular DNA structures based on discordant reads (Turner et al.
[272]). In our study, the DM in the 3-Peater was first detected by the analysis of
the short read WGS data, which showed a high amplification of three fragments
that were likely to form a ring structure. We validated this result using long-read
data produced by 10X Genomics Chromium linked-read sequencing.
To investigate the structural heterogeneity and the evolutionary dynamics of
the DM in detail we used the higher depth short read WGS data to map rearrange-
ments within the boarders of the DM defined by the linked-reads. The results show
that there was a generally high genomic instability within the DM fragments and
high structural heterogeneity. In the primary, treatment-naïve tumour, the data
shows multiple, highly supported, junctions within the DM, suggesting multiple
stable variants at this time point. In the recurrences, we see many novel, but
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less supported, junctions. One variant carrying all the oncogenes emerges as the
dominant form, probably as a result of selective pressure imposed by treatment.
Other original variants, including the variant lacking AQP1, were eliminated by
surgery and/or radiation and chemotherapy.
The data show topographical segregation of subclones due to regional tumour
heterogeneity. For example, R1B showed strong support for a junction between
the end of fragment 3 and INMT-FAM188B on fragment 2, which was not detected
in the other two samples of the first recurrence. As DMs segregate unequally to
daughter cells during cell division (Lundberg et al. [176]), it is not clear how these
variants are distributed amongst cell clones and some cells will contain multiple
copies of the DM, while others will contain only a few (Turner et al. [272] and
deCarvalho et al. [50]). As each of these copies could gain different mutations
during each replication cycle, DMs are prone to an accelerated rate of evolution
compared to the rest of the genome. Single cell sequencing could elucidate this
problem. Multiple DMs, carrying different oncogenes can co-exist in the same
tumour and have been shown to be preserved during tumour progression (de-
Carvalho et al. [50]).
Our data show a two stage evolutionary process; in the primary and first re-
currence the selective advantage was provided by copy number changes rather
than point mutations. Until the second recurrence there were only three SNVs,
one of them clonal, present in all DMs. Only with the TMZ-induced hypermutation
did the number of point mutations increase, at which point the DM developed a
branched evolutionary trajectory. Other studies have also shown that DMs evolve
within the tumour independently of the chromosomal evolution of the tumour, as
a result of treatment-initiated selective pressure (Turner et al. [272] and Xu et al.
[300]). Xu et al. found novel mutations (both point mutations, and CNVs) which
arose after the formation of the DM. They propose a branching model of DM
evolution within the tumour which accords with our own model of the DM phylo-
geny after TMZ-induced hypermutation. From our own observations, and those
of Xu and colleagues, we can see that the DMs provide a mechanism by which
useful adaptations can be achieved quickly, and effectively distributed, regardless
of whether these adaptations are the result of point mutations or copy number
changes.
R2CL, where did the DM go?
It is long known that some DMs are unstable in cell culture; when the selective
pressure is removed, the number of DMs decreases, which makes working with
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DMs in cell culture very difficult (Hahn [98]). The maintenance of EGFR ampli-
fication in cell culture depends on the cell culture conditions (addition of serum,
EGF and bFGF) and whether cells are grown as monolayer or neurospheres. For
instance, cells grown in serum-containing medium (Humphrey et al. [120]) or in
the presence of EGF and FGF (Schulte et al. [238]) were reported to lose EGFR
amplification, and withdrawal of EGF from the medium was shown to promote
its maintenance (Schulte et al. [238]). However, the EGF and bFGF dependent
loss of EGFR amplification is not consistent, suggesting that EGFR is sometimes,
but not always indispensable (deCarvalho et al. [50]). This hypothesis has to be
taken with care though, as DMs often contain genes co-amplified with EGFR and
its maintenance of amplification could be the result of an in vitro selective advant-
age conferred by these other genes. As EGFR amplification is not observed to
be lost in xenografts (Humphrey et al. [120] and deCarvalho et al. [50]), some
research on EGFR in GBM is conducted by serial transplantation of PDCLs with
EGFR amplification in immunosuppressed mice (Carlson et al. [34]).
In R2CL, the cell line derived from the second recurrence of the tumour, we
could not detect DMs visually by performing FISH. We also show an almost total
reduction of the DM-associated CN amplification, but traces of the DM could be
found in the WGS data by specifically looking for the junctions involved in the
most abundant form of the DM. Despite there being only a few reads spanning
the junctions (five reads connecting fragment 1 and 2 and and six reads connect-
ing fragment 2 and 3), all three junctions were validated by PCR. These results
suggest that the DM is still present in the cell line, but in very low numbers with an
average of less than one DM per cell. Of note, while there were only a few reads
supporting the junction between fragments 1 and 2, and 2 and 3, there were 41
reads spanning fragment 3 and 1. Further experiments and analysis needs to be
done to explain this observation, but it suggests that this particular junction is still
under selective pressure in cell culture conditions providing a growth advantage
for the cells.
Starlozzi et al. found DMs and HSRs consisting of identical amplicons, thus
they concluded that these DMs and HSRs share the same molecular origin
(Storlazzi et al. [254]). This study supports a model in which HSRs are formed
by the reintegration of pre-existing DMs (Coquelle et al. [43], Campbell et al. [30]
and Storlazzi et al. [254]). Carrying out a detailed analysis of MYC-containing
DMs and HSRs of six different cancer cell lines derived from AML, smallcell lung
cancer and colon cancer, they found co-existing heterogeneous amplicons, which
differed in their complexity and chromosome content, indicating a multistep evol-
utionary process in the genesis of these regions (L’Abbate et al. [146]). Nathan-
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son et al., focusing on DMs carrying EGFRvIII, also detected HSRs containing
the same oncogene as the DM in patient derived GBM39 cells (Nathanson et al.
[190]). Treatment with Erlotinib resulted in a loss of the DM containing EGFRvIII,
but an increase of EGFRvIII containing HSRs. As DMs re-emerged after drug
withdrawal Nathanson and colleagues postulated that these HSRs may serve as
a latent reservoir for EGFRvIII in Erlotinib resistant cells (Nathanson et al. [190]).
These results were based on FISH images and no sequencing was performed.
While they did not fully address the question of whether one ecDNA structure
arose from the other, the study provides clear evidence for the quick adaptability
of DM-bearing cancer cells when challenged with a treatment which targets the
oncogene amplified on the DM (Nathanson et al. [190]).
We could not find any evidence for a HSR carrying the same oncogenes as the
DM or a possible integration of the oncogenes into chromosomes. DeCarvalho et
al. tested how genomically heterogeneous tumour cell populations are affected by
selective pressure arising from the transition from tumour to culture to xenograft
(deCarvalho et al. [50]). Their results showed that the percentage of cells carrying
extra chromosomal MET amplification decreased in neurosphere culture, but in-
creased again in vivo, independent of PDX location (orthotopic or subcutaneous)
(deCarvalho et al. [50]). As in our patient, they did not find signs of reintegra-
tion of the DM into chromosomes, but they found evidence supporting the post-
replication segregation-based model of DM formation (Vogt et al. [282]); a small
subpopulation of cells from one of the MET amplified tumours showed three cop-
ies of chromosome 7 of which one copy had lost the MET gene (deCarvalho et al.
[50]).
4.4 Characterisation of the R2CL phenotype
Neoplastic cells frequently reveal pleomorphism showing many different histologic
features such as small homogeneous cells with scant cytoplasm, fibrillary shaped
cells, cells with pleomorphic nuclei and cytoplasm and multinucleated giant cells.
If the latter phenotype dominates with more than 20% of all neoplastic cells being
giant, bizarre-looking multinucleated cells, the GBM is diagnosed as giant cell
glioblastoma. Less than 5% of primary GBMs fall into this category. Giant cell
GBM patients are significantly younger than those with other glioblastomas and
show a tendency for longer survival (Homma et al. [114]). Genetically, giant cell
GBM is characterised by frequent TP53 mutations (78%) and infrequent EGFR
amplification (6%) (Kleihues, Cavenee and International Agency for Research on
Cancer [143] and Homma et al. [114]). Multinucleated cells are also frequently
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observed in cell culture, when cells have undergone DNA damaging treatment,
such as radiation therapy or DNA damaging drugs, and arrest in G2 followed by
apoptosis (Firat et al. [67], Cornago et al. [44] and Higuchi et al. [111]).
In our patient, multinucleated cells were not present in the primary tumour
or the first recurrence and the tumour was not classified as giant cell GBM. A
statement about the presence of multinucleation in the second recurrence cannot
be made as there are no paraffin embedded samples or diagnostic histopatho-
logy slides. R2CL, derived from the second recurrence of the tumour, showed a
multinucleated phenotype, and the fraction of multinucleated cells increased over
time and with each passage, while the proliferation rate decreased. Giant mul-
tinucleated cells have been reported to be generally non-proliferating in a study
looking at Ki67 expression in cells of GBM sections (Giangaspero et al. [80]). The
increase of multinucleated cells and the decrease of the proliferation rate of R2CL
could be explained as follows: normal, mononucleated cells do still proliferate, but
their division is impaired due to the hypermutation which probably affects genes
involved in mitosis and cell cycle regulation. Thus, faulty chromosome segregation
or cytokinesis occurs in some cells, but these cells survive due to disregulation
of apoptotic pathways as a result of the hypermutation. With every division of
mononucleated cells, multinucleated cells are generated and these stop dividing,
leading to an overall decrease of proliferation in the culture.
In the the MMR knockdown experiment hypermutated cells showed a similar
behaviour and a similar phenotype as R2CL, with the appearance of multinuc-
leated cells and a decrease in proliferation after an initial phase of recovery from
TMZ, which was marked by high proliferation. It is not clear if this phenotype
and behaviour can be found in patients. To test this, sections of primary tumour
and matching hypermutated recurrences need to be analysed for the presence
of multinucleated giant cells. A primary tumour and matching non-hypermutated
recurrence cohort could serve as control group.
4.5 Failed experiments
4.5.1 Isolation of the DM
When we first discovered the potential ring structure in the samples of the patient
by WGS I tested different techniques to enrich the DM, which would improve the
long range sequencing quality of the ecDNA. The use of HMW DNA is a require-
ment for all downstream techniques.
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Firstly, I tried Pulsed-field-gel-electrophoresis (PFGE), a technique used for
the separation of large DNA molecules (up to 2 Mb). Compared to normal
agarose-gel-electrophoresis, the electric field applied to the gel matrix changes
direction periodically and is given in short pulses of equal length in three differ-
ent directions (-60҅, +60҅ and vertical), thereby allowing a net forward migration
of DNA molecules. In standard DNA electrophoresis, shorter DNA fragments mi-
grate based on their size, but the resolution is size limited to 30-50 kb, where
fragments will migrate at the same rate and will appear as a single diffuse band in
the gel. However, PFGE can overcome this limitation as larger pieces of DNA will
be slower to realign their charge when the field direction changes, while smaller
pieces will be quicker to realign. With the consistent changing of directions, each
band will begin to separate more and more even at very high molecular weight.
The process of separating large DNA molecules takes longer than normal gel-
electrophoresis, the PFGE may need to run for a full day depending on the size
of DNA. I performed two separate runs, but could not detect any DNA.
Secondly, I tried to enrich the DM by performing a pull down with biotinylated
oligos designed to hybridise to the region of MERTK found on the DM. Testing for
a CN change in MERTK using a probe detecting a region present on the DM I
could see an enrichment of MERTK in the pull-down samples, but this was only
successful using the hybridisation and clean up buffers provided with the Illumina
TrueSeq exome kit and the enrichment was rather inefficient. The cost of this
technique, given the low efficiency of the assay and the uncertainty of the results,
proved prohibitive.
4.5.2 Quantitative FISH analysis of R2CL metaphase spreads
In order to get a better understanding of the EGFR and AQP1 CN status and
their location in the genome, I tried to perform more FISH analysis of R2CL meta-
phase spreads with probes for AQP1, EGFR, Cen7 (centromere 7) and Cen8
(centromere 8) as a CN neutral region (based on the CN analysis). The multinuc-
leated phenotype of cell line R2CL made it difficult to get cells in metaphase, due





I have shown that it is possible to reproduce the hypermutation phenotype in the
MGMT promoter methylated cell line JR2M by TMZ treatment following CRISPR-
Cas9 mediated MSH2 or MSH6 knockout in a subpopulation of cells. As part of
this experiment I also used the MGMT promoter unmethylated cell line J3T6 and
collected DNA for sequencing. Upon TMZ treatment the J3T6 MMR efficient con-
trol cells did not die after three weeks, as observed in JR2M, but proliferated at a
rate comparable to the TMZ treated MMR knockout cells. This observation sug-
gests that selection of J3T6 MMR knockout cells by TMZ treatment probably did
not happen. The killing effect of TMZ in MGMT -unmethylated patients is reduced
as MGMT removes the methyl adducts from the DNA, conferring TMZ resistance
(see Figure 1.5 on page 33). Sequencing the DNA isolated from J3T6 MMR
knockout and control cells will show if the MMR knockout cells had an advant-
age over the MMR efficient cells, expanding under TMZ treatment and potentially
acquiring hypermutation in an MGMT -unmethylated background. I also want to
sequence DNA isolated from JR2M MMR efficient cells which were treated with
a low dose of TMZ (2 µM, reduced to 1 µM after four weeks) every two days for
nine weeks. Like the TMZ treated MMR knockout cells from the experiment, these
cells were also left to recover for at least three weeks before harvesting. The aim
of this experiment is to test if the hypermutation phenotype can be provoked in
cell culture even without a knockdown in the MMR system.
To test the aggressiveness of hypermutated cell lines in vivo, I want to sub-
cutaneously inject the hypermutated and matching non-hypermutated cell lines
into the flank of mice. The tumours will be left to grow for eight weeks, or until
the first tumours reach the allowed limit of 12 mm in diameter specified in the
Home Office regulations. This experiment could answer the question of whether
hypermutated GBMs are more or less aggressive than non-hypermutated GBMs.
It would also be interesting to analyse the xenografts on a genetic level and test if
the mutational landscape has changed in the more physiological environment.
4.6.2 Double minutes
Functionality of double minutes
In order to refine the gene expression analysis of genes on the DM, and to detect
fusion genes on the DM more accurately, Dr Lynch will build a contig with the
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coordinates of the DM based on the most abundant junctions defined by the 10X
data. The mRNA expression will be reanalysed by mapping the reads to this new
reference genome. So far, the analysis was performed by mapping the mRNA
reads to the hg19 reference genome, which may result in a bias towards the ex-
clusion of some reads spanning the different fragments. In particular, reads span-
ning different chromosomes, such as connections between the part of MERTK,
originating from chromosome 2, and either fragment of chromosome 7, could be
lost. I will perform PCR validation of putative fusion transcripts and potentially
interesting candidates will be analysed at the protein level by mass spectrometry.
As discussed earlier, the loss of DMs in cell culture is an interesting aspect
of their biology, which might result from the loss of the selective pressure, which
drives the DM emergence in the first place. The DM of the 3-Peater contained
three highly expressed genes, SEC61G, AQP1 and EGFR, suggesting that all
three genes were important for the tumour. We could not detect the DM by FISH
and only when specifically looking for it could we detect a few reads of the WGS
data supporting the DM in the cell line R2CL, but PCR with primers spanning
the three breakpoints of the DM showed that the fusions of the fragments were
present in the cell line, suggesting that the DM may still be present at very low
numbers in some cells.
Despite the difficulty working with R2CL, due to its low proliferation rate and
the multinucleated phenotype, I want to try two different strategies, altering the
cell culture conditions, to put selective pressure back on the DM. Firstly, I want
to slowly reduce the amount of EGF in the medium, which should put selective
pressure on EGFR amplification and EGFR mutants with ligand-independent ac-
tivation, such as the G598V mutant present on the DM. There is evidence that
EGFR amplification can be retained in cell culture under the right conditions (Wil-
liam et al. [295] and deCarvalho et al. [50]).
Secondly, I want to expose the cell line to ER stress by treating it with tunica-
mycin, which is a mixture of homologous nucleoside antibiotics blocking N-linked
glycosylation. Tunicamycin causes cell cycle arrest in late G1 and activation of the
UPR (Ishii and Volpe [126]). As the re-emergence of the DM relies on replication,
the right concentration needs to be determined to avoid all cells arresting in G1.
The drug could also be given intermittently to allow cells to recover. UPR can be
measured by testing for the expression of SEC61ౘ and GRP78, an ER chaperone
protein and central regulator of ER homeostasis whose upregulation is used as a
sentinel marker for ER stress under pathologic conditions (Lee [152]). Finding a





The historical merits and drawbacks of case reports are well known (Nissen and
Wynn [198]). Many scientists criticise their lack of generalisability, their inability to
show cause and effect and the danger of over-interpretation, but case reports also
add value to the field; the major merits of case reports are detecting novelties and
generating hypotheses, pharmacovigilance and delivering in-depth understanding
and educational value. However, in recent years advances in high-speed genomic
analysis, including the advances in sensitivity that make liquid biopsies possible,
are making personalised medicine an increasing reality. In this context case stud-
ies gain an added utility, in that they make researchers aware of the complex
interplay of factors that happen in individual patients, and that make each case
unique. The GBM case presented in this thesis is rare by European standards as
the resection of a second recurrence is often advised against in order to maximise
the remaining quality of life for the patient. In this case, both spatially and longit-
udinally distinct samples were collected to follow the progression of the tumour.
Figure 5.1 is an illustration of the approximate tumour phylogeny of the 3-
Peater. Chromosomal changes in the tumour were an early event in the primary
lesion, including the formation of the DM, which carries the oncogene EGFR
mutant G598V and two potential oncogenes, SEC61G and AQP1. The primary
tumour appears to carry many possible variants of the DM, one of them exclud-
ing AQP1. All samples of the primary tumour were of low purity and limit the
resolution of the phylogeny at this time point. Both the primary tumour and the
first recurrence show low intra-tumour heterogeneity; on the genetic level, PA and
PC are one sample and R1B and R1C are also one sample. The stem of the
main tree consists of ҩ7000 mutations. In the primary tumour an additional ҩ550
mutations could be detected (A), which were lost in the first recurrence. The first
recurrence on the other hand gained an additional ҩ2500 mutations. In the first
recurrence we also find evidence of another clone (I), which is independent of the
primary lesion and was not detected in the primary samples. This clone appears
only at a rate of approximately 4% in the first recurrence. This additional lineage
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is also found in the second recurrence, where it appears at a rate of approximately
15%. With the hypermutation in the second recurrence intra-tumour heterogeneity
increased and the main tree branched.
Figure 5.1 Illustration of the approximate tumour phylogeny of the 3-Peater
Due to a low tumour purity (ҩ6%), samples PB and R1A have been excluded from the phylogenetic
analysis. The composition of the samples is estimated as follows: PA and PC are one sample and
are 100% A, R1B and R1C are one sample and consist of 96% B and 4% I, samples R2A (70%
E, 15% C, 15% J), R2B (70% G,15% D, 15% J), R2C (70% H, 15% C, 15% J). The dashed lines
indicate the treatment of the patient. The right side of the illustration provides a summary of the
main findings in each time point.
By looking into the DM of the 3-Peater I did not focus on the unusual (as
many case reports do) as DMs are a frequent event in GBM, but I have provided
more deeper information on their functionality in GBM biology. Both fragments of
chromosome 7 that are involved in the formation of the DM carry genes that are
either known oncogenes (EGFR) or potential oncogenes (AQP1 and SEC61G)
that are currently under investigation. Their appearance on a DM and their high
expression in our patient supports their potential role in oncogenesis. To date,
no one has studied the development of a DM through three longitudinal sample
sets, the primary tumour and two consecutive recurrences. There is evidence for
the existence of several different DMs, especially in the primary treatment-naïve
tumour, involving the same fragments but featuring different junctions. This finding
suggests a) that there is generally a high instability in these genomic regions of
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the patient and b) that the formation of DM is influenced by the selective pressure
on the genes falling within the regions of instability.
While our work on the patient was conducted retrospectively, other studies ac-
company the disease from the onset until passing and help to determine optimal
treatment (Favero et al. [63]). With decreasing sequencing costs and the develop-
ment of ready-to-use analysis pipelines, guiding the personalisation of treatments
will become feasible in clinical practice. Looking at the data of the 3-Peater from
a clinical perspective the additional use of EGFR inhibitors alongside the stand-
ard treatment for the primary tumour could have improved the progression free
survival of the patient, as the main driver of the disease appeared to be the DM
carrying the EGFR mutant G598V. We, and others, have demonstrated that failure
of the MMR system renders TMZ treatment useless as a cytotoxic agent. Had it
been possible to monitor ctDNA in the patient for mutations in the MMR pathway
during the 16 months that elapsed between the first and second recurrence, she
could have been spared the second TMZ treatment. However, the question then
arises of whether a hypermutated tumour is more aggressive or less aggressive
and of whether the patient would benefit from treatment with immunotherapy. Im-
munotherapy has been shown to be effective in other hypermutated brain tumours
or metastasis, but none of these were primary GBMs (Bouffet et al. [18] and Jo-
hanns et al. [134]). If hypermutation renders the tumour more susceptible to im-
munotherapy, then TMZ treatment may be useful beyond its cytotoxic function.
By generating patient derived, TMZ-induced hypermutated cell lines I created a
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A. Supplementary Material: The 3-Peater
A | Supplementary Material: The
3-Peater
Figure A.1 MRI scans showing the primary tumour and both recurrences of the 3-Peater
MRI scans taken before resection of each tumour (top panel) and scans taken post-operatively
(bottom panel).
Table A.1 Tumour estimates by Crambled




































































































































































































































































































































































A. Supplementary Material: The 3-Peater
Figure A.3 MSH6 indel validation
161






















































































A. Supplementary Material: The 3-Peater
Figure A.5 | Mutational landscape (exomes) of JR2M with MSH2 knockout after treatment
with TMZ.
Controls are JR2M unaltered, JR2M with control construct eV, JR2M F93, JR2M F93 DMSO
treated.
A| Hypermutation of the TMZ-treated JRM2 line with MSH2 knockout (F93). Shown are the num-
ber of SNVs per thousand detected in each sample
B| Fraction of base pair changes in all samples.
C| C>T transitions in their base pair context for JRM2 cells with F93 construct untreated, DMSO
treated and TMZ-treated.
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A. Supplementary Material: The 3-Peater
Figure A.6 | MSH2 and MSH6 knockout in J3T6.
Protein level of MSH2 and MSH6 in cell line J3T6 transfected with MSH2 knockout construct (F93),
MSH6 knockout construct (F98). Transfected cell lines have not been selected after transfection.
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A. Supplementary Material: The 3-Peater
Figure A.7 Sunrise plot of R2CL showing tetraploidy of the cell line
Figure A.8 | CNV of genes listed in the Heidelberg Panel for brain tumours
Shown are CNA in all genes listed in the Heidelberg Panel of brain tumours.
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A. Supplementary Material: The 3-Peater
Figure A.9 Detection of EGFR and AQP1 in R2CL using Fluorescence in situ hybridisation
(FISH)
FISH on metaphase spreads of R2CL were performed to detect EGFR (red), AQP1 (aqua) and
chromosome 7 (green). Chromosomes and nuclei are stained with DAPI. Images were taken with
a 100x oil objective.
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SEC61G
Sec61G is amplified on the DM of the 3-Peater samples and shown to be ex-
pressed at the mRNA level (Figure 3.23 on page 93). To test its expression at the
protein level, I performed a western blot analysis on all nine tumour samples and
the cell line R2CL derived from the second recurrence (Figure A.10A). Sec61ౘ is
a subunit of the Sec61 complex, a central component of the protein translocation
apparatus of the ER membrane. The manufacturer of the antibody showed that
it detects a band with a molecular weight of approximately 20 kDa in their test
data. As I detected multiple bands per samples with molecular weights around
50 kDa, I repeated the western blot with additional samples ZP1 (a primary GBM
sample), JR2M (a PDCL) and two human breast cancer cell lines (MDA MB and
T47D) (Figure A.10B). A band of 20 kDa only appeared in the cell line JR2M and
T47D, but several other bands suggest that the antibody is not very specific. In-
triguingly, in the cell line R2CL no band was detected, whereas all other 3-Peater
samples show two or three bands (Figure A.10A). All samples of low tumour cell
content share a common pattern and all samples of high tumour purity share a
common pattern different to that of the low tumour purity samples. Sample Z1P
is unrelated to the samples of the 3-Peater, but shows the same band pattern as
the high tumour purity samples of the 3-Peater. These results are sufficiently sug-
gestive to warrant repeating the experiment with another antibody. Alternatively,
the specificity of this antibody needs to be tested by performing an immunising
peptide blocking experiment.
Figure A.10 Protein expression of Sec61ౘ
A| Sec61ౘ expression in the samples of the 3-Peater.
B| Sec61ౘ expression in other glioma samples (ZP1), PDCL (JR2M) and two breast cancer cell
lines MDA MB and T47D.
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A.1 Tumour phylogeny markdown by Dr Lynch
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##    	
##          0      1	
##   0 440201   1672	





























##      Group.1        x	
## 37   3-1v4-2 61777442	
## 10   2-0v2-1 13721152	
## 6    1-0v2-1  7534365	
## 18   2-1v1-0  4346994	
## 20   2-1v2-0  3474135	
## 27   3-0v2-0  1577813	
## 9    2-0v1-0  1482299	
















##    0    1    2    3    4    5    6    7    8    9  118 	





##      	
##       FALSE  TRUE	
##   0   12075  2949	
##   1    6581  2388	
##   2     218  1199	
##   3      21   460	
##   4      22   141	
##   5      16    52	
##   6       1    11	
##   7       0     5	
##   8       0     4	
##   9       0     2	
##   118     0     1	













##                    chr      pos ref mut A019 A014 A018 A016	
## chr7:55221822_C/T chr7 55221822   C   T    0  102    0    8	
## chr7:54806316_G/A chr7 54806316   G   A    0  544  487  118	





##      [,1] [,2] [,3] [,4]	
## [1,]    0 0.19 0.00 0.05	
## [2,]    0 0.90 0.88 0.62	
## [3,]    0 0.01 0.41 0.03	








##        	
##          FALSE   TRUE	
##   FALSE 431866   2538	









##  C>A  C>G  C>T  T>A  T>C  T>G 	









##  C>A  C>G  C>T  T>A  T>C  T>G 	















##  C>A  C>G  C>T  T>A  T>C  T>G 	










##  C>A  C>G  C>T  T>A  T>C  T>G 	
## 0.07 0.07 0.38 0.05 0.35 0.06	
Again,	A004	and	A013	are	essentially	identical	in	terms	of	the	SNVs	present	in	all	cells.	












##                    chr      pos ref mut A019 A014 A018 A016 A002 A004 A013	
## chr7:55193351_A/G chr7 55193351   A   G    0    1    1    1    1  206  227	
## chr7:54806316_G/A chr7 54806316   G   A    0  544  487  118   17 2559 2383	
## chr7:55233043_G/T chr7 55233043   G   T    0    5  221    5    9 2267 2124	
## chr7:55069787_C/T chr7 55069787   C   T    0    3    0    0    0   26   17	
## chr7:55169004_C/T chr7 55169004   C   T    0    0    0    0    0   48   17	
## chr7:55143148_G/A chr7 55143148   G   A    0    0    0    0    0   98  110	
## chr7:55149358_G/A chr7 55149358   G   A    0    0    0    1    0   47    0	







##      [,1] [,2] [,3] [,4] [,5] [,6] [,7]	
## [1,]    0 0.00 0.00 0.01 0.02 0.08 0.10	
## [2,]    0 0.90 0.88 0.62 0.25 0.97 0.98	
## [3,]    0 0.01 0.41 0.03 0.15 0.95 0.95	
## [4,]    0 0.01 0.00 0.00 0.00 0.01 0.01	
## [5,]    0 0.00 0.00 0.00 0.00 0.02 0.01	
## [6,]    0 0.00 0.00 0.00 0.00 0.04 0.05	
## [7,]    0 0.00 0.00 0.01 0.00 0.03 0.00	
## [8,]    0 0.19 0.00 0.05 0.00 0.00 0.00	
Time Point 3 









































table((c(A9M,A9R)[which(c(A9M,A9R) %in% c(GTR,GTL,GBR))] %in% sure0413))	
## 	
## FALSE  TRUE 	
##   462  8194	










##                    chr      pos ref mut A019 A014 A018 A016 A002 A004 A013	
## chr7:55193351_A/G chr7 55193351   A   G    0    1    1    1    1  206  227	
## chr7:54806316_G/A chr7 54806316   G   A    0  544  487  118   17 2559 2383	
## chr7:55233043_G/T chr7 55233043   G   T    0    5  221    5    9 2267 2124	
## chr7:55069787_C/T chr7 55069787   C   T    0    3    0    0    0   26   17	
## chr7:55169004_C/T chr7 55169004   C   T    0    0    0    0    0   48   17	
## chr7:55143148_G/A chr7 55143148   G   A    0    0    0    0    0   98  110	
## chr7:55149358_G/A chr7 55149358   G   A    0    0    0    1    0   47    0	
## chr7:55221822_C/T chr7 55221822   C   T    0  102    0    8    0    0    0	
##                   A005 A007 A012	
## chr7:55193351_A/G  907   76 1052	
## chr7:54806316_G/A 1064 2353 1296	
## chr7:55233043_G/T  934 2250 1130	
## chr7:55069787_C/T   19   22   22	
## chr7:55169004_C/T    0    0    0	
## chr7:55143148_G/A    0    0    0	
## chr7:55149358_G/A    0    0    0	







ABL Abelson murine leukemia viral oncogene homolog 1
BCR Breakpoint cluster region
CDK4 Cyclin-dependent kinase 4
CDKN2A/B Cyclin-dependent kinase Inhibitors 2A and B
CIC Capicua
CRHR2 Corticotropin Releasing Hormone Receptor 2
FAM188B Family With Sequence Similarity 188 Member B
FUBP1 Far upstream element-binding protein 1
IGF1R Insulin-like growth factor 1 receptor
INMT Indolethylamine N-Methyltransferase
LTBP4 Latent transforming growth factor beta binding protein 4
MDM2 Mouse double minute 2 homolog
MERTK MER Proto-Oncogene, Tyrosine Kinase
NF1 Neurofibromatosis type 1
PRDM2 PR/SET Domain 2
PTEN Phosphatase and tensin homolog
PTPRD Protein Tyrosine Phosphatase, Receptor Type D
RB Retinoblastoma-associated
SEC61G Sec61 Translocon Gamma Subunit
TP53 Tumour protein 53
2-HG 2-hydroxyglutarate
5-ALA 5-aminolevulinic acid
A1 Bcl-2-related protein A1
AGT O6-alkylguanine alkyltransferase
AID Activation-induced cytidine deaminase
AKT Protein kinase B (PKB)
ALT Alternative lengthening of telomeres
AML Acute myeloid leukaemia
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Acronyms
APOBEC Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like
AQPs Aquaporins
ATP Adenosine triphosphate
ATRX ౖ-thalassemia/mental retardation syndrome X-linked
BAK Bcl-2 homologous antagonist/killer
BAX BCL2 Associated X
BBB Blood-brain-barrier
BCL-2 B-cell lymphoma 2
Bcl-w Bcl-2-like protein 2
Bcl-xL B-cell lymphoma-extra large
BER Base excision repair
Bev Bevacizumab
BLAST Basic Local Alignment Search Tool
BMDMs Bone marrow-derived macrophages
bMMRD Biallelic mismatch repair deficiency
CCL Chronic lymphocytic leukaemia
CML Chronic myeloid leukaemia
CMMRD Constitutional Mismatch Repair Deficiency
CNA Copy number alteration
CNS Central nervous system
COSMIC Catalogue Of Somatic Mutations In Cancer
ctDNA Circulating tumour DNA
DAG Diacylglycerol





EGF Epidermal growth factor
EGFR Epidermal growth factor receptor
EGFRvII EGFR variant II
EGFRvIII EGFR variant III
EGFRvIII EGFR variant III
EGFRvV EGFR variant V
EMT Epithelial-mesenchymal transition
ER Endoplasmic reticulum
ERK Extracellular signal-regulated kinases





FDA Food and drug administration
FECH Ferrochelatase
FGR Fluorescence-guided surgical resection
FNIII Fibronectin type III
G-CIMP Glioma-CpG island methylator phenotype
GABP GA-binding protein
GBM Glioblastoma multiforme
GFAP Glial fibrillary acidic protein
GSCs Glioma stem cells
Gy Gray
H&E Hematoxylin and eosin
HBSS Hank’s Balanced Salt Solution
HCPS Hereditary cancer-predisposing syndrome
HGG High-grade glioma
HIF-1ౖ Hypoxia-inducible factor 1 alpha
HMW High molecular weight










LOH Loss of heterozygosity
MAPK Mitogen-activated protein kinase
Mcl-1 Induced myeloid leukemia cell differentiation protein
MET Mesenchymal-epithelial transition
MGMT O6-methylguanine-DNA methyltransferase
MiB Molecular immunology Borstel
MLH1 MutL homolog 1
MLH3 MutL homolog 3
MMR Mismatch repair
MPG N-methylpurine DNA glycosylase
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Acronyms
MRI Magnetic resonance imaging
MSH2 MutS homolog 2
MSH6 MutS homolog 6
MSI Microsatellite instability
mTOR Mechanistic Target of Rapamycin
NER Nucleotide excision repair
NF-౟B Nuclear factor ’౟-light-chain-enhancer’ of activated B-cells
NHEJ Non-homologous end joining
NK Natural killer
NOD Non-obese diabetic
NOS Not Otherwise Specified
O6-meG Methylated O6-position in guanine
OS Overall survival
PCNA Proliferation cell nuclear antigene
PD-1 Programmed cell death protein 1
PD-L1 Programmed cell death ligand 1
PDCLs Patient-derived cell lines





PKC Protein kinase C
PLC Phospholipase C
PMS1 Postmeiotic segregation increased homolog 1
PMS2 Postmeiotic segregation increased homolog 2
POLౙ Polymerase delta
POL౰ DNA polymerase epsilon
PPIX Protoporphyrin IX
RD Regulatory Domain
RFC Replication factor C
ROS Reactive oxigen species
RTK Receptor tyrosine kinase
SCID X-linked severe combined immunodeficiency
Src Tyrosine kinase sarcoma
SSC Saline-sodium citrate





TCGA The Cancer Genome Atlas
TERT Telomerase reverse transcriptase
TET2 Tet methylcytosine dioxygenase 2
TILs Tumour infiltrating lymphocytes
TK Tyrosine Kinase
TM Transmembrane
TML Tumour mutation load
TMZ Temozolomide
TSC1/TSC2 Tuberous sclerosis 1/2
UPR Unfolded Protein Response
VAF Variant allele frequency
VEGF Vascular endothelial growth factor
WHO World Health Organisation
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